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Wnt–β-catenin signalling regulates diverse developmental and homeostasis processes. Aberrant
regulation of this pathway is observed in numerous cancers. β-catenin, whilst largely dispensable
in adult haematopoiesis, has a critical role in the development, disease progression and drug
resistance of Acute Myeloid Leukaemia (AML). One of the most frequent chromosomal
translocations in AML involves KMT2A, also known as Mixed Lineage Leukaemia protein
(MLL). MLL-fusions initiate transformation of haematopoietic stem cells (HSCs) and
progenitors such as the Granulocyte-Macrophage Progenitors (GMPs) into Leukaemia Stem
Cells (LSCs). Recently we demonstrated that β-catenin is required for the development of
MLL-ENL transformed LSCs originating from GMPs but not from HSC enriched populations.
This study aims to uncover key targets of β-catenin and dissect mechanisms by which β-catenin
controls transcription in LSCs arising from distinct cellular haematopoietic populations. To
investigate β-catenin targets in AML, haematopoietic progenitors of specific origin were taken
from a β-catenin conditional mouse model and transformed by retroviral MLL-ENL expression.
To this end, we performed global transcriptional profiling by RNA sequencing (RNA-
Seq) on transformed cells in the presence or absence of β-catenin. β-catenin has been shown to
recruit histone modifying enzymes and other epigenetic regulators; to elucidate mechanisms by
which β-catenin modulates its targets in AML, ChIP sequencing (ChIP-Seq) was produced for
promoter and enhancer defining histone modifications. β-catenin targets in LSCs were found to
be enriched in cytokine signalling and immune pathways and contrast with those in other cell
types suggesting that β-catenin may perform unique roles in AML. Interestingly, one of the few
genes differentially up regulated in GMP derived LSCs upon β-catenin deletion included Gadd45a,
a DNA damage inducible growth arrest mediator. Whilst showing little effect in vitro, Gadd45a
overexpression eliminated leukaemia in vivo. Combined global ChIP-Seq and RNA-Seq analyses
revealed β-catenin dependant changes at promoter regions suggesting that β-catenin could be
actively involved in histone modification. However, further study with improved experimental
design is required to ensure that the observed effects are specific to β-catenin activity.
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Acute Myeloid Leukaemia (AML) is a cancer which originates from haematopoietic stem or
progenitor cells which in normal circumstances would fully differentiate and give rise to mature
blood cells. Malignant transformation prevents progenitor cells from differentiating into mature
blood and dramatically increases proliferation, leading to a pathogenic accumulation of immature
cells. 2,856 cases of AML, 0.8% of all new cancer cases, were diagnosed in the UK in 2012. For
those diagnosed with AML, aged 14 or younger, 66% survive 5 years or more, at 15-24 this drops
to 60%, at 25-64 it is 40% and at 65 or older just 5% (Cancer Research UK 2015).
Improvements in the treatment of AML over the past few decades can be mostly
attributed to supportive care and better diagnosis (Thein et al. 2013). Therefore therapies that
effectively target the biological mechanisms underpinning the disease need to be developed. To
unravel the causes of AML and therefore novel targets for therapy, we must first understand
what blood is composed of and the processes involved in blood formation and transformation.
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1.1 The Haematological System
Haematopoiesis is a cascade of cellular and molecular events resulting in the formation of all blood
cellular constituents. Although highly complex, haematopoiesis is one of the most comprehensively
studied developmental systems. Thus, the haematological system has become somewhat of a
paradigm for stem cell maintenance and renewal. Classical haematopoiesis is organised into a
pyramidal hierarchical structure, with Haematopoietic Stem Cells (HSCs) at the apex. Rare,
long-lived, multipotent HSCs give rise to larger populations of increasingly restricted, committed
intermediates, or progenitors, ultimately producing terminally differentiated, functional blood
cells (Till and McCulloch 1980). HSCs are classed into two groups, Long Term reconstituting
HSCs (LT-HSCs) which replenish the stem cell pool and Short Term reconstituting HSCs
(ST-HSCs) which go on to form all blood lineages (Weissman et al. 2001).
Before distinct lineages are specified, ST-HSCs generate Multipotent
Progenitors (MPPs), MPPs are uncommitted yet display weaker self-renewal potential. From
MPPs, myelopoiesis and lymphopoiesis are segregated by the formation of their common
oligopotent progenitors, Common Myeloid Progenitors (CMPs) and Common Lymphoid
Progenitors (CLPs) (Weissman et al. 2001). From CMPs arise Granulocyte-Monocyte
Progenitors (GMPs) and Megakaryocyte-Erythroid Progenitors (MEPs), progressing to
dendritic cells, monocytes, granulocytes, erythrocytes, megakaryocytes and platelets. From
CLPs arise Early T-cell Precursors (ETPs) and B-cell Precursors (proBs), leading to Natural
Killer Cells (NKs), T and B cells. The current models of haematopoiesis in mouse and human
including the surface marker expression of each individual population, is illustrated in
Figure 1.1.
The process of haematopoiesis is understood in great detail due to pioneering work
in mice, leading to the discovery and functional assessment of haematopoietic populations
(Weissman et al. 2001). In the mouse embryo, primitive haematopoiesis begins in the yolk sac
blood islands at Embryonic Stage (ES) 7.5 (day 7.5 after fertilisation), producing firstly Red
Blood Cell (RBC) precursors, followed by lymphoid precursors (Haar and Ackerman 1971). Other
haematopoietic sites emerge once the circulatory system begins to develop. HSCs emerge at
the Aorta-Gonad Mesonephros (AGM) region at ES10.5 and then in the placenta. Fully fledged
haematopoiesis occurs in the foetal liver (ES13.5), thymus, spleen and then finally in the Bone
Marrow (BM) after birth (Orkin and Zon 2008; Costa et al. 2012).
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The concept of the HSC existed over 100 years ago, when Russian biologist Maximow
(1909) explained observations of morphological diversity of bone marrow by suggesting that
haematopoiesis arises from a common precursor. The atomic era brought irrefutable evidence for a
HSC population when radiation exposure was found to cause lethal BM failure. It was discovered
that exposed animals could be rescued after injection of healthy spleen or BM cells (Lorenz et al.
1951). Models of haematopoiesis have been built upon cell purification, transplantation and in
vitro clonal assays. Firstly cell separation was done by density, sensitivity to antimitotic agents
and then surface glycoprotein. Cell surface markers or differentiation “antigens” allowed for the
identification, isolation and observation of stem cells and progenitors using monoclonal antibodies.
A rare population of cells displaying HSC characteristics was identified in mice (Spangrude et al.
1988; Okada et al. 1992). This population is lineage-specific negative, Sca-1 and c-Kit positive,
therefore commonly known as Lineage-specific negative, Sca-1 and c-Kit positive (LSK) cells.
Cell surface markers have been better refined over the years (Figure 1.1) and are now
commonly utilised in FACS or Magnetic-Activated Cell Sorting (MACS) to isolate the specific
haematopoietic populations with very good purity (Yeung and So 2009). Functional assays
continue to reform the standard model, for example, the discovery of Lymphoid-primed Multi-
Potent Progenitor (LMPP) in mouse Adolfsson et al. (2005) revealed that the first lineage branch
after HSC determines megakaryocyte/erythroid potential, rather than just myeloid/lymphoid.
Fascinatingly, by monitoring HSC divisions in mouse, it was demonstrated that MEPs can arise
directly from HSCs (Yamamoto et al. 2013).
Human haematopoiesis has been considered largely consistent with mouse
haematopoiesis (Doulatov et al. 2012). Recently, the widely accepted model of haematopoiesis
has been challenged in humans. (Notta et al. 2015) hypothesised a developmental shift to a “two
tier” hierarchy in adult human haematopoiesis. Using a improved sorting scheme to better
resolve the human CD34+ cell compartment in the different tissues, they revealed that whilst
large, distinct populations of oligopotent progenitors were found in foetal liver, only multipotent
and unipotent progenitor classes prevailed in adult bone marrow. This suggests that oligopotent
progenitors with the same immunophenotype, thus belonging to the same purification fraction,
display different levels of differentiation potential. It is therefore vital that we take care in






































































































Figure 1.1: Current models of lineage fate determination in the haematopoietic
system Adapted from Doulatov et al. (2012).
Haematopoiesis is governed by precise control of gene expression. Expression of genes
promoting multipotency and self-renewal are shut down whilst expression of genes essential for
specific cell functions are tuned up along branches of differentiation. To further understand
the process of haematopoiesis on a molecular level, we must recognise the mechanisms of gene
expression control.
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1.2 Cell Identity and Transcriptional Regulation
Due to precise spatial-temporal regulation of gene expression, cells that are genetically identical
become distinctive cell populations with defined roles in discrete tissues. The study of gene
expression regulation is called epigenetics. “Epi-” comes from Greek, meaning “outside of” or
“on top of”, thus the literal meaning of epigenetics is the external modification of DNA. The
epigenetic landscape concept was famously illustrated by Conrad Waddington in (Waddington
1957). Marbles or cells, roll down a hill, competing for the grooves or lineages, then finally come
to rest at different locations at the bottom of the hill or their terminal cell fates. When the field
first emerged, epigenetics was defined as “The study of mitotically and/or meiotically heritable
changes in gene function that cannot be explained by changes in DNA sequence” by Russo
et al. (1996). Modern usage of the term “epigenetics” commonly describes any perturbations of
chromatin state (Bird 2007).
Approximately two meters of DNA are packed into the nucleus of a human cell. To
protect the genome from damage and arrange it so that functional loci can be accessed, DNA
is packaged with proteins such as histones into a structure known as chromatin. For a gene to
be transcribed, the basic transcriptional machinery, consisting of RNA polymerase II (pol II)
and General Transcription Factors (GTFs), must bind to the core promoter. The core promoter,
usually containing a TATA box, named by its literal nucleotide sequence, is immediately upstream
of the Transcription Start Site (TSS) (Butler and Kadonaga 2002). Transcription is enhanced by
interaction of further regulatory DNA elements; the proximal promoter and enhancer regions
contain recognition sites for Transcription Factors (TFs) and other transcriptional activators,
recruiting coactivators to the core promoter. Regulation of gene expression is mediated by a
combination of many factors: DNA methylation, chromatin remodelling, histone variants, histone
modifications, histone modification readers, transcription factors, co-activators or repressors and
various non-coding RNAs.
1.2.1 DNA Methylation
DNA methylation is the quintessential epigenetic mechanism as much is known about the
mechanisms of its heritability and its established effects on gene expression. DNA Methyl-
Transferases (DNMTs) methylate the 5-methyl of Cytosine (5mC) in DNA. This often occurs at
a Cytosine followed by a Guanine (CpG) but can occur at non-CpGs (Lister et al. 2009; Xie
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et al. 2012). The binding of proteins can be inhibited by methylation. 5mC readers are found in;
the Methyl-CpG Binding Domain (MBD) family, the Zinc Finger (ZF) family and the SET and
RING finger-Associated (SRA) family (Klose and Bird 2006). Cytosine to Tyrosine mutations
are promoted by methylation as 5mC is susceptible to deamination. CpG Islands (CGIs) are
regions enriched for CpGs and are broadly unmethylated. 50% of CGIs are associated with
promoters of predominantly housekeeping genes (Illingworth and Bird 2009), whilst some are
developmentally regulated (Deaton et al. 2011). While CGI promoter methylation implies stable
repression, methylated gene bodies do not prevent elongation but a skew in methylation in exons
is thought to affect splicing regulation (Jones 2012).
1.2.2 Chromatin Organisation
Primarily, the level of chromatin compaction influences DNA accessibility and thus its activity,
several distinct forms have been characterised; heterochromatin is compact, often contains
repetitive elements and is generally transcriptionally silenced whilst euchromatin is open
permitting active transcriptional regulation. Chromatin is firstly organised into nucleosomes,
146 bp of DNA wraps around an octamer arrangement of histone proteins, inter-dispersed by
linker DNA, often visually described as “beads on a string” (Luger et al. 1997). Histone
octamers contain two copies of the canonical histones: H2A, H2B, H3 and H4. Further
compaction of chromatin is achieved in nucleosome arrays and then chromatin fibres.
Chromatin arrangements are not only a scaffold for DNA, but a precise enzyme controlled
method of transcriptional regulation. ATP hydrolysis is used by Chromatin Remodelling
Complexes (CRCs) to remove nucleosomes, slide them along DNA or exchange histone proteins
(Hargreaves and Crabtree 2011). Nucleosomes are shifted to allow transcriptional, replication
and DNA repair machinery to make contact. Nucleosomes are also shifted or removed to deny or
allow access to protein recognition sites (Narlikar et al. 2013). Canonical histones are dependent
on replication for their incorporation into chromatin, however, replication independent histone
variants can be incorporated into chromatin via CRCs.
Histone variants have unique properties over their canonical counterparts, some have
specific functions. For example, H2A.Z locates at the 5′ end of genes and may control
transcriptional regulation (Zilberman et al. 2008; Catherine 2013). Neighbouring nucleosomes
interact via their unstructured N-terminal and C-terminal tails. More often than their globular
domains, unstructured N-terminal histone tails are modified by acetylation, methylation,
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phosphorylation, sumoylation and ubiquitination, facilitating structural regulation. Other
modifications, most with unknown function have been found (Tan et al. 2011).
1.2.3 The Histone Modification Code
Patterns and sequences of histone modifications or “marks” along histone tails are interpreted
somewhat as a code, each combination resulting in a specific regulatory effect (Strahl and Allis
2000). However, only a small proportion of the potential combinations have been observed
(Rando 2012), but functional classes of genes show some preference with specific combinations
(Kurdistani et al. 2004). Already characterised in 1964 (Allfrey and Mirsky 1964), two of the
best studied histone marks are acetylation and methylation of lysine residues. Histone tail
modifications are abbreviated by the histone protein name, followed by the one letter amino
acid code of the residue, the amino acid position in the tail and finally its chemical group. For
example, H3K4me3 can be understood as a tri-methyl group on a lysine residue at the fourth
amino acid position of Histone 3.
Histone acetylation of lysine residues is performed by Histone Lysine Acetyl-Transferases
(KATs) and reversed by Histone De-ACetylases (HDACs). The enzymes responsible for the
regulation of lysine acetylation were discovered only relatively recently in 1995 (Brownell and
Allis 1995; Kleff et al. 1995; Taunton et al. 1996). Acetylation levels are balanced by dynamic,
antagonistic action and even interaction of the enzymes. Found at active promoters and open
chromatin, acetylation is usually an activating modification (Bannister and Kouzarides 2011).
Lysine is positively charged, therefore addition of a negatively charged acetyl group neutralises
this charge and reduces its interaction with negatively charged DNA increasing its availability
and activity (Zentner and Henikoff 2013). Chromatin modulators with bromodomains can also
bind and regulate chromatin structure at acetylated lysines (Bannister and Kouzarides 2011).
Methylation marks can be found at arginine and lysine residues on histone tails
(Bannister and Kouzarides 2011). Varying regulation is applied by mono-, di- or trimethylation
occurring at lysine residues. Long after methylation modifications were discovered, the first
histone Lysine Methyl Transferase (KMT), KMT1A was found in 2000 (Rea et al. 2000). KMTs
are specific for both methylation level and peptide residues (Bannister and Kouzarides 2011).
Their antagonists, Histone Lysine Demethylases (KDMs) have also been discovered only recently,
the first, KDM1A, was found in 2004 (Shi et al. 2004).
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Methylation marks can have an activating or repressive effect depending on the residues
position and methylation level (Bannister and Kouzarides 2011), this is because unlike acetylation,
the charge of a histone is not altered by methylation. For example, at the promoter, H3K4me3
promotes gene expression (Barski et al. 2007). Conversely, H3K27me3 is a repressive mark
generated and read by Polycomb Group proteins (PcGs). The Polycomb Repressive Complex
2 (PRC2) adds this mark and Polycomb Repressive Complex 1 (PRC1) recognises or “reads”
H3K27me3 and causes chromatin to condense (Simon and Kingston 2013).
1.2.4 Transcriptional read-out of histone modification
Cis-regulatory elements, such as enhancers and promoters have distinctive histone modification
patterns as shown in Table 1.1. Enhancers are genetic elements between 200 and 500 bp which
boost transcription at a promoter up to thousands of kilobases away (Calo and Wysocka 2013).
Enhancers regulate gene expression by physically bringing the promoter in to contact with
transcription factors bound to the enhancer (Calo and Wysocka 2013; Smallwood and Ren 2013).
In recent years, the use of next generation sequencing to investigate epigenetics
genomewide, such as Chromatin Immunoprecipitation coupled to high-throughput
Sequencing (ChIP-Seq) has greatly accelerated. ChIP-Seq begins by fixing DNA using
formaldehyde or a combination of other fixing agents. This chemically crosslinks protein to
DNA, the DNA is sheared via enzymes or physical sonication. Antibodies specific to a histone
modification or other proteins can be used to immunoprecipitate the DNA linked to the protein
of interest. This DNA is purified, decrosslinked, sequencing adapters are ligated and the DNA is
then subjected to high-throughput sequencing.
The ENCODE project identified 399,124 regions with enhancer-like features over 1640
datasets in 147 human cell types (ENCODE Project Consortium and others 2012). Enhancers
commonly contain DNAse hypersensitive sites, are bound by p300 and SMARCA4 and are
enriched for H3K4me1 but lack H3K4me3. Active enhancers are marked by H3K27ac and
H3K4me1, poised enhancers are marked with H3K4me1, H3K4me2 and H3K27me3 (Andersson
et al. 2014). Functional experiments show that the epigenetic characterisation of enhancers is in
fact highly predictive of their activity (Calo and Wysocka 2013).
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Table 1.1: Recognised ENCODE histone modifications and variants Adapted from
ENCODE Project Consortium and others (2012). It is important to note that additional histone
variants and modifications have been characterised however, epigenomic data for example of





of Signal Putative Functions
H2A.Z Peak Histone protein variant (H2A.Z) associated withregulatory elements with dynamic chromatin
H3K4me1 Peak/region
Mark of regulatory elements associated with
enhancers and other distal elements, but also enriched
downstream of transcription starts
H3K4me2 Peak Mark of regulatory elements associated withpromoters and enhancers
H3K4me3 Peak Mark of regulatory elements primarily associated withpromoters/transcription starts
H3K9ac Peak Mark of active regulatory elements with preferencefor promoters
H3K9me1 Region Preference for the 5′ end of genes
H3K9me3 Peak/Region Repressive mark associated with constitutiveheterochromatin and repetitive elements
H3K27ac Peak
Mark of active regulatory elements; may distinguish
active enhancers and promoters from their inactive
counterparts
H3K27me3 Region
Repressive mark established by polycomb complex
activity associated with repressive domains and silent
developmental genes
H3K36me3 Region Elongation mark associated with transcribed portionsof genes, with preference for 3′ regions after intron 1
H3K79me2 Region Transcription-associated mark, with preference for 5
′
end of genes
H4K20me1 Region Preference for 5′ end of genes
Given our understanding of the effects of epigenetics on gene transcription, next, I will
describe studies that have led to the discovery of specific roles of epigenetic modulators in normal
and malignant haematopoiesis.
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1.3 The Epigenetic Landscape of Haematopoietic Cells
The plastic chromatin state of HSCs and early progenitors permits access to genes required for
numerous lineages and low level transcription of these genes allows cells to adapt and differentiate
accordingly (Hu et al. 1997; Miyamoto et al. 2002). The general theme follows, throughout
haematopoietic development and differentiation genes conferring ‘stemness’ are down-regulated
whilst differentiation genes are upregulated.
1.3.1 DNA Methylation
Following embryonic development, methylation of DNA was traditionally thought of as a
stable epigenetic modification, however plasticity is retained into adulthood (Meissner et al.
2008). The DNMTs, DNMT3A and DNMT1 are critical for haematopoiesis (Bröske et al.
2009; Challen et al. 2012; Trowbridge et al. 2009). DNMT3A has been shown to be needed
for HSC differentiation, however it is non-essential for lineage fate decisions. Transplanting
DNMT3A Knock-Out (KO) HSCs into irradiated mice resulted over-proliferation of HSCs,
however transplant of KO progenitors did not drastically affect differentiation (Challen et al.
2012). Therefore, DNMT3A must be important for silencing stem cell maintenance genes and
de-repressing differentiation genes in the HSC. DNMT1 is required for both differentiation and
lineage determination.
Indeed, Bröske et al. (2009) showed that DNMT1 deletion resulted in BM failure. A
hypomorphic DNMT1 mutation, that is a mutation causing reduced activity or expression was
used to elucidate the role of DNMT1 in haematopoiesis by performing in vivo repopulation
assays. Stem cell maintenance genes were downregulated reducing self-renewal and lineage
commitment was skewed to myeloid as myeloerythroid TFs were up-regulated and lymphoid
genes were down-regulated. DNA methylation maintenance appears to be needed for lymphoid
but not myeloid differentiation, the literature illustrates that in myeloid cells methylation is lost
whilst lymphoid cells actually gain sites of increased methylation (Bock et al. 2012; Bocker et al.
2011; Hodges et al. 2011; Hogart et al. 2012).
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In anticipation, committed progenitors show these methylation differences. Methylation
changes occur at transcription factors and specific mature cell activity genes (Bock et al. 2012).
Methylation also occurs at TF binding sites and enhancers (Bock et al. 2012; Hodges et al.
2011; Shen et al. 2012). In lymphoid cells, myeloid specific gene promoters and sites where their
transcription factors bind are methylated, thus preventing myeloid lineage development. Ageing
HSCs show a skew towards the myeloid lineage; this may be because hypomethylation of genes in
ageing HSCs is seen at genes that are demethylated in myeloid development (Bocker et al. 2011;
Pang et al. 2011). While DNA demethylases TET2 and TET3 are simultaneously expressed in
peripheral blood, only TET2 is expressed in the BM (Lorsbach et al. 2003). KO of TET2 results
in a shift to development of monocytic cells and HSC expansion and leukaemia occurs in young
TET2 KO mice (Butler and Dent 2013).
1.3.2 Chromatin Remodelling
Multiple CRCs have been attributed important roles in normal haematopoiesis and their
dysregulation often contributes to malignancies. For example, in murine bone marrow,
accumulation of erythroid progenitors alongside a reduction in all other progenitors and vast
proliferation of HSCs occurs when the catalytic subunit of the Nucleosome Remodelling and
Deacetylase (NuRD) complex is deleted (Yoshida et al. 2008). In mice it was found that bone
marrow failure could be induced by depletion of BAF53a of the BRG1- or BRM-Associated
Factors (BAF) complex (Krasteva et al. 2012). A myeloid maturation block could be induced in
vitro by expression of a dominant negative mutant form of Brg1, one of the potential catalytic
cores of BAF (Vradii et al. 2006).
1.3.3 Histone Acetylation
Higher H3 and H4 acetylation is seen globally in HSCs and early progenitors than in differentiating
cells (Chung et al. 2009). Turnover was also more dynamic suggesting that chromatin is open
and more malleable. Whilst not needed for differentiation, the KAT enzyme KAT6A as part of
the MOZ (monocytic leukaemia zinc finger protein) complex, is required for HSC and progenitor
maintenance (Thomas et al. 2006). In mice, knocking out histone deacetylase 1 and histone
deacetylase 2 (Hdac1 and Hdac2 respectively) in progenitors prevents formation of erythrocytes
and megakaryocytes (Wilting et al. 2010).
28
1.3.4 Bivalent Promoters
Bivalent promoters are modified simultaneously by repressive H3K27me3 and active H3K4me3
marks, this means that whilst transcriptionally suppressed, they are also poised for transcription.
Cell type specific genes and those involved in differentiation, including key transcription factors
of haematopoiesis frequently possess bivalent promoters (Abraham et al. 2013; Adli et al. 2010;
Bernstein et al. 2006). The repressive H3K27me3 mark is lost at various stages of haematopoiesis
and regained after cell fate is determined (Abraham et al. 2013).
Untimely derepression of bivalent B cell genes in HSCs can be induced by depletion or
mutation of BMI1, the PcG component of PRC1, leading to aberrantly enhanced B cell formation
and HSC reduction (Oguro et al. 2010; Park et al. 2003). As one might expect, conversely, HSC
self-renewal increases when BMI1 or the KMT of the PRC2 complex, EZH2 are overexpressed
causing aberrantly maintained repression of bivalent promoters of stage specific transcription
factors (Kamminga et al. 2006). In mice, overexpression of EZH2 additionally increases myeloid
growth (Hidalgo et al. 2012) and mutation affects B cell formation (Mochizuki-Kashio et al.
2011). KDMs are also important in haematopoiesis; expression of lineage restrictive genes is
controlled by KDM1A via its relationship with the GFI1 repressor (Saleque et al. 2007).
In HSC, H3K4me2 was found to be enriched at promoters of multiple genes important
for B cell development. In B cells H3K4me3 was found in place of H3K4me2, whilst in T cells K4
methylation was removed altogether (Maës et al. 2008). Transcriptionally silent promoters with
H3K4me2 present and void of H3K4me3 in HSCs were overrepresented by lineage fate determining
genes. When erythroid differentiation was initiated, erythroid genes gained H3K4me3, unrelated
genes lost methylation (Orford et al. 2008), suggesting that H3K4me2 may be an alternative
mark for poised promoters and characteristic of a recurring theme of bivalency as a measure of
differentiation potential in HSCs.
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1.3.5 Mixed lineage leukaemia protein
Lysine Methyltransferase 2A (KMT2A), also known as Mixed Lineage Leukaemia protein (MLL),
is a H3K4 methyltransferase encoded by KMT2A located at human chromosome 11q23 (Benjamin
et al. 1995). Clustered Homeobox (Hox) genes are among the best studied MLL downstream
targets, critical for HSC renewal (Jude et al. 2007; McMahon et al. 2007). Complete MLL
KO experiments revealed failed Hox gene expression during embryonic development and the
mice died before birth (Benjamin et al. 1995). Later, biochemical studies showed direct binding
and transcriptional regulation of Hox genes by MLL (Milne et al. 2002; Yokoyama et al. 2004).
As MLL knock out is lethal to embryonic development, conditional deletion models have been
utilised to study the role of MLL in haematopoiesis (McMahon et al. 2007; Jude et al. 2007).
Firstly McMahon et al. (2007) showed that MLL KO resulted in a decrease of HSCs in the foetal
liver. Contrastingly, in adult haematopoiesis they showed that MLL was not essential, however
KO HSCs were found to have impaired reconstitution abilities. Using a different model, (Jude
et al. 2007) demonstrated that induced KO of MLL in adult mice results in bone marrow failure
and death within just 3 weeks.
Following translation of MLL, the protein is proteolytically cleaved into two units, the
amino-terminal (MLLN) and the carboxy-terminal (MLLC). These fragments, combined with
additionally recruited proteins, form a large complex with histone methyltransferase, histone
acetyltransferase and chromatin remodelling functions (see Figure 1.2). MLLC is responsible for
enhancing transcription of targets both directly through H3K4 methylation catalysed by the
SET (Suppressor of variegation Enhancer of zeste Trithorax) domain and through its associated
proteins. H3K4 methylation is further facilitated by ASH2L and RBBP5 which stabilise the MLL
complex in its active confirmation (Southall et al. 2009). WRD5 recognises H3K4 methylation
and is theorised to promote consecutive histone modification (Dou et al. 2006). H3K16 acetylation
is achieved by MOF in association with MLLC (Dou et al. 2005). MLLN ensures that activation
of transcription is targeted to the correct genes. The CxxC region binds only to unmethylated
DNA and therefore targets transcriptional activation through MLLC to unmethylated regions.
Depending on association of CYP33 with the Plant Homeodomain (PHD), the CxxC region
also recruits HDAC and PcG proteins including BMI-1 (Xia et al. 2003). MLLN also contains
AT-hook DNA-binding motifs, which bind preferentially to A-T rich kinks in DNA (Zeleznik-Le
et al. 1994). Menin, a tumour suppressor binds to MLLN allowing the interaction of LEDGF,
























Figure 1.2: The MLL Complex. Adapted from Slany (2009). Following translation, a
complex is formed from the proteolysis of the amino-terminal (MLLN) and carboxy-terminal
(MLLC). The following functional domains are highlighted in yellow: AT=AT hooks, CxxC
= motif recognizing unmethylated CpG di-nucleotides. PHD = plant homeodomain, SET =
histone methyltransferase active site. Histone acetyltransferase activity requires the cooperation
of MOF. Other associated proteins are described in the text.
1.3.6 Transcription Factors
In the bone marrow, myeloid differentiation is initiated by cytokine or growth factor signalling
produced mostly by stromal cells (Kleer et al. 2014). In peripheral tissues and blood, cytokines,
antigens and other external factors induce signalling cascades in the cell leading to terminal
differentiation (Geissmann et al. 2010). Cytokines are required to control lineage-instructive TF
expression (Mossadegh-Keller et al. 2013; Rieger et al. 2009). The transcription factors PU.1,
CEBPα and GATA1 have been shown to be required for myeloid differentiation (Laslo et al.
2006; Scott et al. 1994). Furthermore, reprogramming of cells or transdifferentiation induced
by transcription factors has been widely reported. For example PU.1 and CEBPα can cause
fibroblasts to transdifferentiate into macrophages (Feng et al. 2008). Furthermore, CEBPα can
transdifferentiate B cells into macrophages, the TF allows B-cells to acquire macrophage-specific
gene expression programs (Bussmann et al. 2009).
Transcription factors are of course also responsible for maintaining expression of
epigenetic modulators; HDAC7 which represses macrophage-specific genes is down-regulated by
CEBPα. Lineage specific TFs also control chromatin modifying enzyme recruitment, priming
chromatin for secondary TFs to bind which depend on external stimuli (Heinz et al. 2010;
Ostuni et al. 2013). Some of the suggested interactions between epigenetic regulators and TFs
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Figure 1.3: Epigenetic control of myeloid differentiation A) Adapted from Álvarez-
Errico et al. (2015). Yellow boxes highlight key TFs, blue boxes show DNA methylation enzymes,
HDACs in orange Histone Acetyl-Transferases (HATs) in blue. B) Adapted from Chen et al.
(2014), a BLUEPRINT project publication. This diagram depicts a riverplot, the thickness of
the lines represents the expression level of each of the key transcription factors.
32
1.3.7 Characterisation of the Epigenome in Haematopoiesis
In recent years numerous genome wide transcriptional and epigenetic sequencing experiments
have been conducted in haematopoietic cells to locate epigenetic modifications, TF binding sites
TF Binding Site (TFBS) and Long non-coding RNA (LncRNA) binding sites. There are several
initiatives which aim to provide next generation sequencing datasets which are easy to obtain
and apply to research in haematology and haemato-oncology.
The CODEX project aims to organise publicly available NGS data including histone
modification ChIP-Seq, DNase-Seq, which captures open chromatin profiles and RNA Sequencing
(RNA-Seq). These data are vetted as to be directly comparable no matter which laboratory they
were generated in. CODEX is split into two repositories, ESCODE for embryonic stem cells
and HEAMCODE for haematopoiesis (Sánchez-Castillo et al. 2014). The BLUEPRINT project
aims to generate more than 100 reference epigenomes, that is ChIP-Seq datasets using defined
human samples from both healthy and diseased individuals. At the top of their agenda are blood
disorders including autoimmune disease and common leukaemias (BLUEPRINT Consortium
2015). It can be seen from Chromatin Immunoprecipitation (ChIP) sequencing of key histone
marks that differentiation is facilitated by activation and inactivation of lineage specific enhancers
(Lara-Astiaso et al. 2014).
As it has often been discussed in this section, genetic changes causing epigenetic and
transcriptional dysregulation can lead to blocks in differentiation and expansion of progenitors
leading to haematopoietic malignancies including leukaemia. Development of drugs targeting
epigenetic modifications is a feasible and attractive pursuit as epigenetic regulation can be
reversed. Epigenetic marks can also be utilised as prognostic factors or biomarkers. Due to
the importance of precise transcriptional and epigenetic control in haematopoiesis, it comes as
little surprise that transcription factors and epigenetic modulators are frequently mutated in
leukaemia. In the next section, I will describe leukaemia, its subtypes and their causes with an
emphasis on epigenetic regulation.
1.4 Leukaemia and its Subtypes
Leukaemia, is a malignant disease indicated by an accelerated expansion of abnormal blood cells or
blasts that accumulate in the bone marrow and impede normal blood cell development. In general,
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leukaemia can be classified into four primary groups: CML, AML, CLL and ALL. Additionally,
other classifications of leukaemia arise from haematological malignancies of mixed linage or
ambiguous lineage such as mixed lineage leukaemia (not to be mistaken with the MLL protein) and
acute Biphenotypic Leukaemia (ABL). Chronic Myeloid Leukaemia (CML) and acute myeloid
leukaemia (AML) are myeloproliferative disorders, meaning that the disease presents with
abnormally high numbers of myeloid cells. In CML, abnormal mature cells accumulate in blood
and BM. In contrast, in AML the majority of abnormal myeloid growth in peripheral blood and
the BM is composed of immature myeloid blast cells. Chronic Lymphocytic Leukaemia (CLL) is an
accumulation of lymphocytes. Acute Lymphoblastic Leukaemia (ALL), the most prevalent cancer
in children, encompasses B-cell Acute Lymphoblastic Leukaemia/Lymphoma (B-ALL) and T cell
acute lymphoblastic leukaemia/lymphoma T-cell Acute Lymphoblastic Leukaemia/Lymphoma
(T-ALL). As the most common acute leukaemia in adults is AML, in this section I will focus on
AML.
Genetic abnormalities arise during the proliferation and differentiation of haematopoietic
stem cells and progenitors such as: mutations, chromosome copy alterations and translocations.
These abnormalities may cooperate to alter differentiation, cell death, proliferation and self-
renewal resulting in high amounts of abnormal progenitors in the peripheral blood, bone marrow
and infiltration of tissues characteristic of AML. Symptoms include anaemia, fatigue, bleeding,
and susceptibility to infection (Lowenberg et al. 1999). AML is a heterogeneous disease, therefore
it is critical for patients to be further classified prior to treatment (Grimwade et al. 2010).
Originally the French-American-British (FAB) system defined leukaemia as cases of
>30% blasts in the bone marrow, AML was then categorised using cell morphology and
cytochemistry (Bennett et al. 1976). More recently, that has been modified by the World Health
Organisation (WHO) (Vardiman et al. 2002). Now a minimum of 20% blasts in BM are
sufficient for AML diagnosis and stratification methods additionally utilise cytogenetics and
gene mutations (Vardiman et al. 2009; Vardiman et al. 2002). AML can also occur as a
secondary malignancy in patients with unrelated neoplasms. Alkylating agent treatment of
other cancers such as breast cancer, can stimulate AML (Leeuwen 1996). Moreover, AML can
evolve from other diseases of the blood such as Myelo-Dysplastic Syndrome (MDS), it was also
suggested that predisposition to AML can be promoted by germline polymorphisms involving
the CEBPα gene (Smith et al. 2004).
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M0 Undifferentiated acute myeloblasticleukaemia 5% Worse
M1 Acute myeloblastic leukaemia with minimalmaturation 15% Average
M2 Acute myeloblastic leukaemia withmaturation 25% Better
M3 Acute promyelocytic leukaemia 10% Best
M4 Acute myelomonocytic leukaemia 20% Average
M4 eos Acute myelomonocytic leukaemia witheosinophilia 5% Better
M5 Acute monocytic leukaemia 10% Average
M6 Acute erythroid leukaemia 5% Worse
M7 Acute megakaryoblastic leukaemia 5% Worse
Table 1.3: WHO classification of AML
Acute myeloid leukaemia with recurrent genetic abnormalities
• Acute myeloid leukaemia with t(8;21)(q22;q22), (AML1/ETO)
• Acute myeloid leukaemia with abnormal bone marrow eosinophils and inv(16) (p13q22) or
• Acute promyelocytic leukaemia with t(15;17)(q22;q12), (PML/RARα) and variants
• Acute myeloid leukaemia with 11q23 MLL abnormalities
Acute myeloid leukaemia with multilineage dysplasia
• Following MDS or MDS/MPD
• Without antecedent MDS or MDS/MPD, but with dysplasia in at least 50% of cells in 2 or
more myeloid lineages
Acute myeloid leukaemia and myelodysplastic syndromes, therapy related
• Alkylating agent/radiation-related type
• Topoisomerase II inhibitor-related type (some may be lymphoid)
Acute myeloid leukaemia, not otherwise categorized classify as:
• Acute myeloid leukaemia, minimally differentiated (M1)
• Acute myeloid leukaemia without maturation (M0)
• Acute myeloid leukaemia with maturation (M2)
• Acute myelomonocytic leukaemia (M4)
• Acute monoblastic/acute monocytic leukaemia (M5)
• Acute erythroid leukaemia (M6)
• Acute megakaryoblastic leukaemia (M7)
• Acute basophilic leukaemia
• Acute panmyelosis with myelofibrosis
• Myeloid sarcoma
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Whole genome sequencing studies revealed that AML has a much lower mutational
background compared to solid tumours (Cancer Genome Atlas Research Network et al. 2013).
The Cancer Genome Atlas analysed 200 AMLs consisting of each subtype represented in real-
world proportions. On average only 13 mutations were found in AML cells compared to healthy
somatic cells, this average dropped in those exhibiting fusion proteins. In contrast, solid tumours
average between 30 nonsynonymous mutations in breast cancers and 200 in lung cancer and
melanoma (Vogelstein et al. 2013).
Mutations in 23 genes were found to reoccur with statistical significance amongst the
200 AMLs, on average just 5 of these were present in each patient (Cancer Genome Atlas
Research Network et al. 2013). AML mutations can be grouped into: myeloid TFs, TF fusions,
tumour suppressors, signalling proteins, epigenetic modifiers, further highlighting the impact
of transcriptional and epigenetic dysregulation in disease development. Of note, cohesin and
spliceosome mutations are also recurrently identified in AML (Cancer Genome Atlas Research
Network et al. 2013).
Although these mutations are common in AML the prognostic impact in particular
in the case of the mutations in epigenetic modifiers is currently unknown. Of the 200, it was
found that 44% had mutations in genes involved in DNA methylation and 30% had mutations in
chromatin modification (Cancer Genome Atlas Research Network et al. 2013). In cancer, tumour
suppressors are often silenced via hypermethylation of local CpG islands (Sandoval and Esteller
2012). Mutations in DNMT3A occur frequently in AML and confer poor prognosis (Ley et al.
2010; Walter et al. 2011; Yan et al. 2011). Mutations in the gene TET2 are frequent in myeloid
leukaemia (Chan and Majeti 2013). Leukaemia, often myeloproliferative, occurs spontaneously
in TET2 KO mice (Butler and Dent 2013). Common to AML, IDH1 and IDH2 mutations are
mutually exclusive with TET2 mutations. The normal product of IDH1/2 is α-Ketoglutarate
(α-KG), mutated IDH1/2 produces 2-hydroxyglutarate instead. TET2 function is dependant on
α-KG therefore IDH mutations are functionally equivalent to nonsense mutations in TET2, thus
presenting a similar disease (Chan and Majeti 2013).
As mentioned earlier in subsection 1.3.1, normal myeloid differentiation requires DNA
demethylation, therefore mutations resulting in hypermethylation could lead to a block in
differentiation. On the other hand DNMT3A nonsense mutations also cause methylation,
therefore locus specific methylation is important. AML frequently harbours loss of function
mutations in the components comprising PRC2 such as EZH2. In striking contradiction, gain
of function mutations in EZH2 are reported in ALL (Butler and Dent 2013). Protein arginine
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N-methyltransferases (PRMTs) mono- or di-methylate arginine residues including on histones
and TFs, some of which are overexpressed in leukaemia (Greenblatt and Nimer 2014).
Myeloid differentiation was preferentially induced with PRMT4 knockdown in human
CD34+ cells and the Kasumi-1 leukaemia cell line suggesting that PRMT4 blocks myeloid
differentiation (Vu et al. 2013). Genetic lesions affecting KDMs of the Jumanji C family are also
involved in the initiation of leukaemia, for example; translocations leading to fusions between
NUP98 and JARID1A (KDM5A) exist in 10% of acute megakaryoblastic leukaemia (Rooij et al.
2013) and inactivating mutations of UTX are frequently present in AML and ALL (Mar et al.
2012).
The most informative standalone prognostic factor is considered to be cytogenetic
analysis (Mrózek et al. 1997). Interestingly, in more than one third of AML patients chromosomal
rearrangements can be identified and the majority involves Leukaemia Transcription Factors
(LATFs). Therefore understanding how aberrant LATF gene fusions function is imperative to
developing novel therapies treating this leukaemia. Among the most unfavourable chromosomal
genetic lesions are MLL (11q23) rearrangements (Slovak et al. 2000) and in the next section I
will describe common LATFs rearrangements with a focus on MLL-fusions.
1.5 Gene Fusions
Recurrent chromosomal translocations, more frequently in haematological cancer than in other
cancers, give rise to chimaeric fusion proteins. LATF fusions initiate the transformation of
HSCs and myeloid progenitors into AML stem cells. Remarkably, for those diagnosed with
AML, 25% of adults and 35% of children harbour 1 of 4 of the most recurring chromosomal
translocations: t(8;21) AML1-ETO, inv(16) CBFβ-MYH11, t(15:17) PML-RARα and 11q23
MLL-fusions (Doulatov et al. 2012).
Interestingly one of these translocations (11q23) directly involves the MLL gene with
epigenetic modifying functions, and all recurrent fusion proteins invariably recruit epigenetic
modifying proteins. Moreover, some of the less recurrent chromosomal translocations often involve
genes encoding epigenetic modifying functions such as translocations between the KATs MOZ or
MORF and the KATs CBP (Panagopoulos et al. 2001; Rozman et al. 2004) or KMT NSD1 that
fuses to NUP98, a nuclear pore protein (Rosati et al. 2002). Acute leukaemia harbouring mixed
lineage leukaemia MLL gene translocations has been described as a “prototypical epigenetically
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driven cancer” (Neff and Armstrong 2013). Of all haematological cancers, AML with 11q23
translocations is one of the poorest prognostic subtypes, in infants it is particularly severe with
3 year overall survival of 5% (Taki et al. 1996). MLL translocations occur in 5-10% of AML in
adults and children and 70% of childhood ALL (Neff and Armstrong 2013).
Intriguingly, more than 70 different MLL translocation partners have been identified
in AML patients (Broad Institute 2017; Slany 2009), however 85% of 11q23 translocation cases
involve only six of these, see Table 1.4. In an MLL fusion, the C-terminus of MLL including the
SET domain is invariably replaced by the fusion partner which is fused in frame immediately after
the CxxC domain. At least 4 mechanisms have been proposed for how MLL fusions deregulate
transcription in an MLL fusion partner dependant manner (Figure 1.4). These include: histone
H3K79 methylation by DOT1L recruitment, histone acetylation by CBP/p300, histone H4R3
methylation by PRMT1 recruitment and dimerisation of the MLL fusion transcriptional complex.
All MLL fusions activate the transcription of key downstream targets such as Hox genes (Zeisig
et al. 2004) as well as transcriptional programmes such as leukaemic stem cell maintenance
(Somervaille et al. 2009). As a result, these epigenetic and transcriptomic changes initiated by
MLL fusion proteins lead to leukaemic transformation.
Importantly, other molecules which are not direct targets of the MLL fusion
transcriptional complex such as CEBPα and β-catenin have been found to be critical in MLL
fusion transformation (Ohlsson et al. 2014; Wang et al. 2010a; Yeung et al. 2010), although the
mechanisms of their contribution is currently unknown. While a recent report revealed that
CEBPα dependent myeloid differentiation may be a prerequisite to MLL fusion mediated
transformation (Ye et al. 2015), no mechanistic insights into the role of β-catenin in MLL
transformation have been reported, highlighting the need for further dissection to uncover these
molecular mechanisms.
Table 1.4: The 6 most common MLL-fusion partners Adapted from Slany (2009).
Name Gene Alias Features
ENL MLLT1 Binds histone H3, assembles EAP elongation/chromatinmodification complex
AF9 MLLT3 ENL homolog, also found in EAP
AF4 AFF1/MLLT2 Founder of AF4 family, member of EAP
ELL Elongation factor, interacts with a protein related to AF4
AF10 MLLT10 Interacts with DOT1L histone methyltransferase
AF6 MLLT4 Dimerisation domain
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Leukaemia appears to be organised in a hierarchical structure similar to normal
haematopoiesis, with Leukaemia Stem Cells (LSCs) residing at the apex (Bonnet and Dick 1997;
Bonnet 2005), and like normal HSCs, possess ability to self-renew and give rise to differentiated
progeny. LSCs are thought to be the source of patient relapse after aggressive treatments and
developing drug resistance (Chan and Huntly 2008; Estrov 2009; Konopleva and Jordan 2011).
Therefore it is imperative to understand the properties of LSCs and potentially their origin to
facilitate direct treatments to them. In the next section I will describe the clinical relevance of













































































D dimerizationC histone H4 arginine methylation
A histone H3 lysine methylation, Pol II phosphorylation
Figure 1.4: Mechanisms of transcriptional regulation by MLL-fusions Adapted
from Slany (2009). A) Partners ENL and AF4 form the EAP complex. DOT1 provides
H3K79 methylation whilst pTEFb phosphorylates the C-terminus of RNApol II stimulating
transcriptional elongation. B) CBP and P300 can fuse to MLL and acetylate histones. C) The
adaptor SAM68 binds EEN in MLL-EEN and recruits PRMT1, the H4R3 methyltransferase. D)
Aberrant transcription is activated by unknown means when fusion dimerise via dimerisation
domains of the fusion partner.
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1.6 The Origin of Leukaemia Stem Cells
Most of what we know about Cancer Stem Cells (CSCs) is derived from experiments involving
both normal blood and leukaemia, this research was accelerated with the discovery of lineage
surface markers (Bonnet 2005). The first identification of CSCs was reported in 1997 when
sorted CD34+/CD38- but not CD34+/CD38+ AML cells induced leukaemia in recipient
immunodeficient mice possessing the Prkdcscid mutation, (known as NOD SCID or SCID mice);
this made AML the first malignancy to demonstrate proof of the cancer stem cell concept
(Bonnet and Dick 1997).
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Figure 1.5: Cell-of-origin and clonal evolution model of LSCs Adapted from Zeisig
et al. (2012). A stem cell or progenitor cell takes a genetic hit which transforms it into a
Pre-Leukaemic Stem Cell (Pre-LSC). A cooperating genetic event, likely a signalling protein,
establishes the LSC, this is the “two-hit hypothesis”. LSCs progeny can then go on to produce
subclones with advantageous mutations. After chemotherapy treatment, the bulk of the tumour,
LSC progeny die, however LSCs are allowed to proliferate. This means that after treatment, a
different clone may dominate.
CD34+CD38- AML cells are tolerant to drugs and provoke little immune response in
vitro (Costello et al. 2000) and also show high drug resistance levels when transplanted into mice
(Saito et al. 2010). Although CD34+CD38- frequency is a valuable prognostic factor at diagnosis
(Terwijn et al. 2014), it is important to note that also other fractions such as CD34+/CD38+
have recently been shown to contain LSC activity (Majeti and Weissman 2011). Moreover,
about 20% of AML constitutes of only CD34- cells (Taussig et al. 2010), thus the LSC activity
resides within CD34- AML cells in these patients. Feuring-Buske and Hogge (2001) identified
a population of cells enriched in both stem cells and CSCs “Side Population cell”, using flow
cytometry to measure expulsion of fluorescent Hoechst33342. Additional markers such as ALDH
activity as well as gene expression programs have been reported to identify HSCs and LSCs
(Eppert et al. 2011; Feller et al. 2013).
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Like HSCs, leukaemia stem cells LSCs have self-renewal capacity, their progeny are
short lived and undergo some level of differentiation. LSC progeny can go on to become subclone
neoplasms with other mutations resulting in a number of different clones in different proportions
making up the leukaemia Figure 1.5. Although LSCs share many properties with HSCs, the
origin of LSCs remains ambiguous. The transformative property of gene fusions provides an
opportunity to investigate the potential cell-of-origin in leukaemia and give insight into their
characteristics.
1.6.1 Retroviral Cell-of-Origin Models
Retroviral/lentiviral transduction and transformation assays Retroviral Transduction
and Transformation Assay (RTTA) (Zeisig and So 2009) revealed that oncogenic fusion proteins,
such as MLL fusions can transform haematopoietic stem/progenitor cells into immortalized so
called Pre-Leukaemic Stem Cells with unlimited self-renewal in vitro. Due to a significant increase
in latency between Pre-LSCs and secondary transplants, it is believed that Pre-LSCs acquire an
additional cooperating event to produce LSCs that can initiate leukaemia in mice (Figure 1.5),
such as FMS-like tyrosine kinase 3 (FLT3), internal tandem repeat mutations (FLT3-ITD). For
example, while MLL fusions were shown to transform murine HSC, CMP and GMP populations
to induce AML (Cozzio et al. 2003; Krivtsov et al. 2013; So et al. 2003), BCR-ABL was only able
to transform HSC but not GMPs (Huntly et al. 2004). Similarly, MOZ-TIF2 transformed HSC
and GMP, but MN1 only transformed CMP (Heuser et al. 2011; Huntly et al. 2004), suggesting
that multiple haematopoietic populations are susceptible to leukaemic transformation in an
oncogene/fusion gene dependent manner.
Whilst retroviral transduction models have been instrumental in the study of MLL
fusion leukaemia (Cozzio et al. 2003; So et al. 2003; Huntly et al. 2004; Krivtsov et al. 2013;
Heuser et al. 2011), the limitations of these models must be considered when interpreting these
data. Firstly, as the retrovirus promoter is much stronger than the endogenous MLL promoter
and the number of inserted copies is generally poorly controlled, retroviral transduction leads
to expression of the fusion which may be much greater than physiological levels. Moreover,
retroviral integration has the potential of introducing unintentional mutations by integrating
into gene bodies or aberrant expression of genes when inserting into enhancers or promoters.
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Curiously, genome wide studies have revealed that retroviruses preferentially insert
into actively transcribed regions as they are more available for insertion, in particular this has
been observed for the Murine Stem Cell Virus (MSCV) in haematopoietic cells (Aker et al.
2006). Indeed, exploiting this nature of retroviruses and more recently, transposons, lead to
the development of insertional mutagenesis models for oncogene discovery (Uren et al. 2005;
Rad et al. 2010). This is also a concern for gene therapy strategies utilising retroviruses (Baum
et al. 2003). Another caveat of the transduction process is that it allows selection for exceptional
cells in the population such as: contaminating cells from FACS impurity or particular mutants.
Finally, gamma-retrovirus integration is dependent on active proliferation, consequently quiescent
populations such as HSCs can’t be targeted without modification.
1.6.2 Knock-in Mouse Cell-of-Origin Models
Mouse models expressing MLL fusions have also been used to investigate LSC cell-of-
origin. In contrast to retroviral models, using a knock-in MLL-AF9 model Chen et al. (2008)
showed that under endogenous expression, GMPs were unable to produce leukaemia. On
further inspection, it was found that the expression of MLL-AF9 and its targets was higher in
HSCs than GMPs suggesting that dosage is critical for activation of Hox genes and subsequent
leukaemic transformation. Dox-inducible MLL-AF9 (Stavropoulou et al. 2016) and MLL-ENL
(Stavropoulou et al. 2018; Ugale et al. 2014) mouse models have also been used to investigate
cell-of-origin with varying results. Stavropoulou et al. (2016), showed that whilst expressing much
lower levels of the fusion, similarly to what is seen using retroviral models (Krivtsov et al. 2013),
Dox-inducible MLL-AF9 transformed HSCs produced a much more aggressive leukaemia than
GMPs. On the other hand, Ugale et al. (2014) showed Dox-inducible MLL-ENL transformation
was possible in a subpopulation of CMPs, known as precursor GMPs (pGMs) but not fully
defined GMPs and surprisingly, not HSCs. Similarly, the inducible Dox-inducible MLL-ENL
model developed by Stavropoulou et al. (2018) also showed that GMPs could not be transformed
by MLL-ENL. However, in contrast, the mouse model from Stavropoulou et al. (2018) resulted
in leukaemic transformation of HSCs.
To create a more physiological model Takacova et al. (2012) inserted MLL-ENL-ERtm
at the endogenous promoter. Intriguingly, activation of MLL-ENL with 4-OHT induced a
state of chronic stress activating DNA damage and inflammation responses forcing cells into a
somewhat quiescent state which could be reversed caffeine treatment. Earlier work using an
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in vivo MLL-ENL translocator mouse model (Forster et al. 2003), showed that MLL-ENL did
not produce a transplantable leukaemia. These studies show MLL-ENL associated leukaemia as
much less aggressive than retroviral models. As described in Figure 1.5, it is likely that MLL-ENL
transformed cells go on to acquire cooperating mutations which support leukaemogenesis and
disease maintenance. AML samples with MLL-fusions often harbour RAS mutations (Grossmann
et al. 2013). Retroviral models were used to show that RAS mutations cooperate with MLL
fusions to produce a more aggressive leukaemia (Zuber et al. 2009; Ng et al. 2014).
It remains unclear if cancers arising from different cells of origin inherit epigenetic
features of their cell-of-origin type allowing them to switch on different mechanisms of self
renewal, prevent differentiation and apoptosis. Critical self-renewal pathways in both HSCs
and LSCs include Hedgehog, Hox, polycomb/Mll, PTEN, telomerase, GSK3 and Wnt/β-catenin
(Copland et al. 2009). Indeed, MLL fusion expression increases Homeobox A9 Hoxa9, Myeloid
Ecotropic Viral Integration Site 1 Meis1 and β-catenin expression levels (Zeisig et al. 2004;
Balgobind et al. 2011), suggesting that these pathways may be utilized for MLL fusion mediated
transformation. Recent work from our lab and others show that β-catenin has an important
role development of MLL fusion LSCs (Yeung et al. 2010; Wang et al. 2010a; Gandillet et al.
2011; Siapati et al. 2011; Griffiths et al. 2010). Interestingly, while β-catenin is essential for other
adult stem cells it is dispensable for HSCs maintenance, suggesting that the role of β-catenin in
HSCs is different from other tissue stem cells (Cobas et al. 2004). The fact that β-catenin is not
essential in adult HSCs also makes it is an attractive target for therapy. Considering MLL as an
example of epigenetic disease and β-catenin as regulatory hub protein provides an opportunity to
explore cascade of molecular events leading to LSC formation. β-catenin dependent transcription
has been shown to be responsible for aberrant self-renewal in other cancers. First, we must
understand how β-catenin comes to regulate gene expression.
1.7 Wnt Signalling in Development and Disease
In humans, β-catenin is encoded by the gene Catenin Beta 1 (Ctnnb1 ) at chromosome 3 p21.
β-catenin has a dual function as a coordinator of cell adhesion and as the terminal effector of
Wnt signalling, activating gene expression (Barker and Clevers 2000; Brault et al. 2001). Wnt
signalling is essential in embryonic development, responsible for directing cell fate in tissue
morphogenesis, adult stem cells continue to utilise Wnt signalling for directing growth and
differentiation to maintain tissue homoeostasis and respond to damage (Holland et al. 2013).
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There are two categories of the Wnt pathway: canonical and non-canonical. In the
canonical Wnt pathway, Wnt signalling induces transcriptional activation dependent on β-catenin.
Therefore canonical Wnt signalling is referred to as Wnt/β-catenin signalling. Non-canonical
Wnt pathways act independently of β-catenin, these are split into two branches, categorised
by utilising either calcium (Wnt/Ca2+) or the c-Jun N-terminal kinase (Wnt/JNK) to initiate
signalling cascades (Lien and Fuchs 2014).
As Wnt/β-catenin signalling is so important for morphogenesis and control of cell
proliferation, inappropriate activation causes severe hereditary syndromes and malignancies
(Clevers 2006; Lien and Fuchs 2014). β-catenin deficient, mice die in utero due to failed mesoderm
and axis formation (Haegel et al. 1995; Huelsken et al. 2000). Conditional inactivation of β-
catenin further into development in mice produces lethal brain and craniofacial malformations
(Brault et al. 2001). Indeed there is substantial evidence regarding β-catenin’s roles in normal
and malignant haematopoiesis.
The basic pathway is described in Figure 1.6A. A large number of proteins which
interact with β-catenin directly or through multi-subunit complexes have been confirmed in
multiple animal model species (Brault et al. 2001), suggesting that Wnt targets are under
complex regulatory mechanisms. Co-activators of β-catenin often influence gene expression
through perturbation of chromatin conformation, some of these co-activators are illustrated
in Figure 1.6B. (Barker et al. 2001) showed that the chromatin remodelling enzymes of type
SWI/ SNF (SWItch/Sucrose Non-Fermentable) can be recruited by β-catenin, additionally
β-catenin mediated recruitment of the protein ISWI (imitation SWI) was shown by Song et al.
(2009). Furthermore, acetyl-transferases have shown to be recruited by β-catenin both acetylating
β-catenin itself and modifying surrounding histones, such as p300 (Lévy et al. 2004), CBP (Wolf
et al. 2002), and Tip60 (Kim et al. 2005).
Additional co-factors link enhancers via TFs to RNA pol II, through components of
the Mediator complex and the Paf1 complex (Carrera et al. 2008; Kim et al. 2006; Mosimann
et al. 2009; Parker et al. 2008). Intriguingly, it has been reported that β-catenin can recruit the
MLL1 complex to DNA (Sierra et al. 2006; Wend et al. 2013). Sierra et al. (2006) conducted
time-course ChIP quantitative PCR (ChIP-qPCR) at Wnt target genes to investigate β-catenin
mediated regulation of H3K4 trimethylation. Upon β-catenin stimulation, β-catenin was found
to be co-bound to the Myc enhancer with MLL2 along with SET1 subunits Ash2 and Menin
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Figure 1.6: Canonical Wnt signalling A) OFF: Groucho is bound to Wnt responsive
elements Wnt Responsive Elements (WREs) and recruits HDACs, repressing gene expression.
Destruction of the continuously transcribed effector protein β-catenin is carried out by the Axin
complex containing Axin, APC, GSK-3 and CKI. β-catenin is phosphorylated in the cytoplasm
firstly via GSK-3 followed by CKI, marking it for ubiquitination by b-Trcp and subsequent
degradation by the proteasome. APC and Axin act as tumour suppressors suppressing β-catenin,
mutations in these genes occur frequently in Familial Adenomatous Polyposis (FAP) and sporadic
colorectal cancers (Nishisho et al. 1991; Kinzler and Vogelstein 1996). In the nucleus, WREs are
bound by T cell factor/lymphoid enhancer factor TCF/LEF and recruit co-repressor Groucho
which recruits HDACs, repressing gene expression (Cavallo et al. 1998; Lien and Fuchs 2014).
ON: At the cell surface, Wnt ligand binds to the frizzled receptor (Fz) and its co-receptor
lipoprotein receptor related protein (LRP5/6). Subsequently Dishevelled (Dsh) disrupts the Axin
complex, β-catenin accumulates in the cytoplasm leading to nuclear translocation. β-catenin
competitively displaces Groucho and binds to TCF/LEF TFs via its armadillo domains to activate
gene expression (Daniels and Weis 2005; Behrens et al. 1996; Molenaar et al. 1996). β-catenin
recruits various cofactors which remodel chromatin for transcription. The lower portion of this
figure shows known co-factors of β-catenin which interact with the N-terminal or C-terminal
transactivation domains reviewed in Mosimann et al. (2009).
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While most studies using a mammalian system utilised epithelial or embryonic stem cells
(Mosimann et al. 2009), it is currently unclear if the described Wnt/β-catenin mechanisms are also
active in haematopoietic cells. Although β-catenin is not directly bound to chromatin, recently
gene expression regulation via β-catenin has been investigated genome wide using ChIP-Seq
on several occasions, mostly in human colorectal cancer cells (Bottomly et al. 2010; Schuijers
et al. 2014; Watanabe et al. 2014) and more recently in Embryonic Stem Cells (ESCs) (Estarás
et al. 2015; Funa et al. 2015). However, quality datasets have not been achieved in healthy
and malignant haematopoietic cells in human or mouse. It has been proposed that numerous
transcription factors tether β-catenin to DNA besides TCF/LEF (see Table 1.5). However,
Schuijers et al. (2014) suggested that β-catenin binding is exclusively determined by TCF/LEF
as both β-catenin bound regions with low and high levels of TCF4 binding were diminished when
a dominant negative form of TCF4 (DNTCF4) was expressed.
Table 1.5: TFs proposed to recruit β-catenin Adapted from Schuijers et al. (2014).
Protein Citation(s)
cJun Nateri et al. (2005)
ERα Kouzmenko et al. (2004)
Foxo1/4/3a Essers et al. (2005)
Hif1α Kaidi et al. (2007)
LRH-1 NR5A2 Botrugno et al. (2004)
Oct4 Kelly et al. (2011), Zhang et al. (2013)
Sox17 Sinner et al. (2004)
Indeed there is substantial evidence regarding β-catenin’s roles in normal and malignant
haematopoiesis. Wnt signalling was first found to have a role in haematopoiesis when Reya et al.
(2000) found proliferation of B lymphocyte progenitors was Wnt dependent by knocking out
the Wnt responsive TF Lymphoid Enhancer Binding Factor (Lef1 ) in mice. Thereafter it was
reported that expression of constitutively active β-catenin in HSCs lead to maintenance of an
immature state (Reya et al. 2003). Moreover Scheller et al. (2006) discovered that expression of
constitutively active β-catenin in HSCs leads to death due to bone marrow failure as HSCs were
unable to generate differentiated blood cells.
As one may expect, β-catenin has been implicated in AML (Simon et al. 2005). Although
activation of β-catenin impairs normal haematopoiesis, β-catenin loss on the other hand, has
46
been reported to have little effect on HSCs and haematopoiesis (Cobas et al. 2004). β-catenin
deletion in adult HSC does not affect self-renewal nor haematopoiesis as HSCs could give rise to
all normal haematopoietic cells (Cobas et al. 2004). Jeannet et al. (2008) further showed that
this is also true in long term studies. Although Zhao et al. (2007) showed that HSC maintenance
decreased upon serial transplantation of β-catenin deleted HSCs, these HSCs remained fully
functional. Moreover, β-catenin deletion in mature T cells revealed that memory T cell functions
were not affected and showed normal proliferation responses to lymphopenia or infection (Prlic
and Bevan 2011).
Because normal adult haematopoiesis does not require β-catenin, this makes it an
attractive target for therapy. To exploit its therapeutic potential, we have to understand Wnt/β-
catenin mechanisms in both normal as well as malignant haematopoiesis. Whilst dispensable for
HSCs, β-catenin is a critical element of MLL LSC maturation. In the following section I will
describe what is known about the role of β-catenin in LSCs, this work provides the foundation
and rationale behind this thesis.
1.7.1 The Role of β-catenin in Leukaemia Stem Cells
Our group and others have revealed β-catenin as a critical component in LSC
maintenance and drug resistance (Gandillet et al. 2011; Griffiths et al. 2010; Siapati et al. 2011;
Wang et al. 2010a; Yeung et al. 2010; Rathert et al. 2015; Fong et al. 2015). As previously
mentioned, aberrant β-catenin pathway regulation has been studied primarily in epithelial
cancers often harbouring mutations in either β-catenin or other proteins involved in the
destruction complex leading to increased β-catenin protein. On the other hand, mutations in
these genes are very rare in leukaemia, therefore β-catenin must be activated via alternative
mechanisms. Possible genetic mechanisms include FLT3-ITD mutations through tyrosine
phosphorylation of β-catenin promoting nuclear translocation (Kajiguchi et al. 2007). In the
absence of cooperating mutations, β-catenin activation can be promoted through extracellular
signalling the bone marrow niche (Lento et al. 2013). Cell-of-origin also plays a part in the
activation of β-catenin, HSCs have activated β-catenin compared with GMPs (Lento et al. 2013).
It was shown that MLL-AF9 can activate β-catenin in GMPs however HOXA9 MEIS1
transformed GMPs do not produce leukaemia unless constitutively active β-catenin is also
expressed (Wang et al. 2010a). Additionally it was demonstrated that β-catenin may be
specifically activated in MLL-AF9 cells though G protein-coupled receptor 84 (GPR84) and Gq
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protein alpha (Gaq) signalling (Lynch et al. 2016; Dietrich et al. 2014; Yi et al. 2013).
Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4 ) is highly overexpressed in
human MLL-fusion associated AML (Bagger et al. 2013). As R-spondin (Rspo)/Lgr4 signalling
has been demonstrated to be critically involved in Wnt/β-catenin signalling, Yi et al. (2013)
tested Rspo and Wnt proteins for their β-catenin activation capabilities in MLL-AF9 LSCs. A
combination of Rspo3 and Wnt3a were found to significantly increase β-catenin activation (Yi
et al. 2013).
Table 1.6: Wnt pathway components expressed in the bone marrow environment
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Increasing evidence has shown that reliance of LSCs on β-catenin is not universal,
but is dependent on disease phenotype, oncogenic mutations and cell-of-origin. Response to
β-catenin down-regulation was shown to be variable amongst primary patient samples (Gandillet
et al. 2011). The BCR-ABL fusion, product of the t(9;21) translocation, produces CML and
Philadelphia Chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). While the chronic
phase of CML is quite stable and disease development is slow, CML frequently transforms into
an acute leukaemia during blast crisis. It was shown that β-catenin deletion in BCR-ABL
transduced cells impaired CML formation in transplanted mice, however allowed ALL to develop
(Zhao et al. 2007). In this case β-catenin loss also resulted in higher latency of disease progression
and impaired self-renewal of CML stem cells, suggesting a potential differential requirement of
β-catenin in ALL and CML.
Imatinib, a drug which targets BCR-ABL, can achieve clinical remission in the chronic
phase of CML however relapse frequently occurs when treatment is ceased (Hu et al. 2009). It
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was found that whilst proliferating BCR-ABL-induced LSCs were sensitive to Imatinib, a subset
of drug resistant LSCs remains which rely critically on β-catenin (Heidel et al. 2012; Hu et al.
2009). In AML, it was found that LSC development from HSCs transformed by HoxA9 and Meis1
requires β-catenin. It was also found that MLL-AF9 transformed GMPs and HSCs required
β-catenin for self-renewal and in vivo disease development (Wang et al. 2010a). However, using a
compound β-catenin Loss Of Function (LOF) and KRAS Gain Of Function (GOF) mutant it
was found that β-catenin is no longer required for MLL-AF9 LSC development (Ng et al. 2014).
The Glycogen Synthase Kinase 3 family (GSK3), key components of the β-catenin
destruction complex (see the previous section 1.7), are often mutated in cancer leading to greater
levels of β-catenin (McCubrey et al. 2014). Seemingly paradoxically, treatment of MLL-fusion
associated with GSK3 inhibitors have demonstrated promising results (Wang et al. 2008; Banerji
et al. 2012; McCubrey et al. 2014). However, in addition being involved in the β-catenin
destruction complex, the GSK3 family are involved in self-renewal pathways central to AML such
Hoxa9/Meis1 (Wang et al. 2010b). As previously mentioned, our group reported that β-catenin
is activated during the development of LSC from MLL fusion transformed pre-LSCs. Moreover,
these LSCs displayed increased drug resistance to GSK3 inhibitors and could be re-sensitized by
β-catenin depletion (Yeung et al. 2010). More recently, in addition to GSK3 inhibitor resistance,
it has been demonstrated that β-catenin may contribute to acquisition of resistance to BET
inhibition (Rathert et al. 2015; Fong et al. 2015).
In addition to disease and genetics, we recently demonstrated that cell-of-origin can
dictate β-catenin requirement of LSCs (Siriboonpiputtana et al. 2017). Although GMPs express
only low levels of HoxA9 and β-catenin, they are both needed for transformation by MLL fusions.
HSCs express β-catenin and HoxA9 at higher levels than GMPs, however can still be transformed
without one of these. Biologically, while β-catenin deleted GMP-MLL-ENL did not produce
leukaemia in transplanted mice, MLL-ENL transformed LSKs did not require β-catenin for
LSC development. This result was in contrast with previous studies that showed β-catenin was
required for MLL-fusion associated leukaemia regardless of cell-of-origin (Wang et al. 2010a).
β-catenin cell-of-origin specific dependency was shown to be specific to MLL-ENL and was not
observed for other common MLL fusions (Siriboonpiputtana 2014; Siriboonpiputtana et al. 2017).
In the Siriboonpiputtana et al. (2017) study, KO of Hoxa9, one of the major targets of MLL-ENL
(Zeisig et al. 2004), was also detrimental to GMP-MLL-ENL LSC formation, but not to that of




The epi/genetic events initiating LSC development critically shape the biology, pathology and
response to therapy of AML. Learning from our group’s recent research and others, it appears
that β-catenin dependency in vivo varies with different LATFs and cell-of-origin. The role of
β-catenin in facilitating aberrant gene expression and cancer development has been studied
extensively in solid tumour malignancies. However, it remains unclear how β-catenin influences
transcription in leukaemia. Understanding the mechanisms by which β-catenin facilitates MLL
LSC development in distinct cells of origin may facilitate the design of rational, novel therapies
targeting the poor AML subgroup of MLL-fusion associated leukaemia.
The aims of this PhD thesis are as follows:
• To identify a global set of direct/ downstream target genes of β-catenin in origin specific MLL
transformed cells.
• To investigate the effects of β-catenin target expression perturbation




2.1 Production of β-catenin conditional pre-LSCs
In this section, I will describe the methods that were used to generate both previously published
cell-of-origin specific MLL-ENL transformed Pre-LSC cell lines (Siriboonpiputtana et al. 2017)
and additional cell lines I produced during this study.
2.1.1 β-catenin conditional mouse lines
To investigate the roles of β-catenin in haematopoietic cells transformed by MLL-ENL in vitro
referred to as Pre-LSCs we employed an animal model in which the gene encoding β-catenin,
catenin beta 1 (Ctnnb1 ), could be conditionally inactivated. The mouse model was created
by interbreeding mice harbouring an allele of Ctnnb1, with its critical exons (2-6) flanked by
LoxP (floxed) recombination sites and transgenic mice expressing Cre-recombinase fused an
oestrogen receptor (Cre-ER). In the absence of its ligand, the synthetic antagonist of oestrogen,
4-hydroxytamoxifen (4-OHT), Cre-ER is bound to heat shock protein-90 and confined to the
cytoplasm. 4-OHT bound Cre-ER translocates to the nucleus where Cre recognises LoxP
sequences and induces genetic recombination.
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Exons 2-6 of Ctnnb1 encode the N-terminal and 1-4 armadillo repeats, excision of these
by Cre-recombinase results in loss of function (LOF) of β-catenin. This mouse was originally
produced in the R.Kemler laboratory and is known as Ctnnb1Kem/flox (Brault et al. 2001), the
transgene and recombination product is illustrated in Figure 2.1A.
In addition to this, I also crossed mice harbouring an allele of Ctnnb1 with LoxP sites
flanking exon 3 alone, produced by M.M.Taketo’s laboratory, Ctnnb1Mmt/flox (Harada et al.
1999) with transgenic mice expressing Cre-ER. Exon 3 of Ctnnb1 encodes phosphorylation sites
which are targeted by GSK3β for ubiquitination and destruction of β-catenin. Thus, deletion of
exon 3 results in expression of a permanently active form of β-catenin which cannot be degraded
by the β-catenin destruction complex. Constitutively active β-catenin builds up in the cytoplasm
leading to subsequent nuclear translocation and target gene expression. The transgene and
recombination product of Ctnnb1Mmt/flox is illustrated in Figure 2.1B
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Figure 2.1: β-catenin conditional alleles. A. The Ctnnb1 Kem/flox LOF allele: In mouse
ESCs, a loxP site was inserted into the first intron and a neomycin-TK cassette was inserted
into the sixth intron of Ctnnb1. Prior to production of chimeric mice, transient Cre-recombinase
expression using a vector was used to remove the neomycin-TK cassette leaving exon 2-6 floxed.
B. The Ctnnb1 Mmt/flox GOF allele.
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2.1.2 Genotyping PCRs
To determine the genotype of mice, ear biopsies were taken, and DNA was extracted using
alkaline lysis buffer (25 mM NaOH; 0.2 mM EDTA) at 95°C for 20-60 minutes. After returning
to room temperature an equal volume of Neutralizing Buffer (40 mM Tris-HCl) was added
to samples. Once neutralised, the ear biopsy DNA is ready for genotyping Polymerase Chain
Reaction (PCR). The DNeasy Blood & Tissue Kit (QIAGEN, catalogue number 69581) was
used to extract DNA from in vitro cell lines and the liver, spleen, bone marrow and blood of
experimental mice.
Genotyping primer sequences for Ctnnb1 Kem/flox loss of function LOF were taken
from Brault et al. (2001) and are shown in Table 2.1. Primer sequences for Ctnnb1 Mmt/flox
GOF were taken from our collaborator and are shown in Table 2.2. To perform genomic PCR,
primers were ordered from Sigma. The PCR reaction mix was prepared with the appropriate
primers at 0.5 µM, 0.2 mM of mixed dNTPs (Roche), 2 µL 10 × DreamTaq™ Green buffer
(Fermentas), 0.5 µL of DreamTaq™ DNA Polymerase (Fermentas) and ddH20 up to 20 µL for
each reaction. PCR was performed using a thermocycler with the following program: 94°C for 5
minutes to denature dsDNA followed by 30 cycles at 94°C, 56°C then 72°C each for 30 seconds.
PCR products were separated by electrophoresis on a 1.5% agarose gel. Ctnnb1 Mmt/flox
genotyping PCR resulted in 3 possible discretely visible bands at 221 bp, 324 bp and 500 bp for
wildtype, floxed and deleted Ctnnb1 respectively. Two separate genotyping PCRs for Ctnnb1
Mmt/flox were used to distinguish the wildtype and mutant alleles detected as a single band at
around 100 bp.
Table 2.1: LOF Ctnnb1Kem/flox genotyping primers
Primer Sequence (5’ to 3’)
RM41 AAG GTA GAG TGA TGA AAG TTG TT
RM42 CAC CAT GTC CTC TGT CTA TTC
RM43 TAC ACT ATT GAA TCA CAG GGA CTT
Table 2.2: GOF Ctnnb1Mmt/flox genotyping primers
Primer Reaction Sequence (5’ to 3’)
WT Fwd Wildtype GCA AGA GCA AGT AGC TGG TAA AG
WT Rev Wildtype CCA GCC CTG TCA AGA AAC TTA ATG
Mutant Fwd Mutant CGT CCA GCC AAG CTT AGG AT
Mutant Rev Mutant CGG TGG CTT GCT GAT TAT TTC AC
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2.1.3 Haematopoietic stem cell and progenitor sorting
Bone marrow BM was harvested from mice with the appropriate genotype, and GMP and LSK
were Fluorescence-Activated Cell Sorted FACS as previously described (Yeung and So 2009).
Briefly, bone marrow cells were flushed from femur and tibias with Sorting Media (SM) containing
0.2% Foetal Bovine Serum (FBS), 1% Penicillin/ Streptomycin in 1× Phosphate-Buffered Saline
(PBS) and filtered through a 40 µm nylon cell strainer. Throughout the sorting process, cells
were kept on ice to preserve viability. To isolate white blood cells, cells were centrifuged at 1250
rpm for 5 minutes at room temperature and resuspended in 1 mL red cell lysis buffer (155 mM
NH4Cl, 12 mM NaHCO3 and 0.1 mM EDTA) and incubated for 10 minutes. The cells were
resuspended with SM to wash before centrifugation. Cells were counted with a haemocytometer
and a small aliquot of cells were taken to act as a negative control to aid in FACS compensation.
To increase the FACS efficiency and reduce machine processing time, BM samples
were depleted of lineage committed cells by magnetic bead selection. Cells were incubated in
0.5 mL SM per mouse harvested with 1:200 of unconjugated rat IgG antibodies targeting the
following lineage markers; Ter119, Mac1, gr1, CD3e, CD4, CD8 and B220 for 30 minutes at
4°C. After incubation cells were washed in SM, pelleted by centrifugation and resuspended in
SM. A small aliquot was taken at this stage to act as a positive control for lineage markers and
to monitor success of lineage depletion. 1 mL of sheep anti-rat IgG Dynabeads® (Invitrogen)
were prepared per 1×108 cells counted. Lineage-stained cells were washed and then transferred
to capped FACS tubes and incubated with prepared Dynabeads® for 30 minutes at 4°C on a
rotator to bind lineage positive cells. The cell and bead mix were then applied to a magnet, and
the supernatant enriched for lineage negative cells was collected. The beads were washed twice
to recover additional unbound cells, recovered cells were then washed and pelleted.
Lineage-depleted and the lineage positive aliquot were then incubated with secondary
antibody anti-rat-TR (Texas Red) 1:10 for 30 minutes at 4°C in darkness. After washing the
cells with SM, lineage depleted cells were incubated with rat IgG (Sigma) to block for 30 minutes
at 4°C. Lineage depleted BM was washed in SM and stained with c-kit-PE (1:100), sca1-PECy-
7(1:50), CD34-FITC(1:25), CD16/32-APC (1:75) for 30 minutes at 4°C in darkness. Following
incubation, cells were washed again and passed through a 40 µm cell strainer to avoid machine
blockage. Lineage positive and lineage depleted cells were resuspended in SM with 1 µg/mL
Propidium Iodide (PI) to detect dead cells.
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Finally, cells were sorted using a BD Aria cell sorter (BD biosciences, Oxford, U.K.) into
pre-warmed R20 (RPMI, 20% FBS and 1% Penicillin/Streptomycin). The LSK compartment
cells, which are enriched for HSCs were isolated by the immunophenotype Lin- c-Kit+ Sca-1+,
and myeloid progenitors GMP cells with Lin- c-Kit+ Sca-1- CD34+ CD16/32high/+. After
sorting up to 2 ×104 cells, these were resuspended in 250 µL R10 (RPMI with 10% FBS and
1% Penicillin/Streptomycin) with 20 ng/mL SCF, 10 ng/mL IL3 and 10 ng/mL IL6 added to
maintain stemness. Cells were seeded into 96 well plate and incubated at 5% CO2 and 37°C
overnight to recover.
2.1.4 Retroviral transduction and transformation assay
To create MLL-ENL transformed cell lines, cells were transduced with MLL-ENL expressing
retrovirus. The MLL-ENL fusion was previously cloned into Murine Stem Cell Virus (MSCV)
plasmids obtained from our clone database. RTTA was carried out as previously described
(Zeisig and So 2009).
Virus packaging
3×106 GP2-293 retrovirus packaging cells cells (Clonetech) were seeded in 8 mL of D10 (Dulbecco’s
Modified Eagle Medium (DMEM), 10% FBS, 1% penicillin and streptomycin) in 10cm plates
and were left to adhere overnight. The next day, transfection was either carried out using the
Calcium phosphate precipitation method or the polycation polyethylenimine (PEI) method.
Both methods work by facilitating DNA to bind to the cell surface which can then be taken up
by endocytosis. For Calcium phosphate precipitation, 15 µg of the construct was mixed with 8
µg pVSV-G, 61 µL of 2M CaCl2, and 500 µL 2×HBS. For PEI transfection, 8 µg of the construct
was mixed with 2 µg pVSV-G and diluted to 1 mL in culture media containing no serum. 30
µL PEI was added dropwise to the diluted DNA, the mixture was then mixed using a vortex
mixer immediately for 30 seconds and incubated for 15 minutes. Finally, the mixture was added
dropwise to the plates. 24 hours after transfection the media was aspirated and replaced with
fresh D10 to avoid plasmid and reagents from appearing in the virus collection.
Viral supernatants were collected 48h after transfection and filtered with a 0.45 µm
filter before concentration with the Optima™ L-100 XP Ultracentrifuge, Beckman Coulter at
25,000 rpm, 4° C for 3 hours and subsequently stored at -80°C. Virus collection was repeated at
72 hours post-transfection.
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Viral Transduction and Transformation
Approximately 150 µL of R10 was aspirated from the wells containing LSK and GMP sorted cells
leaving only 100 µL. 100-200 µL of concentrated virus, supplemented at a final concentration of
20 ng/mL SCF, 10 ng/mL of IL3, 10 ng/mL of IL6, and polybrene (10 mg/mL) was added to
each well. To increase contact between cells and viral particles and thus increase transduction
efficiency cells were centrifuged or “spinoculated” for 2 hours at 800 g and 32°C. 24 hours later
cells were plated in methylcellulose (MethoCult™ GF M3434) with 20 ng/mL SCF, 10 ng/mL of
IL3, IL6, penicillin, 100 µg/mL streptomycin. GM-CSF at 100IU/mL was also added prior to
plating to encourage cells to move towards the myeloid lineage. To isolate cells which had been
successfully infected with virus containing the MLL-ENL fusion, the media also contained the
appropriate antibiotic for which resistance gene was expressed by the construct 1.3 µg/mL and 1
µg/mL was used for Puromycin and Blasticidin respectively. Methylcellulose was dispensed into
a 24 well plate with a 18G blunt-end needle and unused wells were filled with water to increase
humidity inside the plate and prevent the media from drying out.
Colonies were allowed to grow a further 5-7 days and then their phenotypes were
scored. Colonies were extracted by dissolving methylcellulose in PBS and approximately 10,000
viable cells were replated in methylcellulose. After 3 rounds of plating, only cells with enhanced
self-renewal capacity form colonies, whereas non-transformed cells exhaust their proliferative
capacity in previous rounds of plating. Cell lines were established by growing 3rd round colonies
in R20/20 (RPMI1640, 20% FBS, 20% WEHI, 100U/ML penicillin and 100 µg/mL streptomycin).
WEHI is a conditioned media, a source of IL3 produced by culturing WEHI cells in RPMI before
harvesting and filtering. This resulted in MLL-ENL transformed immortal cell lines of LSK and
GMP with conditional deletion of β-catenin, which were used for all experiments in this study
(Ben-David et al. 2018).
2.1.5 In vivo Leukaemogenesis assay
Swiss Jim Lambert (SJL) mice or C57BL/6, also known as Black 6 mice were sub-lethally
irradiated with two rounds of 1100 rads. 5×105 - 1×106 Pre-LSCs or LSCs were prepared in
150 µL PBS per mouse for tail vein injection. Mice were monitored daily for loss of condition
(symptoms including, weight loss, hunched posture, flat laying ears, piloerection, reduced
movement and hind leg paralysis). Mice were euthanised upon signs of leukaemia development
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and peripheral blood, spleen, liver and bone marrow were processed for analysis. On first
inspection, leukaemic mice often present with enlarged spleen and liver (termed splenomegaly
and hepatomegaly respectively) and the bone marrow appears pale alluding to high concentrations
of myeloid (white) cells. Depending on progression of the disease, infiltration of leukaemic cells
may be visible in the liver as white spots and the blood may appear anaemic (low red blood cell
count). Invariably, leukaemia is identified if there are donor cells in the bone marrow, identified
by FACS, distinguishable from the recipient cells with CD45 markers. Additionally, cells were
stained for c-Kit (D7 clone), Mac-1 (M1/70 clone) and, Gr-1 (RB6-8C5 clone) to confirm myeloid
disease.
2.2 Cell Culture and Ctnnb1 Knock-out
The previously prepared cell lines were retrieved from stock in the cryogenic storage, with two
biological replicates taken each for GMP and LSK MLL-ENL transformed cell lines. Cells were
briefly rinsed with RPMI (Sigma-Aldrich), span down and then grown in R20/20 media, and
cell viability was assessed after 24 hours. Each cell line was treated with Density Gradient
Centrifugation (Ficoll 400, Sigma Aldrich) to remove dead cells. These cells were allowed to
recuperate for 48 hours and cell viability was assessed again. When the viability reached above
90%, cells were harvested and frozen for future use. Approximately 200 million cells were grown
between two T175 flasks for each condition in R20/20 media with 0.25 × cytokines SCF GM-SCF,
IL6 and IL3 at 5% CO2.
To introduce the β-catenin deletion for the selected cell lines, cells were treated with
20 nM 4-Hydroxytamoxifen (4-OHT) in ethanol suspension (deletion) or 0.1% total ethanol
(control) for 72 hours. Media were replenished including appropriate concentrations of drug or
vehicle as the acidity indicator in the media began to turn yellow. Cells were checked daily for
viability using a haemocytometer and Gibco™ trypan blue (Thermo Fisher Scientific), and were
discarded if viability declined below 80%. To prepare the cells for extracting RNA, DNA and
protein, aliquots of 2-4 million cells were pelleted at 1300 rpm and snap-frozen at -80°C. The
remaining cells were harvested for formaldehyde fixation and subsequent ChIP experiments. This
procedure guaranteed that ChIP, RNA and DNA sequencing had been performed on exactly the
same cells under the same conditions. This approach facilitates meaningful comparisons across
the different types of data. A schematic of the experimental set-up is illustrated in Figure 2.2.
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2.3 Quantitative Reverse Transcriptase Polymerase Chain
Reaction (RT-qPCR)
RNA was extracted with mirVana miRNA Isolation Kit™ (ThermoFisher Scientific, catalogue
number AM1560) or the RNEasy kit (Qiagen). cDNA was produced for each sample by adding
1 µg of template RNA to 1 µL oligo dT 100 µM and 1 µL 10 mM dNTPs. The mixture was
incubated for five minutes at 65°C and then on ice for one minute. The first strand buffer was
added in combination with 0.1M DDT, 1 µL RNAse out and 1 µL SuperScript™ III Reverse
Transcriptase (Thermo Fisher). This mixture was then placed in a thermocycler with the
following program: 25°C for 5 min 50°C for 60 min and 70°C for 15 min. Previously designed
Reverse Transcriptase quantitative PCR (RT-qPCR) primers were used (Brault et al. 2001) and
can be found in Table 2.3.
Table 2.3: RT-qPCR primers











Cyclin D1 Forward AAGTGCGTGCAGAAGGAGAT
Cyclin D1 Reverse TTAGAGGCCACGAACATGC
2.4 Western Blot
Protein was extracted from frozen cell pellets in 100 µL sample buffer per 1× 106 cells. Samples
were placed at 95°C for 5 minutes. 20 µL of each protein sample and 10 µL of protein ladder
were ran on 2-20% SDS polyacrylamide gels at 150 V for 90 minutes. Protein was transferred to
nitrocellulose membrane (Amersham™ Hybond™ ECL) at 100 V for one hour. The membrane
was blocked with PBS with 2% milk and 0.1% tween for one hour at room temperature. 1 in 2,000
dilution of mouse anti-β-catenin antibody (Purified Mouse Anti-β-catenin Clone 14/Beta-Catenin,
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BD Transduction Laboratories™) overnight at 4°C. It was washed with PBS-T (5 minutes, 4
times) and incubated with secondary antibody or β-actin antibody conjugated with HRP (Actin
(I-19; SC-1616) HRP, Santa Cruz Biotechnology) for one hour at room temperature. Then the
membrane was washed with PBS-T (5 minutes, 4 times). Chemiluminescent signal was detected
by using ECL Western Blotting Detection System (Amersham™, GE Healthcare, UK). Signals
were developed on X-Ray film (Amersham Hyperfilm™, ECL).
2.5 RNA-Sequencing (RNA-Seq) and analysis
2.5.1 A note on experimental design
Differential gene expression analysis aims to uncover statistically significant differences in mRNA
levels between conditions of interest. Statistical hypothesis testing allows us to formally reject
the null hypothesis, if assuming the null hypothesis is correct and the data approximately fits a
known distribution, the probability (P.value) of obtaining the observed data is very low.
However, the likelihood of exceptional data increases as more hypotheses are tested,
this is known as the “multiple testing problem”. To mitigate this, mathematicians have developed
multiple test correction methods such as the Bonferroni correction. The correction is applied by
testing each hypothesis at the desired P.value needed to convincingly reject the null hypothesis
(often 0.05 as proposed by R.A. Fischer in the 1920’s), divided by the total number of hypotheses
tested. Nevertheless, high-throughput technologies such as RNA-Seq present an additional
hurdle as the Bonferroni correction is found to be too stringent when a large number of
variables/hypotheses are tested (many thousands of genes). Furthermore, false discovery rate
methods such as the Benjamini Hochberg (BH) method were developed (Benjamini and Hochberg
1995) and are used by popular differential expression analysis software such as EdgeR (Robinson
et al. 2010) and DESeq2 (Love et al. 2014).
To determine if a gene is significantly differentially expressed, like any other statistical
comparison, we rely on being able to reliably estimate the variability across multiple observations.
Making up this variability is both technical; due to samples processing, sequencing and biological:
natural variability existing in the population and in response to treatment. In RNA-Seq, technical
variance is generally very low compared to the biological variance if experiments are carefully
controlled.
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Biological variance comes from both the stochastic character of gene expression itself
and differences in expression between individuals of the same group. Reducing confounding
biological variability can be done where possible by using organisms of the same sex, age and
litter at the same time. However, as long as there is a record of potential confounding factors, we
may remove some of this during analysis by modelling for known sources of variation. Too much
variability can reduce our ability to detect differential gene expression caused by the experimental
condition we are interested in.
Biological replicates can be defined depending on the inference to be made by the
biological question. To allow us to make generalisations about the effect of a treatment in a
particular cell line, biological replicates can be made by processing and treating the same cell line
separately. However, if we want to make a generalisation about an experimental condition in a
variable population, such as MLL-ENL transformed pre-LSCs, biological replicates from different
individuals and are more appropriate. Separate sorting and transduction of biological replicates
also encapsulates biological variation introduced by the sorting and MLL-ENL transformation
process.
2.5.2 RNA-Seq Libraries
RNA was extracted using the mirVana miRNA Isolation Kit™ (ThermoFisher Scientific, catalogue
number AM1560). Importantly, this RNA extraction kit retains micro RNAs. RNA concentration
was measured, and purity was assessed using NanoDrop 8000 (Thermo Fisher Scientific). The
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) was used to measure
RNA integrity (RIN), all RIN scores were determined to be between 9 and 10. The TruSeq
Stranded Total RNA kit with RiboZero Gold (Illumina, Inc., catalogue number RS-122- 2201)
was used to produce the library according to manufacturer’s protocol. Appropriate size selection
was confirmed using Agilent 2100 Bioanalyzer DNA high sensitivity chip (Agilent Technologies,
catalogue number 5067-4626). The final library concentrations were measured using Qubit®
dsDNA HS Assay Kit (ThermoFisher Scientific, catalogue number Q32854) and lanes were
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Figure 2.2: Schematic of experimental set-up In this schematic, the experimental set-up
of the previous work and currently performed work are described. Firstly, bone marrow was
extracted from Ctnnb1fl/fl mice, LSKs and GMPs were sorted by flow cytometry. GMPs and
LSKs were spinoculated with MSCV expressing MLL-ENL and puromycin resistance. The
transduced cells were then grown in methylcellulose containing puromycin. The resulting colonies
were extracted and re-plated two times. The third round colonies were grown in R20/20 in the
presence of cytokines to establish the cell line. Cells were grown in the presence of either tamoxifen
4-OHT or Ethanol (ETOH) for 72 hours. Previously, Ctnnb1fl/fl and Ctnnb1 -/- Pre-LSCs were
transplanted into recipient mice to monitor disease progression. For ChIP experiments, the cells
were massively expanded in T175 culture flasks before treatment. A small number of cells were
aliquoted for RNA, DNA and protein extraction. The remaining cells, approximately 200 million
per experiment, were fixed in 1% formaldehyde, aliquoted and frozen for ChIP.
2.5.3 RNA-Seq Processing
In this section I provide details of the initial processing pipeline for RNA-Seq, further details
are provided in subsection 3.2.3. Initially, quality checking of raw reads was performed using
the software FASTQC v0.11.4 (Andrews 2015), and reads were trimmed for adapters and low
quality bases using Trim Galore! v0.4.0 (Krueger 2015). Trimmed reads were then mapped
to the mouse reference genome version GRCm38 (obtained from the Ensembl FTP server
ftp://ftp.ensembl.org/pub/) using the short read mapper Tophat2 v2.1.0 (Kim et al. 2013).
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The GRCm38 genome assembly uses the same scaffold as UCSC’s mm10 however they
are each based on GENCODE and RefSeq annotation respectively. Notably, when compared,
GENCODE transcripts have more exons and therefore describe more gene variants than RefSeq
(Frankish et al. 2015). Picard tools MarkDuplicates and CollectRnaSeqMetrics v2.0.1 (Broad
Institute 2017) were used to mark duplicates and obtain other RNA-Seq mapping statistics.
Read counts per gene were obtained using htseq-count v0.11.1 (Anders et al. 2015) using union
mode and the “strandedness” option set as reverse.
2.6 Gadd45a overexpression
Mouse Gadd45a (NM007836) open reading frame (ORF) clone tagged with DYKDDDDK was
purchased from GenScript (Catalog No: OMu16639D). To express Gadd45a stably in MLL
transformed leukaemic cells, the ORF was cloned into MSCV retroviral expression vectors.
Firstly, the Gadd45a plasmid was PCR-ed with Easy-A High-Fidelity PCR Cloning Enzyme
(Agilent) to introduce the appropriate restriction enzyme sites as shown in Table 2.4. I designed
primers against the Open Reading Frame (ORF) and added restriction enzyme site sequences
(GAATTC for EcoRI and CTCGAG for XhoI) on each end creating “sticky ends” for ligation.
To increase efficiency of restriction cutting “AATT” was also added prior to each restriction
site. PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) following
manufacturers instructions.
Table 2.4: Primers to amplify Gadd45a ORF and add restriction sites






Briefly, MSCV plasmids with the appropriate antibiotic resistance gene were cut with
restriction enzymes (FastDigest, ThermoFisher Scientific) at 37°C for 20 minutes. The digested
plasmid was run on a 0.8% agarose gel. The linearised plasmid was cut out of the gel with a
clean scalpel and purified using the QIAquick Gel Extraction Kit (Qiagen). The Gadd45a PCR
product and the linearised plasmid were then ligated overnight at 16°C with T4 ligase (NEB).
Competent DH5 alpha cells were transformed with the ligation product and spread onto LB agar
plates containing ampicillin. Several single clones were picked and grown in 5 mL LB media at
37°C overnight. DNA was extracted from 4 mL of each clone with the QIAPrep Miniprep Kit
and digested with the appropriate enzymes.
The digestion products were run on a 0.8% agarose gel to pick promising clones for
sanger sequencing. The remaining cultures which perfectly sequence matched the ORF in the
correct orientation were used to prepare the plasmid for virus production with the QIAPrep
Maxiprep Kit (Qiagen). Retroviral particles were produced as described in section 2.1.4, using
the PEI method. Approximately 3-5 million cells were seeded into a 6 well plate and resuspended
with viral supernatant and polybrene at a final concentration of 4 µM. Cells were spinoculated
for 2 hours at 800 g and 32°C. The next day, the viral supernatant was removed and replaced
with fresh R2020 supplemented with cytokines. 48 hours after spinoculation, cells were treated
with the appropriate antibiotic in vitro. 72 hours after selection, viable cells were collected for
RNA and protein, 5000 cells were plated in methylcellulose and cells were taken for MTT assay,
cytospin and RT-qPCR.
2.7 Gadd45a knockdown
Short Hairpin RNA (shRNA) sequences against Gadd45a were generated using Sigma’s online
tool and the top 3 predictions were selected. Sequences were added to either end of the oligos to
allow for cloning into the pLKO lentivirus backbone (Stewart et al. 2003), the resulting sequences
were ordered from sigma and are shown in Table 2.5.
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Table 2.5: Gadd45a shRNA Sequences
shRNA
name Primer name Sequence
sh 1 NM_007836.1-575s1c1_Gadd45a_F
CCG GCC TGC CTT AAG TCA ACT TAT TCT CGA
GAA TAA GTT GAC TTA AGG CAG GTT TTT G
sh 1 NM_007836.1-575s1c1_Gadd45a_R
AAT TCA AAA ACC TGC CTT AAG TCA ACT TAT
TCT CGA GAA TAA GTT GAC TTA AGG CAG G
sh 2 NM_007836.1-251s1c1_Gadd45a_F
CCG GGC TCG GAG TCA GCG CAC CAT TCT CGA
GAA TGG TGC GCT GAC TCC GAG CTT TTT G
sh 2 NM_007836.1-251s1c1_Gadd45a_R
AAT TCA AAA AGC TCG GAG TCA GCG CAC CAT
TCT CGA GAA TGG TGC GCT GAC TCC GAG C
sh 3 NM_007836.1-550s1c10_Gadd45a_F
CCG GCC CAC ATT CAT CAC AAT GGA ACT CGA
GTT CCA TTG TGA TGA ATG TGG GTT TTT G
sh 3 NM_007836.1-550s1c10_Gadd45a_R
AAT TCA AAA ACC CAC ATT CAT CAC AAT GGA
ACT CGA GTT CCA TTG TGA TGA ATG TGG G
The first step in the shRNA cloning process was to anneal the oligos to form double
stranded DNA. Oligos were resuspended in double distilled water (ddH2O) at 20 µM and then
5 µL of each oligo were combined with 5 µL of 10×NEB buffer. ddH2O was added for a total
volume of 50 µL and the mixture was denatured at 95°C for 4 minutes. Oligos were incubated
at 70°C for 10 minutes and then allowed to cool to room temperature by slowly reducing the
temperature to facilitate annealing.
The pLKO vector was digested by both BshTI and EcoRI restriction enzymes
(FastDigest, ThermoFisher Scientific) for 30 minutes at 37°C. The digested plasmid was run on a
0.8% agarose gel. The linearised plasmid (7 kb) was cut out of the gel with a clean scalpel and
purified using the QIAquick Gel Extraction Kit (Qiagen). The concentration of the digested
vector was measured using the NanoDrop™ 2000 (Thermofisher Scientific). 2 µL of annealed
oligo, 20 ng digested pLKO, 0.5 µL T4 DNA ligase (NEB) and 2 µL 10× NEB T4 DNA ligase
buffer was combined and the final volume was brought to 20 µL with ddH2O. The ligation
reaction was incubated at 16°C for overnight. Competent DH5 alpha cells were transformed
with 2 µL ligation mix and spread onto Lysogeny Broth (LB) agar plates containing 100 µg/mL
Ampicillin. 4 clones were picked and grown in 5 mL LB media at 37°C overnight. DNA was
extracted from 4 mL of each clone with the QIAPrep Miniprep Kit (Qiagen) and was sent for
Sanger sequencing. The remaining cultures with perfectly matched sequences of the shRNA in
the correct orientation were used to prepare the plasmid for virus production with the QIAPrep
Maxiprep Kit (Qiagen).
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Lentiviral particles were produced using the Polyethyleneimine (PEI) method, similarly
to retroviral production in section 2.1.4, however non-GP2 expressing Hek293 cells were used
for packaging and lentiviral packaging plasmids were used. β-catenin conditional cells were
transduced with lentiviral particles expressing the 3 shRNAs. RNA was collected for RT-qPCR
to check knock down efficiency prior to cre mediated excision of β-catenin. The shRNA which
showed the greatest reduction in mRNA was used in further experiments.
2.7.1 MTT assay
Cellular metabolic activity can be reliably investigated by measuring the metabolic reduction of
tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide). Clear yellow
MTT when reduced by cellular dehydrogenases is converted into purple formazan. This colour
change can be measured using a spectrophotometric reader and is linearly related to active cell
numbers. After seeding equal cell numbers in equal volumes of media for at least 24 hours and
avoiding confluency above 80%, 100 µL of culture was aliquoted in triplicate into a 96 well plate.
100 µL of MTT reagent (CT01-5 Sigma-Aldrich), was added to cells and placed back in the
incubator for 1-3 hours before measuring spectrophotometric signal. 100 µL of fresh media was
used as a background control to normalize the absorbance values.
2.7.2 Cytospin
To examine the morphology of cells, I resuspended 10,000-20,000 cells in 200 µL PBS and
centrifuged them at 300 rpm for 5 minutes onto microscope slides using a Cytospin™ 4
Cytocentrifuge (Thermo Scientific™). In order to distinguish nuclei from the cytoplasm I
stained the slides with the May-Grünwald stain (Sigma Aldrich) for 3 minutes. After rinsing the
slides in water, I proceeded to stain the slides with Giemsa stain (1:20, Sigma Aldrich) for 20
minutes. Following a final wash with water and briefly drying, slides were examined under a
microscope and photographs were taken.
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2.7.3 Annexin Staining
Approximately 1 × 106 cells were washed in ice cold PBS twice and resuspended in 1 mL of 1×
Binding Buffer (BD Biosciences). 100 µL of cell suspension was transferred to a FACSs tube, 2
µL Propidium Iodide (PI) was added to the cells and the mixture was left to incubate at room
temperature for 15 minutes in the dark. After incubating, cells were washed in 1 mL 1× Binding
Buffer. 0.5 µg Streptavidin-Fluorescein Isothiocynate (SAv-FITC, Cat. No. 554060) was diluted
in 100 µL 1× Binding Buffer and added to the cells. Cells were incubated in the dark for another
15 minutes. After incubation, FACS tubes were topped up to 400 µL with 1× Binding Buffer
and analysed by FACS.
2.8 Chromatin Immunoprecipitation coupled to
high-throughput sequencing (ChIP-Seq) Generation
To uncover the chromatin configuration in cells with or without β-catenin present, I conducted
ChIP-Seq of cells treated with antibodies against histone marks indicating open chromatin:
H3K4me1, H3K4me3, and H3K27ac or associated with repressed chromatin: H3K27me3. An
outline of the ChIP-Seq methodology is illustrated in Figure 2.3. Previously prepared cell cultures
(section 2.2) were subjected to fixation at 1% formaldehyde for 10 minutes at room temperature.
The cross linking reaction was quenched using 0.25M Glycine for 2 minutes at room temperature.
Cells were rinsed in ice cold PBS, aliquoted and snap-frozen at -80°C. ChIP was then carried out
as described below using an optimised protocol derived from the Agilent and Upstate protocol for
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Figure 2.3: ChIP-Sequencing Schematic A) The histone octamer. Each histone protein
has a tail in which amino acids, such as lysine at position 27 or 4, may be covalently modified
for example by addition of an acetyl or methyl group. B) Schematic of ChIP-Seq method: 1.
Firstly, cells are subjected to fixation with formaldehyde or another cross-linking agent. This
permanently links bound proteins such as histones or transcription factors to the DNA molecule.
Theoretically, cross-linking should also fix factors bound to transcription factors, however often
cells are often subjected to several fixation agents to increase likelihood of this. 2. Next, cell
lysate is subjected to mechanical shearing by sonication. This may also be done enzymatically. 3.
Immunoprecipitation: Specific antibodies bound by magnetic beads are incubated with sheared
cross-linked chromatin. Exposed epitopes bind to specific antibodies. DNA crosslinked to the
protein of interest are separated from the solution with a magnet. Unbound DNA is removed by
washing the beads. 4. Following immunoprecipitation, chromatin is de-cross-linked and purified.
5. Library preparation: Adapters are ligated to the DNA and the library is amplified, sequenced
and analysed for signal enrichment.
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Table 2.6: ChIP Lysis Buffers
Lysis Buffer 1 Lysis Buffer 2 Lysis Buffer 3
50 mM Hepes (pH 7.5) 200 mM NaCl 1 mM EDTA (pH 8)
140 mM NaCl 1 mM EDTA (pH 8) 0.5 mM EGTA (pH 8)
1 mM EDTA (pH 8) 0.5 mM EGTA (pH 8) 10 mM Tris-HCL (pH 8)
10% Glycerol 10 mM Tris-HCL (pH 8) 100 mM NaCl
0.75% Triton X-100 0.1% Na-Deoxycholate
0.25% NP-40 0.5% N-Lauroylsarcosine
Table 2.7: ChIP Wash Buffers
Low Salt Wash High Salt Wash LiCl Wash TE Wash
0.1% SDS 0.1% SDS 250 mM LiCl 1 mM EDTA
1% Triton X-100 1% Triton X-100 1% NP 40 10 mM Tris (pH 8)
2 mM EDTA 2 mM EDTA 1% Sodium Deoxycholate
20 mM Tris-HCL (pH 8) 20 mM Tris-HCL (pH 8)
150 mM NaCl 500 mM NaCl
The ChIP-Seq protocol is initiated by a series of lysis steps, aiming to isolate the cell
nuclei, and then break up the chromatin so that it is accessible to the antibodies; cells from the
previously frozen cell pellets were resuspended in Lysis Buffer 1 (Table 2.6) and were mixed at
4°C for 60 minutes. Cells were centrifuged at 1350 g for 5 minutes and resuspended in Lysis
Buffer 2 (Table 2.6), then mixed on a rotating platform for 20 minutes. Cells were pelleted again
at 1350 g and resuspended in Lysis Buffer 3 (Table 2.6) containing 2% SDS and mixed for 60
minutes. The nuclear fraction was then sonicated using the Bioruptor® Pico sonication device
from Diagenode for 10 cycles (30 seconds on/off). The sonicated chromatin was span at 17900
rpm with 1% Triton-X-100 to pellet remaining cell debris.
For histone modification ChIP, 3 µg of histone antibody and 15 µL of Protein G
Dynabeads® (Invitrogen) was used per 5 million cells. 15 µL of Protein G Dynabeads® were
blocked with 0.5% BSA and 1× protease inhibitor cocktail. Antibodies used were Anti-Histone
H3 (mono methyl K4) antibody (abcam cat no. ab8895), Anti-Histone H3 (tri methyl K4)
antibody (abcam cat no. ab8580), Anti-Histone H3 (tri methyl 27) antibody (Merck Millipore
07-449) and Anti-Histone H3 (acetyl K27) antibody (abcam cat no. ab4729) (abcam, Cambridge,
UK). Antibody was incubated with beads on a rotational wheel with beads for 4-12 hours at
4°C. Approximately 5-10 million fixed cells were used for each histone ChIP.
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50 µL Protein G magnetic beads per 10 million cells of sonicated supernatant were
blocked with 0.5% BSA. Beads were coupled with chromatin for 60 minutes to “pre-clear”
chromatin of DNA which non-specifically binds to the beads. To act as quantitative control for
both ChIP-qPCR and next generation sequencing, a small fraction (5-10%) of chromatin was
taken from each sonication at this point and elution buffer was added and left at 65°C for 12
hours for reverse cross-linking. Whilst sonication causes DNA to fragment in a mostly randomised
fashion, there is a slight bias towards breakage at open chromatin. This fragmentation bias,
depending on the chromatin confirmation of the cells and the method of fixation and sonication,
can cause false enrichment at open chromatin in ChIP-Seq. We can compensate for this bias by
sequencing input DNA from each condition to facilitate enrichment cut-offs used in subsequent
data analysis.
Remaining chromatin was added to the antibody conjugated beads for at least 12 hours
at 4°C. To remove low affinity binding chromatin from the ChIP sample, chromatin and beads
were washed sequentially for 10 minutes on a magnetic stand with the wash buffers listed in
Table 2.7 the first wash,“Low Salt Wash” was repeated twice. Chromatin was then eluted and
reverse cross-linked as the input sample was. Any remaining RNA from the input or ChIP
sample was removed from the DNA by incubating it in 0.2 µg/mL RNAse for one hour at 37°C
and 0.2 µg/mL Protease K for at least 2 hours at 55°C. QIAquick PCR purification (Qiagen)
was performed on all sample ChIP DNA.
2.8.1 ChIP q-PCR
Percentage input, the proportion of total input DNA pulled down by the ChIP assay, was
calculated using the ΔCt method. The first step of the ΔCt method is to calculate the average
Ct value for the ChIP-ed DNA and a known fraction of the total input DNA. As input samples
represent just 5% of the whole DNA input in the ChIP assay, the next step of the calculation is
to adjust the Ct value obtained for the input to 100%. Assuming the input fraction and ChIP
DNA are eluted in the same volume, we do this by subtracting the logarithm base 2 of the
dilution factor from the average Ct value, in this case the dilution factor for 5% is 20. Next,
the average Ct value for the ChIP DNA is subtracted from the adjusted input Ct to get ΔCt.
Finally, we calculate 2 to the power of ΔCt and multiply this by 100 to get the percentage input.
Primers used for ChIP-qPCR are listed in Table 2.8.
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Table 2.8: ChIP-qPCR primers
Primer Orientation Sequence (5’ to 3’)
Meis1 TSS Forward GCGTCGCTGAGCATAAAAGC
Meis1 TSS Reverse CCTCCCACTGCTGTCTTGGT
Meis1 Enhancer 9 Forward TTTCCAAGCTCAATGGAATGC
Meis1 Enhancer 9 Reverse TTGCTGAGGCCAAGGGTAAC
Hoxa9 TSS Forward GAATTTGCAGGGAAAGGAAA
Hoxa9 TSS Reverse GGCAGGAAGAAGAAAGTGGT
Hoxa9 TSS region 2 Forward TTGATGTTGACTGGCGATTTTC
Hoxa9 TSS region 2 Reverse ATCTGTATGCCTAGTCCCGCTCC
p16 TSS Forward CTTAGAGTTACAGAAAGGGCTGGA
p16 TSS Reverse GAATTTCAAGGAAGTGCTACCCTA
Gene Desert Forward CCACTCTTCTTATAGGACCCTTTG
Gene Desert Reverse CCTGTCTACCTGTTCTTTACATTCT
2.8.2 ChIP-Seq library preparation
ChIP-Seq libraries were produced using the NEXTFLEX ChIP-Seq library kit (Bioo Scientific,
catalogue number 5143-01). For H3K4me3, 10 ng of ChIP-ed DNA and 10 ng input DNA were
used as starting material. For H3K4me1, H3K27me3 and H3K27ac, smaller amounts ranging
between 2.5-6 ng were used. The ratio of beads to sample in the protocol were altered to select for
a larger size range (200-400 bp) using Agencourt AMPure XP beads (Beckman Coulter, A63881).
This process was optimised prior to library production using excess sheared fixed chromatin and
analysis using an Agilent 2100 bioanalyser. The final average library size was determined to be
350 bp for all libraries. The libraries were pooled and normalised to 2 nM using Qubit dsDNA
HS Assay Kit (Thermo Fisher Scientific). ChIP-qPCR primers for the Meis1 putative promoter
were designed using primer3 software (Untergasser et al. 2012). ChIP-qPCR primers for the
Meis1 enhancer were taken from Wang et al. (2014).
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2.9 ChIP-Seq processing and quality assessment
In this section I provide details of the initial processing pipeline for ChIP-Seq analysis which are
briefly referred to in the results section 6.2. Specific analysis used to address biological questions
are detailed within a separate methods section in section 6.2. Firstly, to remove adapters and low
quality bases, I trimmed the resulting reads with Trim Galore! v0.4.0 (Krueger 2015). Next, I
individually aligned each sequencing run to the mouse genome assembly GRCm38 with Bowtie2
v2.2.6 (Langmead and Salzberg 2012). Alignments were filtered for properly mapped pairs
with Samtools v1.2 (Li et al. 2009). To distinguish reads originating from different runs and
avoid excessive duplicate removal, before merging runs by sample, I annotated each Sequence
Alignment Map (SAM) file with a unique read group reference using Samtools v1.2 re-header.
During the ChIP-Seq library preparation, ChIP DNA fragments are amplified to achieve
DNA concentrations required for sequencing. In the case of over-amplification of the library or
low complexity libraries, this may result in PCR duplicates which due to PCR bias can create
false enrichment. PCR duplicates are defined as reads with exactly the same start and end
position in the genome, these reads are unlikely to exist by chance due to the mostly randomised
nature of sonication. Additionally, optical duplicates may be sequenced due incorrect multiple
identifications of a single cluster on the flow cell. To identify and remove both PCR and optical
duplicates I used Picardtools v2.0.1 (Broad Institute 2017).
I called regions of enrichment (peaks) using MACS2 v2.1.0.2 (Zhang et al. 2008) in
paired-end mode using broad peak settings with a broad-cutoff of 0.1, keeping duplicates as
they had already been removed using a more sensitive method. It has been discovered that
some genomic regions accumulate ChIP-Seq reads, and create false peaks (Carroll et al. 2014).
These regions have been complied into a blacklist by Anshul Kundaje as part of the ENCODE
project (ENCODE Project Consortium and others 2012; Kundaje 2014) and can be found at:
https://sites.google.com/site/anshulkundaje/projects/blacklists. The blacklist was
provided in Mm9 coordinates, therefore to make these compatible with my alignment files, I
converted these to GRCm38 coordinates using UCSC LiftOver tools (Hinrichs et al. 2006). The
peaks were then filtered to remove those overlapping blacklisted regions using BedTools v2.27.1
(Quinlan and Hall 2010). Initially, I used the R package ChIPQC v1.6.1 (Carroll et al. 2014) to
determine the quality of ChIP-Seq enrichment.
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Peaks were visualised using Integrative Genomics Viewer (IGV) v2.3 (Thorvaldsdóttir
et al. 2013), coverage tracks normalised to counts per million total reads were generated using
deepTools bamCoverage v2.5.4 (Ramírez et al. 2014; Ramírez et al. 2016). The R package
ChIPSeeker v1.6.2 (Yu et al. 2015) was used to assign peaks to genes and retrieve general metrics
of binding patterns in relation to genes. To plot average profiles of histone marks around the
TSS, I calculated library size normalized genomic coverage using BEDTools genomecov v2.27.1
(Quinlan and Hall 2010). To get normalised coverage, I multiplied the number of reads by a scale
factor, calculated by dividing 1×106 by the total number of properly paired mapped reads after
duplicate removal.
2.10 Immunofluorescence
Cytospins were prepared as described in subsection 2.7.2. Cytospins were fixed in 4% para-
formaldehyde for 10 minutes at room temperature. After fixation, cells were washed in cold PBS
three times and then simultaneously permeablise and blocked by incubation for 10 minutes in
blocking buffer (1× PBS /5% FBS/0.3% Triton TM X-100). Following permeabilisation, cells
were washed 3 times for 5 minutes in PBS. Next, to contain a of droplet containing primary
antibody, an outline was drawn around the cells using a wax pen. Primary antibody (Purified
Mouse Anti-β-catenin Clone 14/Beta-Catenin, BD Transduction Laboratories™) was diluted in
1:100 with antibody dilution buffer (1× PBS/ 1% BSA/0.3% Triton TM X-100) and 200 µL was
pipetted on to each slide within the wax outline. Slides were incubated overnight at 4°C in a
covered box. The next day, slides were washed 3 times for 5 minutes in PBS. The secondary
antibody (FITC-conjugated anti-mouse goat 4409s from Cell Signalling) was diluted at 1:200
and was added to the slides and protected from light at room temperature for 1-4 hours. Slides
were washed 3 times for 5 minutes in PBS. Finally, after drying, mounting medium and cover
slips were placed over the cells before viewing with a fluorescence microscope. The resulting
images were taken with an attached camera and processed in the Leica Application Suite X
(LAS X) by Leica™.
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Chapter 3
Transcriptional profiling of β-catenin
conditional cell lines: Combined
Batch Analysis
3.1 Introduction
The cell populations from which LSCs can arise have been widely debated, the discussion has also
been confounded by the differences in mouse and human haematopoiesis (Doulatov et al. 2012).
Given their similar properties, HSCs seem the most plausible candidates for LSCs origin, but it
has also been proposed that more differentiated haematopoietic stem cells such as GMPs may
become LSCs (Cozzio et al. 2003; So et al. 2003; Huntly et al. 2004; Krivtsov et al. 2013; Heuser
et al. 2011). The key to leukaemogenesis arising from GMPs has been suggested to be aberrant
β-catenin upregulation (Yeung et al. 2010; Siriboonpiputtana et al. 2017). β-catenin is both a key
regulator of cell adhesion and the terminal effector protein of Wnt signalling. Activated β-catenin
translocates to the nucleus where it binds to transcription factors and by recruiting epigenetic
modifiers, modulates gene expression (Mosimann et al. 2009). β-catenin is a key regulator of
both normal stem cell and cancer stem function, activating genes involved in self-renewal (Lien
and Fuchs 2014).
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Others have shown that β-catenin is required for MLL-fusion driven leukaemia, regardless
of cell-of-origin (Wang et al. 2010a). The study from Siriboonpiputtana et al. (2017), which formed
the foundation of my PhD, showed that in contrast with other MLL fusions, the in vivo requirement
of β-catenin for leukaemic transformation and maintenance of MLL-ENL transduced LSCs is
cell-of-origin specific; Pre-LSCs derived from progenitors (GMPs) are dependent on β-catenin
whilst Pre-LSCs derived from a HSC enriched population (LSKs) are β-catenin independent.
RNA-Seq analysis revealed that despite the genome-wide revolution of transcription introduced
by MLL-ENL, some transcriptional differences between GMPs and LSKs are maintained after
MLL-ENL leukaemic transformation, including several Hox genes and Meis1. We hypothesised
that these are indicators of self-renewal programs in LSKs which remain after transformation
and compensate for the loss of β-catenin.
Similarly β-catenin, LSKs were shown not to require HoxA9 for MLL-ENL leukaemic
transformation. Following the hypothesis that HoxA9 is responsible for conferring differential
β-catenin requirement Siriboonpiputtana et al. (2017), deleted both HoxA9 and β-catenin in
tandem, resulting in abolishment of leukaemia development. To investigate potential molecular
links between the effects of HoxA9 and β-catenin deletion, we looked for patterns of gene
expression showing synergistic effects; genes whose expression change following compound KO is
greater than the additive effect of single gene knock-outs. Further RNA-Seq analysis revealed
amongst synergistically affected genes there where several Hoxa9/Meis1 targets including protein
arginine methyltransferase 1 (Prmt1 ) responsible for methylating arginine residues in proteins
including histones. The therapeutic potentials are further discussed in (Cheung et al. 2016).
Furthermore, following on from the Siriboonpiputtana et al. (2017) study which focused
mainly on mechanisms of β-catenin redundancy in MLL-ENL transformed LSK (LSKME), in this
chapter I study the transcriptional effects of β-catenin depletion in cell-of-origin specific MLL
transformed haematopoietic cells. As our ultimate aim is to characterise the potential epigenetic
effects of β-catenin depletion it is necessary that the RNA-Seq data are directly comparable with
ChIP-Seq data in this study. Therefore, in this chapter, I generate new RNA-Seq data from
stored cells originally used in the Siriboonpiputtana et al. (2017) study. This allowed me to not
only increase the sample size and reproducibility of these data, but also obtain RNA-Seq data
from the identical cells that were used for ChIP-Seq with a strict experimental design. Using
linear modelling to control for batch effects, I perform differential expression analysis combining




For this study, we chose to use existing cell lines resulting from two independent Fluorescence-
activated cell sorting FACS experiments of pooled bone marrow cells transduced with the
same construct of MLL-ENL and at the time of the original experiments, were shown to have
cell-of-origin specific dependency on β-catenin in vivo Table 3.1. These two experiments were
referred to as experiment “60” and “69” throughout Dr. Siriboonpiputtana’s doctoral thesis
(Siriboonpiputtana 2014) and this is how I will refer to them throughout this thesis. Each
experiment resulted in two MLL-ENL transformed β-catenin conditional cell lines originating
from either LSK or GMP populations. As the LSK and GMP cell lines were produced in
paired, independent experiments originating from a different mixture of individuals, we may
treat cell lines derived from the same sorted population as biological replicates. These replicates
encapsulate the variation introduced by the sorting procedure and the RTTA, however, variation
between individual mice was lost.
Briefly, as described in section 2.2, I recovered the aforementioned cell lines from liquid
nitrogen storage and following 24 hours recovery in liquid culture, I removed dead cells by
centrifugation with Density Gradient Centrifugation (Ficoll 400, Sigma Aldrich) for 30 minutes
at 800 rcf. To generate new RNA-Seq samples I deleted β-catenin with 20 nM 4-OHT in liquid
culture for 72 hours, exactly following the methods of the Siriboonpiputtana et al. (2017) study.
To obtain RNA for sequencing, I pelleted approximately 3 million cells from each condition,
lysed and snap froze them at -80°C overnight before extracting RNA. RNA was extracted and
RNA-Seq libraries were constructed as described in subsection 2.5.2. Importantly, at the same
time, I harvested cells from the same culture vessels, fixed them with formaldehyde and snap
froze these at -80°C for ChIP-Seq as described in section 2.8. Performing formaldehyde fixation
for ChIP within hours of collecting cells for RNA ensured that the RNA-Seq and ChIP-Seq
would be conducted on cell populations which were as close to identical as possible.
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3.2.2 Confirming β-catenin depletion
For the purpose of our experiment, it was important to confirm that β-catenin had been completely
knocked-out in the vast majority of cells, so I measured the KO using three different methods:
1. Genotyping PCR, 2. RT-qPCR and 3. Western Blot. Firstly, I extracted genomic DNA
from cell pellets using the DNeasy Blood & Tissue Kit (QIAGEN, catalogue number 69581) and
performed PCR using previously designed genotyping primers (see subsection 2.1.2, Table 2.1)
followed by gel electrophoresis with a 1.5% polyacrylamide gel. To further confirm a depletion in
β-catenin mRNA I then produced cDNA from the same RNA used for sequencing and measured
β-catenin mRNA by RT-qPCR as described in section 2.3 using previously designed RT-qPCR
primers (see Table 2.3. Finally western blot was carried out as described in section 2.4.
Additionally, to confirm cell line identity, I checked the mRNA levels of genes shown to
be differentially expressed in different cells of origin (Hoxa9 ) and after β-catenin KO (Tgm2 ) by
RT-qPCR. To further confirm KO after sequencing, I calculated Reads Per Kilobase of transcript
per Million mapped reads (RPKM) normalised coverage using deepTools v2.5.4 (Ramírez et al.
2014; Ramírez et al. 2016) and visualised RNA-Seq reads at β-catenin exons 2-6 in the Integrative
genomic viewer (IGV) v2.4.19 (Thorvaldsdóttir et al. 2013).
3.2.3 RNA-Seq Analysis
In total 24 RNA-Seq samples were analysed, with at least two replicates for each condition
of interest, cell-of-origin and Ctnnb1 KO (Table 3.1). After read counts per gene and quality
control metrics were obtained as detailed in subsection 2.5.3, I conducted downstream analysis in
R using Bioconductor packages (R Core Team 2015; Huber et al. 2015). Quality control metrics
for RNA-Seq generated in this study are shown in Table 3.2.
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Table 3.1: All RNA-Seq samples produced in our lab and analysed in this chapter








ERX994611 Sep-14 1 GMP N/A N/A N/A
ERX994613 Sep-14 2 GMP N/A N/A N/A
ERX994631 Sep-14 1 LSK N/A N/A N/A
ERX994633 Sep-14 2 LSK N/A N/A N/A
ERX994603 Feb-14 51 GMP fl/fl short Blasticidin
ERX994595 Feb-14 51 GMP -/- short Blasticidin
ERX994607 Feb-14 65 GMP fl/fl short Blasticidin
ERX994599 Feb-14 65 GMP -/- short Blasticidin
ERX994605 Feb-14 60 GMP fl/fl long Puromycin
ERX994597 Feb-14 60 GMP -/- long Puromycin
ERX994609 Feb-14 69 GMP fl/fl long Puromycin
ERX994601 Feb-14 69 GMP -/- long Puromycin
ERX994627 Apr-14 60 LSK fl/fl long Puromycin
ERX994615 Apr-14 60 LSK -/- long Puromycin
ERX994629 Apr-14 69 LSK fl/fl long Puromycin
ERX994617 Apr-14 69 LSK -/- long Puromycin
Unpublished-1 Dec-15 60 LSK fl/fl long Puromycin
Unpublished-2 Dec-15 60 LSK -/- long Puromycin
Unpublished-3 Dec-15 60 GMP fl/fl long Puromycin
Unpublished-4 Dec-15 60 GMP -/- long Puromycin
Unpublished-5 Dec-15 69 LSK fl/fl long Puromycin
Unpublished-6 Dec-15 69 LSK -/- long Puromycin
Unpublished-7 Dec-15 69 GMP fl/fl long Puromycin
Unpublished-8 Dec-15 69 GMP -/- long Puromycin
* I produced the samples from Dec-2015, all others were published in (Siriboonpiputtana et al. 2017).
** Experiment refers to retroviral transduction and/or FACS experiment.
*** Ctnnb1 Status; “N/A” means wild-type; fl/fl (floxed) indicates floxed alleles; -/- indicates double
deletion/knock-out.
**** “NA” means not transduced; “short” refers to the MLL-ENL construct containing the minimum
transformation element; “long” refers to the full length MLL-ENL fusion.





mapped % Genic % Intergenic % Ribosomal
Unpublished-1 21,802,759 13272709 74.10% 86.9% 2.31% 0.98%
Unpublished-2 24,589,580 15301022 77.7% 92.5% 1.60% 1.24%
Unpublished-3 21,482,841 16710697 79.8% 91.0% 1.72% 0.89%
Unpublished-4 24,385,310 17978289 75.3% 93.6% 1.43% 0.95%
Unpublished-5 24,941,668 18999975 73.8% 91.0% 1.62% 0.66%
Unpublished-6 25,023,990 15034344 69.4% 91.4% 2.13% 1.30%
Unpublished-7 18,761,283 15840581 74.4% 90.5% 1.86% 0.51%
Unpublished-8 20,230,699 16183220 79.1% 91.3% 1.74% 0.51%
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Differential expression analysis for the effects of cell-of-origin and Ctnnb1 KO in
both LSKME and MLL-ENL transformed GMP (GMPME) was performed using EdgeR v3.28.0
(Robinson et al. 2010; McCarthy et al. 2012; Zhou et al. 2014). First, genes were filtered for
those which were expressed with a Count Per Million (CPM) value greater than one in more
than two samples. To allow visualisation of the raw data, the variance stabilising transformation
function from DESeq2 v1.22.2 (Love et al. 2014) was applied to library size normalised counts.
Next, sources of variation in these data were assessed by Principal Component Analysis (PCA)
of the top 1000 most variable genes. Subsequently, generalised linear models were fitted on
library size normalised counts with design formulas to account for known batch effects discovered
in PCA and described in the results using the glmFit function (EdgeR). Finally, differential
expression was assessed using the glmLRT function (EdgeR) which applies a Log Ratio Test (LRT).
P.values were corrected for multiple testing using the Benjamini-Hochberg (BH) method with the
TopTags function (EdgeR) and differentially expressed genes were taken with an False Discovery
Rate (FDR) cut-off of less than 0.05.
Although modelling for batch effects allows us to adjust for batches when making
statistical inferences, it does so without modifying the data, therefore batch effects are still visible
if expression values are plotted. To assess the effectiveness of modelling known batch effects,
I used the removeBatchEffect function from limma v3.42.0 (Ritchie et al. 2015) on variance
stabilised counts. The removeBatchEffect function effectively works by modelling the given
design including batches and conditions of interest, it then subtracts the specified covariate effect
from these data. Following batch correction, the results of each model were visualised in PCA,
heatmaps and smearplots using functions from pheatmap v1.0.12 and ggplot2 v3.1.1 (Kolde 2019;
Wickham 2016).
To elucidate whether the transcriptional response to β-catenin deletion was specific
to LSKME or GMPME I calculated the Pearson’s correlation using the cor function and a
hypergeometric test with the phyper function in R. For the hypergeometric test, the size of the
gene universe was the number of expressed genes (those with a CPM value of 1 or greater) in this
study. To investigate if there were any patterns of concerted expression changes among groups
of genes with similar functions, I performed hypergeometric test based functional profiling with
the bioconductor packages BiomaRt v2.42.0 (Durinck et al. 2009) and clusterProfiler v3.14.3
(Yu et al. 2012).
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3.3 Results
3.3.1 Validation of β-catenin knock-out
To evaluate the global transcriptional targets of β-catenin, it was vital that complete β-catenin
KO was achieved. Therefore, I used three different methods to confirm complete functional KO
by excision of β-catenin exons 2-6. Firstly, genotyping PCR and gel electrophoresis (Figure 3.1A)
showed that in 4-OHT treated samples, only the deleted band at 500 bp is present, confirming
homozygous genetic knock-out. Notably, gel electrophoresis reveals β-catenin deleted bands are
also present in all untreated cell lines (Figure 3.1A). This indicates that in the absence of 4-OHT
treatment, Rosa-Cre is spuriously activated leading to excision of β-catenin. Next, the absence
of β-catenin protein following KO was confirmed by western blot (Figure 3.1B). Additionally, I
confirmed mRNA depletion of β-catenin with RT-qPCR (Figure 3.1C).
Transglutaminase 2 (Tgm2 ) was identified to be one of the most significant down-
regulated genes after β-catenin deletion regardless of cell-of-origin (Siriboonpiputtana et al.
2017). To further prove the effects of β-catenin KO, I showed significant downregulation of Tgm2
transcription by RT-qPCR (Figure 3.1E). As mentioned in section 3.1, we previously identified
Hoxa9 as being more highly expressed in LSK than GMP-derived MLL-ENL transformed cells.
Consistently I observed higher Hoxa9 expression in the LSKME cell lines, regardless of β-catenin
status, confirming their cell-of-origin identity (Figure 3.1D). Finally, RNA-Seq is a very sensitive
method to detect even low levels of remaining intact β-catenin expression, but we could not
observe any reads on exons 2-6 (Figure 3.1F). In conclusion, all methods concur that we observe









































































































































































































































































































Figure 3.1: Validation of RNA-Seq samples A) Genotyping PCR for β-catenin. Floxed
bands are present at 324 bp and deleted are at 500 bp. B) Western blot for β-catenin and Actin.
C) RT-qPCR for β-catenin expression. Values are normalised to Gapdh expression and are shown
relative to the floxed sample for each line. D-E) RT-qPCR for Hoxa9 and Tgm2 before and after
β-catenin knock. out. F) IGV profile showing KO of exons 2-6.
80
3.3.2 Principal Component Analysis reveals batch effects and bias
Aiming to understand the sources of variance in these data, I visualised each experimental factor
in a series of Principal Component Analysis (PCA) plots. PCA plots show the relationship
between samples by reducing data into dimensions (principal components) with maximal variation,
revealing the overall similarities and differences in global gene expression between samples. Upon
MLL-ENL transformation, PCA reveals that gene expression between samples from different
cells-of-origin become more similar and transformed cells separate altogether from their normal
cells-of-origin (Figure 3.2A, PC1: 48% of variance). In line with previously published data
(Lara-Astiaso et al. 2014), the expression profiles of normal LSK and GMP separate clearly
from each other in PCA (Figure 3.2A, PC2: 21% of variance). Observing only transformed
cells in Figure 3.2B, contrary to expectation, samples do not clearly separate by cell-of-origin,
or treatment. Instead, there is a strong clustering effect from experiment, with PC1 and PC2
separating the samples into 4 clusters, each containing samples from a distinct experiment
(Figure 3.2B).
Isolating only the data used in the Siriboonpiputtana et al. (2017) study, samples
separate by virus used (Full length MLL-ENL with puromycin or the minimal transformation
element of MLL-ENL with blasticidin) explaining 39% of the variance (Figure 3.2C, PC1).
Notably, LSKME replicates in the 2014 study have very little variance compared to GMPMEs.
Comparing this with freshly generated sequencing (Figure 3.2D) we can see that LSKME cell lines
display a similar in-group variation to GMPME, clustering by cell line rather than treatment or
cell-of-origin. I conclude that the strongest determinant of global gene expression is cell-of-origin,
followed by introduction of the fusion. Treatment and cell-of-origin in transformed cells have
modest influence on variance, and there are effects from several other factors, including batch
effects and the transformation element/ antibody used. It is therefore important to model these
additional factors in differential expression analysis.
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Figure 3.2: Experimental variables and batch effects separate samples in principal
component analysis (PCA) A) All RNA-Seq samples in this study including normal cell
compartments. B) All MLL-ENL transformed samples labelled with experiment reference.
Samples with the same sequencing date are labelled and contained within an ellipse. C) Samples
included in Siriboonpiputtana et al. (2017). An ellipse indicates those samples with the full
length MLL-ENL fusion. Samples outside the ellipse utilise the minimum transformation element.
D) Samples independently sequenced in 2015.
3.3.3 Batch Correction for the effect of cell-of-origin
As identified in the previous subsection 3.3.2, there are multiple known covariates which confound
the effect of cell-of-origin. These covariates are, as shown in Table 3.1: Date, Experimental
Reference, MLL-ENL construct and Antibiotic. In a perfectly balanced experiment, we would
attempt model all of these covariates. Unfortunately, some of these covariates are perfectly
confounded and therefore cannot be modelled separately. In order to attempt correction for any
of the observed batch effects, we must remove all samples utilising the minimum transformation
element or Blasticidin as this covariate is unbalanced.
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In the design models I will refer to the cell-of-origin effect as “celltype”. Differential
expression analysis for the effect of cell-of-origin using only cell-of-origin in the design model
(~celltype) yields few differentially expressed genes as samples are poorly separated (Figure 3.3A,
58 up and 44 down). Although it has been shown that sequencing runs on the same machine does
not have a large impact on differential expression analysis, separate RNA-Seq library processing
of RNA has been shown to significantly affect differential expression analyses (Peixoto et al.
2015; Danielsson et al. 2015). In Table 3.1, we can see that all 2014 LSKME samples were
sequenced in April 2014 whilst 2014 GMPME samples were sequenced in February of 2014. It is
not known if the 2014 samples were also processed separately. As “date” perfectly confounds
cell-of-origin we are unable to model “date” and must assume that the effect is much smaller than
cell-of-origin. However, it is certain that the 2015 samples were processed separately so we may
attempt to model for this effect using sequencing “year” instead. Modelling for ~year+celltype
does not result in clear separation by cell-of-origin however significantly increases differentially
expressed gene detection (Figure 3.3B, 152 up and 163 down). Next, we may attempt to model for
experiment, which combines the variation introduced by both FACS experiment and transduction
experiment (Table 3.1). Modelling for ~experiment+celltype does not result in clear separation
by cell-of-origin however mildly increases differentially expressed gene detection over the minimal
model (Figure 3.3C, 77 up and 56 down).
We may also attempt to correct for both year and experiment by adding both of
these covariates to the design model. Modelling for ~year+experiment+celltype only somewhat
improves clustering in PCA and hierarchical clustering but significantly increases differentially
expressed gene detection (Figure 3.3D, 224 up and 237 down). Modelling for year and experiment
as an interaction (~year*experiment+celltype), gives similar results to the additive model and
does not improve clustering (Figure 3.3E, 233 up and 232 down). In conclusion, modelling
unwanted covariates for the cell-of-origin improved differential expression detection. However, it



















































































































































































































































































Figure 3.3: Batch correction to extract the cell-of-origin effect A-E) Differential
expression analysis for the effect of cell-of-origin using different models to account for unwanted
covariates. The design model for each row is specified above the plots in the left and right
columns. For each row, all effects in the indicated model with the exception of “celltype” were
removed. Left column: PCA plots for the 1000 most variable genes, cell-of-origin is indicated by
colour specified by the key (top). Points are labelled with their sequencing year and experimental
reference. Middle column: Hierarchical clustered heatmaps for the 1000 most variable genes.
Groups are specified in the key (right). Right column: Smear plots indicating the results
of differential expression analysis. The number of significantly (FDR < 0.05) upregulated or
downregulated genes are indicated in red and blue respectively.
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3.3.4 Biological themes related to the combined cell-of-origin signature
For the purpose of understanding cell-of-origin related genes that remain differentially expressed
between LSKME and GMPME, I performed pathway analysis on the differentially expressed
genes obtained by modelling for year and experiment (~year+experiment+celltype). Figure 3.4
illustrates Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched in the
combined cell-of-origin signature. Most of the differentially expressed pathways between LSKME
and GMPME are upregulated in GMPME. Amongst these, there are cancer and cell cycle related
pathways including the Wnt signalling pathway which are upregulated in GMPME (Figure 3.4A).
Downregulated pathways in GMPME relate to metabolism (Figure 3.4B).
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Figure 3.4: Biological themes of cell-of-origin signature Networks between KEGG
pathways enriched for significantly up-regulated (A) and down-regulated (B) genes in GMPME
compared to LSKME. The size of nodes represents the number of differentially expressed genes,
indicated by the key (right) within the labelled pathway. The thickness of the edges between
nodes denotes the degree of similarity by shared genes.
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3.3.5 Batch Correction for the effect of β-catenin deletion in GMPME
Similarly to subsection 3.3.3, in this section I attempted to model for unwanted covariates
to extract the effect of β-catenin deletion in GMPME. In the design models, I refer to the
β-catenin deletion effect as “genotype”. Without any batch effect correction (Figure 3.5A,
~genotype), it is clear that samples separate by both year (PC1, 50%) and experiment (PC2,
24%). Addition of year to the design model does not improve clustering in PCA or hierarchical
clustering and detects few differentially expressed genes (Figure 3.5B, ~year+genotype). Similarly,
addition of experiment alone does not improve clustering or differential gene expression detection
(Figure 3.5C, ~year+genotype).
Modelling for both year and experiment together shows significant improvement in
PCA clustering and detection of differentially expressed genes (Figure 3.5D, PC2 21%, 24 up and
21 down). However, samples do not separate by genotype in hierarchical clustering (Figure 3.5D,
middle). Modelling year and experiment as interacting terms finally separates samples clearly
in PCA and hierarchical clustering with a considerable increase in differential gene expression
detection (Figure 3.5E).
3.3.6 Batch Correction for the effect of β-catenin deletion in LSKME
In this section I attempt to model for unwanted covariates to extract the effect of β-catenin
deletion in LSKME. Without any batch effect correction, samples separate clearly by year (PC1,
63%), but not by experiment (Figure 3.6A, ~genotype). Unlike GMPME, addition of year alone
to design appears to improve clustering in PCA, and has considerable effect on the number of
differentially expressed genes (Figure 3.6B, ~year+genotype, 208 up and 71 down). On the other
hand, addition of experiment alone appears to improve clustering in PCA but not hierarchical
clustering and has little effect on the number of differentially expressed genes (Figure 3.6C,
~experiment+genotype, 37 up and 25 down).
Modelling for both year and experiment as additive effects allows clear separation in
PCA (Figure 3.6D ~year+experiment+genotype, PC1, 61%) and hierarchical clustering and
continues to increase the number of differentially expressed genes (336 up and 116 down).
However, as with GMPME, modelling for the interaction between year and experiments yields
the clearest separation in clustering and the greatest number of differentially expressed genes

















































































































































































































































































Figure 3.5: Batch correction for loss of β-catenin in GMPME A-E) Differential
expression analysis for the effect of β-catenin loss in GMPME using different models to account
for unwanted covariates. The design model for each row is specified above the plots in the left
and right columns. For each row, with the exception of genotype all effects in the indicated
model were removed. Left: PCA plots for the 1000 most variable genes, genotype is indicated by
colour specified by the key (top). Middle: Hierarchical clustered heatmaps for the 1000 most
variable genes. Groups are specified in the key (right). Right: Smear plot indicating the results
of differential expression analysis. The number of significantly (FDR < 0.05) upregulated or




















































































































































































































































































Figure 3.6: Batch correction for loss of β-catenin in LSKME A-E) Differential expression
analysis for the effect of β-catenin loss in LSKME using different models to account for unwanted
covariates. The design model for each row is specified above the plots in the left and right columns.
For each row, with the exception of genotype all effects in the indicated model were removed.
Left: PCA plots for the 1000 most variable genes, genotype is indicated by colour specified by
the key (top). Middle: Hierarchical clustered heatmaps for the 1000 most variable genes. Groups
are specified in the key (right). Right: Smear plot indicating the results of differential expression
analysis. The number of significantly (FDR < 0.05) upregulated or downregulated genes are
indicated in red and blue respectively.
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3.3.7 Putative β-catenin target genes in MLL-ENL pre-LSCs are largely
independent of cell-of-origin
β-catenin is a multi-functional protein with context dependent roles in cell function (Valenta et al.
2012), so we wanted to determine if β-catenin downstream targets were the same, or different
in LSK-origin and GMP-origin cells. Immediately, we observe that the majority of deregulated
genes following β-catenin KO are upregulated (Figure 3.7A and previously in Figure 3.5D &
5.6D). As would be expected, the overlaps between β-catenin affected genes in GMPME and
LSKME are statistically significant as determined by hyper-geometric analysis (Figure 3.7D). As
there is great variation between replicate experiments, it would be quite arbitrary to use FDR
cut-offs to determine cell-of-origin unique β-catenin targets. Linear regression for the log fold
change of all genes after β-catenin deletion in LSKME and GMPME shows a strongly positive
correlation (Figure 3.7B, R2=0.444).
The similarities and variations in LSKME and GMPME expression in response to β-
catenin deletion are illustrated further in a heatmap (Figure 3.7C). By colour coding the genes
into common, and “cell-of-origin unique” signature genes we can see that despite not reaching
significance cut-offs in the opposing group, the trend of gene expression of “unique” targets is
remarkably similar in LSKME and GMPME. Furthermore, hierarchical clustering of the signature
genes shown in Figure 3.7C showed clear separation of upregulated and downregulated genes
despite across-group variation. I conclude that these data provide little evidence to support the
hypothesis that β-catenin targets different genes in LSK and GMP derived MLL-ENL Pre-LSCs.
3.3.8 Biological themes related to the combined β-catenin knock-out
signature
In order to understand the biological effects of β-catenin deletion, I performed Gene Ontology
(Gene Ontology (GO)) analysis for GMPME and LSKME targets, the results are shown in the
form of networks in Figure 3.8. From this analysis it was found that the majority of enriched
GO terms are shared between LSKME and GMPME upregulated signatures (Figure 3.8A). These
positively enriched GO terms are related to innate immune response and regulation of cell
adhesion. However, both LSKME and GMPME downregulated signatures are enriched for unique
GO terms related to immune response (Figure 3.8B). Additionally, downregulated genes in
LSKME exhibit unique enrichment for negative regulation of the cell cycle (Figure 3.8B).
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Figure 3.7: Most of the transcriptional effects of β-catenin deletion are independent
of cell-of-origin Differential expression analysis was performed with the design model:
~year*experiment+genotype. A) Volcano plots show the distribution of differentially expressed
genes after β-catenin KO in LSKME (left) and GMPME (right). The top 50 significant genes are
labelled with their gene symbol. The colour of the points reflects the direction of change and
significance (FDR <0.05). B) Scatter plot to visualise the correlation between log fold changes
of gene expression in LSKME β-catenin KO (x-axis) versus GMPME β-catenin KO (y-axis). The
plot is labelled with the Pearson’s correlation. Points are coloured by the group in which they are
significant as indicated by the key (bottom). C) Heatmap visualising all genes deregulated after
β-catenin KO in GMPME or LSKME. Genes (columns) are ordered by hierarchical clustering. The
dendrogram (top) indicates the relationships between clusters. The direction of gene expression
and the comparison in which they are significant in is indicated by colour bars at the top and are
explained by the key below. The rows are grouped by cell type of origin and genotype as indicated
by the colour bars on the left and the key below. D) Venn diagram showing overlaps between
differentially expressed genes after β-catenin KO LSKME and GMPME. “+” and “-” indicates






positive regulation of cytokine production
response to interleukin−1
regulation of tumor necrosis factor production
tumor necrosis factor production
regulation of inflammatory response
cellular response to biotic stimulus
cytokine−mediated signaling pathway
positive regulation of protein secreti on
cellular response to interleukin−1
positive regulation of ERK1 and ERK2 cascade
positive regulation of response to external stimulus
positive regulation of defense response
ERK1 and ERK2 cascade
positive regulation of peptide secretion
cellular response to lipopolysaccharide
regulation of leukocyte migration
interleukin−6 production
neuron death
regulation of neuron death
phagocytosis
positive regulation of leukocyte migration
myeloid leukocyte migration
acute inflammatory response
negative regulation of apoptotic signaling pathway
regulation of tumor necrosis factor superfamily cytokine production
tumor necrosis factor superfamily cytokine production
7
28
response to molecule of bacterial origin
Positively enriched GO in KO




negative regulation of cytokine production
blood vessel remodeling
regulation of chemotaxis
positive regulation of response to external stimulus
positive regulation of chemotaxis
negative regulation of response to external stimulus
regulation of inflammatory response granulocyte activation
negative regulation of secretion
negative regulation of myeloid leukocyte mediated immunity
negative regulation of leukocyte degranulation
regulation of interleukin−1 secretion
regulation of protein serine/threonine kinase activity
T cell activation involved in immune response
negative regulation of cellular component movement
neutrophil degranulation
interleukin−1 secretion
regulation of interleukin−2 production
positive regulation of interleukin−13 production
negative regulation of cell projection organization
translesion synthesis
regulation of dendrite development
regulation of mitotic cell cycle
regulation of cell morphogenesis involved in differentiation
postreplication repair
negative regulation of G1/S transition of mitotic cell cycle
positive regulation of G2/M transition of mitotic cell cycle
negative regulation of cell cycle G1/S phase transition
regulation of response to wounding
positive regulation of cell cycle G2/M phase transition
regulation of mitotic cell cycle phase transition
mitotic cell cycle phase transition
regulation of vascular permeability
negative regulation of cell cycle
positive regulation of neurological system process
regulation of cell cycle phase transition







Figure 3.8: GO enrichment for genes deregulated after β-catenin knock-out
Differential expression analysis was performed with the design model: ~year*experiment+genotype.
Networks between KEGG pathways enriched for significantly upregulated (A) and regulated (B)
genes in GMPME compared to LSKME. The size of nodes represents the number of differentially
expressed genes, indicated by the key (bottom right) within the labelled pathway. The thickness
of the edges between nodes denotes the degree of similarity by shared genes. Each node is
coloured like a pie chart, indicating the proportion of significant genes belonging to the LSKME
or the GMPME signature (purple and green respectively, as indicated by the key labelled “Cell
of Origin”, bottom right)
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3.4 Discussion
In this chapter I produced high quality RNA-Seq data (Table 3.2) which is directly compatible
with the ChIP-Seq data required to address our eventual aim to understand the epigenetic
modifications mediated by β-catenin in MLL-ENL associated AML. Using multiple methods,
I showed that good β-catenin genetic KO was achieved (Figure 3.1). However, comparing all
RNA-Seq samples revealed batch effects and biases (Figure 3.2). There was additional variation
seen in the 2015 dataset, especially between LSKME cells which could have arisen from multiple
technical and biological sources such as heterogeneity of the cell culture and even stochastic
variation. RNA-Seq experiments are often plagued with batch effects due to experimental design
choices which can greatly confound the biological effects of the condition of interest (Conesa
et al. 2016).
First, I attempted to model for the effect of year and cell line to extract a cell-of-origin
signature from the combined dataset. Although greater differentially expressed genes were
detected when modelling for these effects, it is unclear if batch effects were modelled effectively
(Figure 3.3B). The number of differentially expressed genes is markedly reduced when compared
to Siriboonpiputtana et al. (2017), this is likely due to the increases in variation seen in LSKME
in the 2015 study (Figure 3.2D). Upregulation of cancer pathways and cell cycle genes in GMPME
appears contrary to expectation (Figure 3.4A), as LSK derived pre-LSCs are known to be more
aggressive (Wang et al. 2010a; Siriboonpiputtana et al. 2017). However, contradictory pathways
related to senescence, differentiation and immune response are also enriched (Figure 3.4A).
Examining our potential β-catenin targets, we find the majority of these are upregulated
after KO (Figure 3.5, 3.6 & 3.7A). As β-catenin is mostly known for positively regulating gene
expression, therefore we may assume that the upregulation of many of these genes are downstream
events. On the other hand, there is some evidence that β-catenin can also recruit transcriptional
repressors (Bauer et al. 2000; Weiske et al. 2007; Song et al. 2009; Liu et al. 2008). However,
there appears to be greater variance of deregulation amongst upregulated genes as can be seen
in Figure 3.7C which could suggest that this cluster contains more non-specific effects.
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Trying to understand if β-catenin KO yields different downstream effects in LSKME
and GMPME, I compared the transcriptional effects of β-catenin KO in LSKME and GMPME
utilising all available RNA-Seq data. Targets were shown to be mostly the same between LSKME
and GMPME with a strong positive correlation/pattern whether or not genes reached significance
cut-offs (Figure 3.7B & 3.7C) leading to the conclusion that β-catenin targets of LSKME and
GMPME are largely equivalent. In a similar vein, GO analysis revealed terms related to immune
response and cell adhesion which were mostly overlapping in LSKME and GMPME signatures
(Figure 3.8).
When performing differential expression analysis it is typically advised to fit the design
model on RNA-Seq samples from all groups together. The reason for this is that a dispersion
parameter is estimated for each individual gene. This provides us with deviation from the mean
that is to be expected given the variability within groups (Love et al. 2014). Generally, the more
data we have, the more likely that this dispersion parameter will be accurate, decreasing the
rate of false positive discovery and increasing true positive discovery. However, for whatever
reason, the within-group variability may be much higher for some groups. If this is the case,
sub-setting the dataset into groups may be more sensitive. For example, LSKMEs from 2015
have greater in-group variability than the LSKMEs from 2014. This means that the per-gene
dispersion estimate would be higher in the 2015 group than the 2014 group.
Another issue when combining the two datasets is that it changes our original concept
of biological replication. Originally, our biological replicates could be used to estimate the
combined variability between different individuals and independent MLL-ENL transduction and
transformation. If we compare the 2015 and 2014 studies, these would be known as “isogenic
replicates” (ENCODE Project Consortium 2019). Although they are not truly biologically
distinct, the samples were grown separately with two separate deletions. For the purpose of
this chapter, I merged the two data sets into one, however when comparing these data with its
corresponding ChIP-Seq they must be separated. In the next chapter, I will take a deeper look
into the individual batch experiments and compare their results.
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Chapter 4
Transcriptional profiling of β-catenin
conditional cell lines: Separate
Batch Analysis
4.1 Introduction
Given the difficulty of batch correction demonstrated in chapter 3 and conflicting results with
the published dataset (Siriboonpiputtana et al. 2017), we continued to examine these datasets
further with separate analysis and comparison. The first experimental aim of this chapter is to
try to replicate the cell-of-origin signature from (Siriboonpiputtana et al. 2017). In particular
for this study, it is necessary for the effects of β-catenin depletion to be equivalent. Therefore,
the next aim of this chapter is to understand if it is possible to observe similar β-catenin KO
signatures in both existing and newly generated data sets. Finally, as on first inspection the
effects of β-catenin KO do not show deregulation of classical β-catenin transcriptional targets, I
aim to gain deeper insight into the specificity of transcriptional effects of β-catenin depletion in
this study compared to others using the same mouse model.
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4.2 Methods
4.2.1 Differential expression analysis
After read counts per gene and quality control metrics were obtained as detailed in subsection 2.5.3,
I conducted downstream analysis in R using Bioconductor packages (R Core Team 2015; Huber
et al. 2015). The differential expression methods and design models used are explicitly stated
in the figure legends and main body text of the results section 4.3. Initially, to allow accurate
comparison with the published cell-of-origin signature (Siriboonpiputtana et al. 2017), DESeq2
v1.22.2 with Wald statistics (Love et al. 2014) was used to perform differential expression analysis
between LSKME and GMPME. DESeq2 assumes a negative binomial distribution and log fold
changes are shrunken using empirical Bayes statistics. Following the comparison of 2014 and
2015 datasets differential expression for the cell-of-origin signature was repeated using EdgeR
v3.28.0 (Robinson et al. 2010; McCarthy et al. 2012; Zhou et al. 2014). All further analysis of
the cell-of-origin signature was done with the differential expression results obtained with EdgeR
using the design model: ~experiment+celltype.
Differential expression analysis for the effects of Ctnnb1 KO in both LSKME and
GMPME was performed using EdgeR. First, genes were filtered for those which were expressed
in more than 2 samples. Then, differential expression analysis was assessed using an LRT
with a blocked design to account for batch effects (~experiment+genotype). To investigate if
there were any patterns of concerted expression changes among groups of genes with similar
functions, I performed hypergeometric test based functional profiling and Gene Set Enrichment
Analysis (GSEA) with the bioconductor packages biomaRt v2.42.0 (Durinck et al. 2009) and
clusterProfiler v3.14.3 (Yu et al. 2012). Additional plots were generated using pheatmap v1.0.12
and ggplot2 v3.1.1 (Kolde 2019; Wickham 2016).
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4.2.2 Comparison of targets with published β-catenin knock-out expression
data
To shortlist genes whose expression is likely to change as a result of β-catenin knock-out, I
gathered all publicly available β-catenin KO data I could identify originating from the same
mouse model listed in Table 4.1, regardless of which cell-type the experiment had occurred in.
For each of the datasets, where possible, differential expression results were taken from the
supplementary tables of their original manuscript. Those datasets without reported signatures
(GSE49248 and GSE7430) were analysed using the GEO2R online tool (NCBI 2019) using default
settings.
To compare published transcriptomic signatures associated with β-catenin KO with our
β-catenin KO signatures, I applied GSEA analysis with the GSEA function from clusterProfiler
v3.14.3 (Yu et al. 2012) with 10000 permutations. Genes were ranked by their signed P-value,
this was calculated by transforming the log10 P.value by the sign of the log2 Fold Change. It has
been noted that for the GSEA algorithm, normalisation is not accurate for very small (smaller
than 15) or very large (greater than 500) gene sets (Subramanian et al. 2005). Therefore, to
make comparisons with published datasets fair, the top 250 most significantly upregulated genes
and top 250 downregulated genes were used to create custom gene sets for GSEA.
Table 4.1: Published β-catenin deletion transcriptomic data These studies utilised the
same β-catenin mouse model and were used for comparison with our β-catenin KO signature
GEO ID Tissue Platform Citation
GSE9629 Embryonic kidneys Affymetrix MouseGenome 430 2.0 Array (Bridgewater et al. 2008)
GSE49248 MLL-AF9 or MLLAF9/
KrasG12D AML
Affymetrix Mouse
Genome 430 2.0 Array (Ng et al. 2014)
GSE8818 Intestinal crypts Affymetrix MouseGenome 430 2.0 Array (Fevr et al. 2007)
GSE67463 Embyronic gonads Affymetrix MouseGenome 430 2.0 Array (Nicol and Yao 2015)
GSE7430 Embryonic pancreas Affymetrix MouseGenome 430 2.0 Array (Wells et al. 2007)
GSE50620 Hematopoietic stem cells Affymetrix Mouse Gene1.0 ST Array (Lento et al. 2014)
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4.2.3 Comparison of targets with other studies utilising Rosa-Cre-ER
To evaluate if the β-catenin targets found in this study are specific or could be explained by a
treatment-specific effect, I gathered RNA-Seq data from within our group which utilized the
Rosa-Cre-ER system in vitro (listed in Table 4.2). The significance of overlaps between studies
was calculated using both a permutation test and a hypergeometric test. Both hypergeometric
tests and permutation tests rely on establishing the possible gene universe. A gene universe was
created by simply taking those genes which had a CPM value of at least one in at least two
samples. Hypergeometric tests of gene list overlaps were computed using the phyper function in
R.
A permutation test was performed by creating a function in R to simulate re-sampling.
On each iteration, a random sample of the length of each signature to be compared was taken
from the gene universe using the sample function and the overlap of these samples was calculated
with the intersect function. Over 10000 iterations, the number of instances in which the overlap
of the random samples was equal to or exceeded the actual observed overlap of the signatures
was calculated. This number was then divided by the total number of iterations (10000) to
calculate a P.Value.
Table 4.2: In-house 4-OHT treatment transcriptomic data Studies which were
compared with β-catenin KO signature (Unpublished).
Gene KO Oncogene/Fusion Date Treatment Replicates
Bmi1 CDX2 Feb-2018 in vitro 4-OHT 2
Bmi1 MLL-AF9 Feb-2018 in vitro 4-OHT 2
Prmt1 MLL-GAS7 Mar-2018 in vitro 4-OHT 2
Cbfb AML1-ETO Jan-2017 in vitro 4-OHT 2
4.3 Results
4.3.1 The observable cell-of-origin transcriptomic signature is reduced in
2015 samples
Seeing that the separation between cell-of-origin is less clear in my samples (see subsection 3.3.2,
Figure 3.2), I went on to individually compare the 2014 and 2015 cell-of-origin or “celltype”
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signatures. To keep the comparison in this section as close to the results of Siriboonpiputtana
et al. (2017) as possible, differential expression between LSKME and GMPME was conducted
using DESeq2 with the design model: ~experiment+celltype. As a major component of our paper
(Siriboonpiputtana et al. 2017), we describe a cell-of-origin signature as a possible reason for
the difference of β-catenin requirement in LSK and GMP derived MLL-ENL transformed cells.
In the original study, we show that although most transcriptional differences between LSK and
GMP are abolished following MLL-ENL transformation, some differences in expression remain.
The differentially expressed genes between normal LSK and GMP overlapped significantly with
differentially expressed genes between LSKME and GMPME. Therefore, it was argued that the
common signature could be due to an inherited transcriptional “memory” from their cell-of-origin.
One way of showing the distribution of differentially expressed genes is by plotting the
log2 Fold Change of gene expression against the mean average gene expression, known as an
MA plot. If we couple this with significance threshold dependent colouring, this allows us to
observe the relationship between the level of transcript expression and differential gene expression
detection. Similarly to what we show in (Siriboonpiputtana et al. 2017), Figure 4.1A shows
MA plots between: 1. Normal FACS sorted LSK and GMP, 2. 2014 transformed LSKME and
GMPME, 3. Additionally I show LSKME and GMPME from my 2015 experiment. Compared to
normal LSK and GMP (Figure 4.1A, top), MLL-ENL transformation decreases the dispersion of
expression values (Figure 4.1A, centre)., and in 2015 the dispersion is even lower (Figure 4.1A,
bottom).
With an FDR cut-off of <0.05, very few genes in the so-called cell-of-origin “memory”
signature from (Siriboonpiputtana et al. 2017) remain differentially expressed (Figure 4.1B), one
of those being Hoxa9 (Figure 4.1A, bottom). Comparing enriched gene ontologies and pathways
across normal cells, 2014 and 2015 transformed cells (Figure 4.1C), it is apparent that while
many of the enriched pathways in normal cells are also enriched in the 2014 transformed data,
none of the enriched pathways are shared between normal cells and the 2015 transformed data.
The only common cell-of-origin related pathways shared between the 2014 and the 2015 dataset
are related to the ribosome and nonsense mediated decay (Figure 4.1C). I conclude that we
are unable to observe a comparable cell-of-origin signature in the 2015 RNA-Seq data set when
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Figure 4.1: Detectable cell-of-origin signature is markedly reduced in 2015 samples
Differential expression analysis for both 2014 and 2015 datasets using DESeq2. A) MA plots
showing the distribution of gene expression between LSKs and GMPs in normal cells, 2014
MLL-ENL and 2015 MLL-ENL. Colours of points in the MA plots correspond to groups shown
in the Venn diagram (B). Points are coloured depending on in which comparisons they are
significant as indicated by the colours of the overlapping segments in the Venn diagram in B.
Non-significant genes are plotted in grey. Genes which are significant in all comparisons are
highlighted in pink are also labelled with their gene symbol. B) Venn diagram of overlaps of
significantly differentially expressed genes from the three comparisons. C) Dot plots comparing
pathway enrichment (rows) for up and downregulated genes from each comparison (columns).
Each plot is titled with the source of the enriched pathways: KEGG, Reactome and Disease
Ontology. The labels on the x-axes indicate the transcriptional signature. The enriched terms
are listed on the y-axes. The size of each dot indicates the gene ratio; the ratio between the total
number of genes in the enriched term and the number of significantly differentially expressed
genes in the signature in that term. The colour of the dots indicates the adjusted P.value as
shown in the key (bottom).
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4.3.2 β-catenin signature genes significantly overlap with those in the
published dataset
Following on from the differences seen in the cell-of-origin signature, I went on to compare the
effects of β-catenin KO in the published dataset with my own data set. In the published study
(Siriboonpiputtana et al. 2017), differential analysis was conducted using the Limma package.
However, as the results were highly comparable, I chose to continue using EdgeR for this analysis.
The same design model was used for each differential expression comparison to account for the
cell line or “experiment” (“60” or “69”): ~experiment+genotype.
In the published dataset (Siriboonpiputtana et al. 2017), when we knocked-out β-catenin
in LSKME we obtained over 1000 differentially expressed genes. In contrast with LSKME, β-
catenin KO in GMPME allowed detection of less than 200 genes (Figure 4.2A, top & 4.2B). This
difference may be explained by greater biological variation between GMPME replicates than
LSKME replicates, obscuring the transcriptional differences (see subsection 3.3.2, Figure 3.2C).
Similarly, LSKME replicates in the 2015 study exhibit greater within-group variance than the
LSKME replicates in the 2014 study (see subsection 3.3.2, Figure 3.2C & D). Thus, there are
fewer detectable differentially expressed genes for LSKME in the 2015 study than the 2014 study.
However, although differences in significant genes may be explained by reduced statistical power,
it cannot explain the disconnect of log fold changes between the 2014 and 2015 LSKME datasets
shown by an R2 value of 0.09 Figure 4.2A (top). There is also a reduction of observable targets
in GMPME, but less obviously so (Figure 4.2A bottom & Figure 4.2B).
Nonetheless, despite their differences, many of the same enriched pathways remain in the
upregulated genes following β-catenin KO (Figure 4.2C). Upregulated genes in all comparisons
overwhelmingly highlight pathways related to immune response (Figure 4.2C). However, enriched
pathways for downregulated genes such as the HIF-1 signalling pathway in GMPME and cell cycle
pathways in LSKME for 2014 samples were no longer detectable in 2015 samples. As would be
expected, overlaps between the 2014 and 2015 β-catenin KO signatures were found to be highly
significant by permutation test and hypergeometric test ( Table 4.3). Interestingly, comparison
of genes affected by β-catenin loss in GMPME but not LSKME in a Venn diagram (Figure 4.2B)
revealed Growth arrest and DNA damage-inducible protein alpha (Gadd45a) to be consistent
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Figure 4.2: Comparison of transcriptomic effects of β-catenin KO across
experiments A) A comparison of log-fold changes between 2014 and 2015 studies across
all genes in LSKME (top) and GMPME (bottom). As indicated by the key (bottom): Grey points
are non-significant, red points are significant genes unique to the 2014 dataset, blue points are
unique to the 2015 dataset and purple points are significant in both. B) Venn diagram showing
the overlaps between comparisons in each dataset. Gadd45a is highlighted as a target unique to
GMP which is consistently found if the 2014 and 2015 datasets are analysed separately. C) A
comparison of the enriched KEGG pathways (top) and WikiPathways (bottom) for significant
genes in each signature. The labels on the x-axes indicate the transcriptional signature. The
enriched terms are listed on the y-axes. The size of each dot indicates the gene ratio as indicated
by the key (bottom). The colour of the dots indicates the multiple adjusted P.value as shown in
the key (bottom).
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Table 4.3: Significance of overlaps of differentially expressed genes following β-
catenin deletion in LSKME & GMPME Significance of overlaps calculated using a
permutation test and hypergeometric distribution. “N >= obs.” stands for the number of
overlaps greater than the observed in 10000 permutations. “P.val” is the P.value calculated from
a permutation test with 1000 iterations. “phyper” is the P.value determined by hypergeometric
test.
Significantly Up Significantly Down
Comparison N >=obs. P.val phyper
N >=
obs. P.val phyper
14 GMPME Ctnnb1 | 15 GMPME Ctnnb1 0 <1E-04 6.1E-54 0 <1E-04 8.3E-39
14 GMPME Ctnnb1 | 15 LSKME Ctnnb1 0 <1E-04 1.5E-84 0 <1E-04 1.2E-41
14 GMPME Ctnnb1 | 14 LSKME Ctnnb1 0 <1E-04 5E-136 0 <1E-04 7.7E-61
15 GMPME Ctnnb1 | 15 LSKME Ctnnb1 0 <1E-04 1.4E-92 0 <1E-04 3.6E-33
15 GMPME Ctnnb1 | 14 LSKME Ctnnb1 0 <1E-04 4.2E-52 0 <1E-04 1.1E-19
15 LSKME Ctnnb1 | 14 LSKME Ctnnb1 0 <1E-04 1.2E-71 0 <1E-04 4.9E-09
To confirm the cell-of-origin difference in the upregulation of Gadd45a expression
following β-catenin deletion, I performed RT-qPCR with 3 independent 4-OHT treatments in
both biological replicates used for sequencing. As expected, KO of β-catenin in GMP induced
higher expression of Gadd45a in GMPME but not in LSKME cells (Figure 4.3). In conclusion,
whilst there is an overall reduction in detectable differential expression due to β-catenin knock-out,



































Figure 4.3: Gadd45a upregulation is a unique effect of β-catenin deletion in
GMPME RT-qPCR validation of Gadd45a upregulation in GMPME (n=3, P.values are 0.0145
and 0.0231 for replicate 60 and 69 respectively) and insignificant deregulation in LSKME following
β-catenin. (n=3, P.values are 0.3804 and 0.4785 for replicate 60 and 69 respectively)
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4.3.3 Putative β-catenin targets are largely unique to MLL-ENL
transformed GMP and LSK
The main gene ontology themes in both LSKME and GMPME appear to involve inflammatory
response, cell adhesion, cell cycle and DNA-damage response (Figure 3.8 & 4.2). β-catenin has
previously been shown to be involved in cell adhesion and cell cycle processes (Valenta et al.
2012). However, when I compared our potential targets with curated experimentally validated
β-catenin target genes from the Stanford Wnt homepage (Nusse 2019), I did not see common
genes in the expected pattern (Figure 4.4). Indeed, there is a small overlap from the LSKME
signature, but they are regulated in the opposite direction than expected. For example, Matrix
Metallopeptidase 2/9 (Mmp2/9 ) were up-regulated after KO but their expression is known to be
activated by β-catenin. Furthermore, GSEA analysis of our transcriptomic signatures did not








































































Figure 4.4: Comparison of β-catenin knock-out signatures with known targets and
across tissues Simplified heatmap showing the incidence of differentially expressed genes
responding to β-catenin deletion across different tissues. Each column represents a different
experiment with the exception of the first which includes the Wnt/β-catenin targets taken from
the Wnt Homepage (Nusse 2019). Each row is a gene which is coloured by significance in the
experiment as decoded by the key (left). Genes from the LSKME signature which overlap Wnt
Homepage genes are labelled (right).
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Comparing genes which respond to β-catenin deletion in experiments using the same
transgenic mouse model in different tissues and in similar systems such as MLL-AF9 LSCs (Ng
et al. 2014), listed in Table 4.1, there is little overlap (Figure 4.4). In a similar vein, GSEA
analysis does not reveal any enrichment of these transcriptomic signatures in our differential
expression analysis (Figure 4.5). Together, the findings reported in this section suggest that
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Figure 4.5: GSEA enrichment for genes deregulated after β-catenin knock-out. A-H)
The plots are titles (top) by the comparison for which the GSEA was performed. The line graphs
show the running enrichment score for a given gene set. Below this are barcode plots showing
where the genes in fall in the ranked list. At the bottom, a histogram shows the rank values.
The colour of the line and barcode plot indicates the gene set, as decoded by the table on the
right. The Normalised Enrichment Score (NES) and adjusted P.value (p.adjust) for each gene


































































































































































































































































































































































































































































































































































































































































































4.3.4 Many of our β-catenin targets are also seen in experiments using the
Cre-ER system in our lab
As I showed in subsection 4.3.3 that the transcriptional effects of β-catenin KO are largely
unique to this study, even when compared with very similar cell lines, I wanted to investigate
if there were any treatment related effects in our β-catenin KO signature. During my Ph.D.,
I have had the opportunity to analyse plentiful RNA-Seq datasets from different transgenic
leukaemia models generated in our lab. From my experience I have found that some genes are
recurrently significantly differentially expressed following 4-OHT treatment in vitro, regardless
of genetic background or floxed allele. To see if any of our β-catenin targets could be explained
by the treatment required to deplete β-catenin, I gathered RNA-Seq data from the lab which
required 4-OHT treatment in vitro, these are listed in Table 4.2. In Figure 4.6B I show the
β-catenin dependent signatures alongside multiple other knock-outs in different leukaemia cell
lines generated in our group. Surprisingly, a significant amount of these genes overlap suggesting
there may be a non-specific treatment effect. A summary of the overlaps is represented in a
diagram (Figure 4.6A) and their statistics are listed in Table 4.5. These overlapping genes form
part of the transcriptomic signature involving the immune system and extracellular matrix. I
conclude that although there may be unique effects of β-catenin deletion in our system, we must












































































































































Figure 4.6: Specificity of β-catenin target genes compared to others using 4-OHT
The diagram shows whether differentially expressed genes overlap between two studies was
significant as assessed by permutation test. Significance is indicated by the colour of the line
(key above). B) Plot showing differentially expressed genes in other studies in our lab which use
4-OHT in vitro. Significance is decoded in the key (right). Some of the most recurrent genes are
named by their gene symbol.
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Table 4.5: Significance of overlaps of differentially expressed genes following 4-OHT
treatment in other studies Significance of overlaps calculated using a permutation test and
hypergeometric distribution. “obs. overlap” is the number of genes which overlap in the
comparison defined in the first column. “N >= obs.” stands for the number of overlaps greater
than the observed in 1000 permutations. “P.val” is the P.value calculated from the permutation
test. “phyper” is the P.value determined by hypergeometric test.








14 GMPME Ctnnb1 | CDX2 BMI1 27 0 <1E-04 4.4E-11 40 0 <1E-04 3.6E-23
14 GMPME Ctnnb1 | MLL-AF9 BMI1 71 0 <1E-04 2.4E-65 48 0 <1E-04 8.6E-49
14 GMPME Ctnnb1 | MLL-GAS7 PRMT1 16 3844 0.3844 0.4154 28 0 <1E-04 2.2E-09
14 GMPME Ctnnb1 | AML1ETO Cbfb 184 0 <1E-04 9.1E-79 42 0 <1E-04 6.8E-12
15 GMPME Ctnnb1 | CDX2 BMI1 8 0 <1E-04 4.9E-06 11 0 <1E-04 1.8E-09
15 GMPME Ctnnb1 | MLL-AF9 BMI1 12 0 <1E-04 2.0E-11 17 0 <1E-04 8.7E-24
15 GMPME Ctnnb1 | MLL-GAS7 PRMT1 1 9562 0.9562 0.8332 9 0 <1E-04 4.7E-06
15 GMPME Ctnnb1 | AML1ETO Cbfb 37 0 <1E-04 2.0E-17 13 0 <1E-04 2.6E-07
15 LSKME Ctnnb1 | CDX2 BMI1 12 0 <1E-04 3.8E-07 25 0 <1E-04 1.6E-14
15 LSKME Ctnnb1 | MLL-AF9 BMI1 15 0 <1E-04 2.5E-11 29 0 <1E-04 1.3E-28
15 LSKME Ctnnb1 | MLL-GAS7 PRMT1 2 9692 0.9692 0.9216 21 0 <1E-04 1.8E-08
15 LSKME Ctnnb1 | AML1ETO Cbfb 64 0 <1E-04 5.1E-28 27 0 <1E-04 6.0E-08
14 LSKME Ctnnb1 | CDX2 BMI1 40 1 1.00E-04 1.4E-05 78 0 <1E-04 3.5E-08
14 LSKME Ctnnb1 | MLL-AF9 BMI1 51 0 <1E-04 1.6E-14 45 0 <1E-04 1.7E-08
14 LSKME Ctnnb1 | MLL-GAS7 PRMT1 34 9979 0.9979 0.9952 59 3687 0.3687 0.3651
14 LSKME Ctnnb1 | AML1ETO Cbfb 304 0 <1E-04 8.7E-47 168 0 <1E-04 5.1E-14
CDX2 BMI1 | MLL-AF9 BMI1 28 0 <1E-04 3.6E-20 128 0 <1E-04 3E-122
CDX2 BMI1 | MLL-GAS7 PRMT1 33 0 <1E-04 1.4E-10 93 0 <1E-04 1.0E-26
CDX2 BMI1 | AML1ETO Cbfb 47 0 <1E-04 1.6E-05 65 5 5.00E-04 2.2E-03
MLL-AF9 BMI1 | MLL-GAS7 PRMT1 17 7 7.00E-04 7.7E-04 37 0 <1E-04 1.3E-09
MLL-AF9 BMI1 | AML1ETO Cbfb 78 0 <1E-04 1.5E-28 43 0 <1E-04 3.3E-06
MLL-GAS7 PRMT1 | AML1ETO Cbfb 73 66 0.0066 0.0709 47 8682 0.8682 0.9792
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4.4 Discussion
The first experimental aim of this chapter was to replicate the cell-of-origin signature in
Siriboonpiputtana et al. (2017). On first inspection, it could be observed that dispersion of
expression values was markedly reduced between LSK and GMP origin cells in the 2015 study
(Figure 4.1A). With the exception of Hoxa9, most of the original cell-of-origin signature genes
were not differentially expressed in the 2015 study (Figure 4.1B). Congruently, no cell-of-origin
differentially regulated pathways common to normal and transformed cells from the 2015 study
were found (Figure 4.1C). However, due to the variance in the 2015 dataset, the experiment was
statistically underpowered with only 2 replicates. Indeed, RNA-Seq experiments with few
replicates lead to results which are highly sensitive to analysis methods (Baccarella et al. 2018).
However, when both datasets are combined and the effects of experiment are modelled, some
interesting cell-of-origin differences remain detectable, such as genes involved in cancer and cell
cycle (Figure 3.4).
Next, I investigated whether the effects of β-catenin were similar to those reported
in Siriboonpiputtana et al. (2017). Although fewer genes could be identified as statistically
significant in both LSKME and GMPME (Figure 4.2A & B), most of these genes were also found
in the published study (Siriboonpiputtana et al. 2017), including Gadd45a (Figure 4.2B & 4.3).
The reduction in number of differentially expressed genes following β-catenin KO between the
2014 and 2015 studies could be explained by a number of factors. Firstly a it can be observed that
there is greater within-group variance of LSKME replicates in the 2015 study than the 2014 study.
The reduction of genes responding to β-catenin deletion in both LSKME and GMPME could also
be explained by “leaky” Cre-recombinase activation as demonstrated in Figure 3.1A. Even very
low expression of Cre-recombinase will result in an accumulation of irreversible deletions in the
cell population. Over culture time, cells may adapt to the altered gene expression caused by
deletions and minor changes in the culturing environment.
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On first examination, it was found that our β-catenin targets do not overlap with
functionally validated canonical Wnt targets (Figure 4.4) which could suggest β-catenin performs
unique roles in leukaemia. In addition, applying GSEA revealed that Wnt/β-catenin pathways
were not enriched in our signatures (Table 4.4). In order to understand how general the
transcriptional effects of β-catenin KO are, I compared our results with other studies (Figure 4.4
& 4.5). However, there was generally little consensus across experiments using the same mouse
model in different tissues (Figure 4.4). In fact, only embryonic ovaries showed reduced expression
in a well known Wnt/ β-catenin target, Leucine-rich repeat-containing G-protein coupled receptor
5 (Lrg5 ). Most surprisingly, β-catenin targets do not overlap with those shown in MLL-AF9
transformed c-kit cells (Ng et al. 2014). The lack of consensus between our β-catenin KO
experiment and other tissues was also confirmed by GSEA (Figure 4.5).
Some of the differences in transcriptomic signatures between published studies may
be explained by the context in which β-catenin was deleted. For example, Ng et al. (2014)
transplanted MLL-AF9 transformed haematopoietic cells into recipient mice and treated them
with polyinosinic:polycytidylic acid (pIpC) to induce β-catenin deletion. RNA was obtained
from GFP positive sorted cells after leukaemia development. As previously mentioned in
section 1.7, LSCs show increased activation of β-catenin over Pre-LSCs and also show an increase
in conventional Wnt signalling target expression (Yeung et al. 2010). This may be due to
secondary genetic events in LSCs such as the FLT3-ITD mutation which has been shown to
increase β-catenin activity in AML (Kajiguchi et al. 2007). β-catenin dependency was shown to
be conditional in vivo however, deletion of β-catenin and subsequent RNA-Seq was conducted in
vitro with Pre-LSCs (Siriboonpiputtana et al. 2017). It is important to note that although β-
catenin is constitutively expressed in most tissues, it is the activation of β-catenin and suppression
of its destruction which is critical for its involvement in transcription (see Figure 1.6). The lack
of canonical target effects could be due to insufficient β-catenin activation in pre-LSCs. Our
β-catenin signature may be further reduced by depletion of β-catenin through leakiness of the
Cre-recombinase in the absence of tamoxifen (Figure 3.1A). However, as the RNA-Seq in Ng
et al. (2014) also failed to show expected Wnt targets (Figure 4.4), it remains unclear which
expression signature is more relevant.
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Furthermore, the absence of known targets in gene expression signatures or unexpectedly
modest phenotypic effects after gene KO is not a phenomenon unique to β-catenin deletion. It has
been hypothesized that this is in part due to transcriptional redundancy mechanisms (El-Brolosy
and Stainier 2017). This effect was first demonstrated in (Rossi et al. 2015) by comparing
Epidermal Growth Factor-Like Protein 7 (egfl7 ) mutants and morphants in zebrafish. The study
found that genetic knock-outs elicited upregulation of egfl7 target genes whilst knockdown did
not. Very recently, further compelling arguments for caution against the use of certain KO models
for unpicking molecular mechanisms of transcription factors were published in Nature. It was
shown that transcription of faulty mRNA in a process called Nonsense Induced Transcriptional
Compensation (NITC) causes increases in the expression of the transcription factor target genes
(Ma et al. 2019). Indeed, a NITC response may by triggered in the β-catenin model we utilise
in this study as a truncated mRNA is still transcribed following KO (see subsection 3.3.1,
Figure 3.1F). The implications of this could also extend to the study of β-catenin in normal
haematopoiesis and may partially explain discrepancies between the effect of Lymphoid enhancer-
binding factor-1 (Lef1 ) KO (Reya et al. 2000) and β-catenin deletion (Cobas et al. 2004; Jeannet
et al. 2008). This research will hopefully influence the design of new models to avoid this response
which may be responsible for widespread irreproducibility in molecular analyses of single gene
knock-outs (Ma et al. 2019).
As mentioned in section 1.3, β-catenin has dual functionality, as well as its diverse
roles in transcription, β-catenin is critically involved in cell adhesion. Consistent with this, GO
terms related to the extracellular matrix were enriched amongst β-catenin targets (Figure 3.8).
Abolishment of homing ability of was shown not be the cause of β-catenin dependency of GMPME
(Siriboonpiputtana et al. 2017). Impaired cell adhesion ability has already been put forward as
a possible reason for requirement of β-catenin in LSCs (Chung et al. 2002; Lane et al. 2011).
Surprisingly however, some validated Wnt targets, such as Matrix Metallopeptidase 2 and 9
(Mmp2/9 ) and Claudin 1 (Cldn1 ) are unexpectedly upregulated after knock-out in LSKME
(Figure 4.4). Mmp2/9 belong to the matrix metallopeptidase family of enzymes involved in
the degradation of the extracellular matrix which have been shown to be critically involved in
metastasis (Conlon and Murray 2019). Cldn1 is involved in formation of tight junctions and like
MMPs are involved in the spread of cancers (Tabariès and Siegel 2017). A possible explanation
could be a non-specific effect of 4-OHT, as Nilsson et al. (2007) showed that Mmp9 and Mmp2
are positively regulated by tamoxifen in human cells in culture.
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With great consistency, deletion of β-catenin seems to cause activation of immune
response genes (Figure 3.8 & 4.2C). Intriguingly, it was recently shown that the Wnt/ β-catenin
pathway may be hijacked by solid tumours to escape and increase tolerance to the host immune
response (Pai et al. 2017). However, I had observed similar gene signatures in differential analysis
of other projects using the same Cre-ER system in vitro in the lab and decided to investigate this
further (Figure 4.6 and Table 4.5). It could be argued that immune response genes are genuine
frequent common targets of transcription factors involved in leukaemia. Indeed, regulation of
inflammation is critical to leukaemia development (Giles et al. 2014). However, Cre-recombinase
activation has been shown to cause toxicity to cells in vitro due to DNA damage and presence of
recombination products triggering an interferon response in vitro (Janbandhu et al. 2014; Liu
et al. 2018; Loonstra et al. 2001; Pepin et al. 2016; Higashi et al. 2009). One particular study has
shown that we see this immune response regardless of the presence of floxed alleles (Janbandhu
et al. 2014). Specifically, Cre-ER toxicity has been noted in haematopoietic cells (Higashi et al.
2009). These studies highlight the possibility that molecular effects of β-catenin depletion may
be overshadowed by Cre-mediated excision side-effects. There are several strategies suggested
to mitigate these issues including self excising retroviral vectors and chemical inhibitors of the
interferon response (Silver and Livingston 2001).
Whether or not the observed expression changes in response to β-catenin deletion are
due to loss of transcriptional regulation mediated by β-catenin or model system effects, the in
vivo consequences of β-catenin deletion in GMPME remain. As I am to attempt to functionally
validate my findings in the same cell lines used for RNA-Seq, I can only count on genes which are
consistent between studies. For functional analysis it would be logical to pursue genes which a
uniquely perturbed in GMPMEs. Simply comparing the overlaps between differentially expressed
genes highlighted Gadd45a as a consistent GMPME unique target (Figure 4.2B & 4.3). Gadd45a
is also a biologically plausible target, as it is a cell cycle arrest mediator regulated by p53, which
has been shown to interact with β-catenin in the context of MLL leukaemia (Lynch et al. 2016).
Additionally, methylation of Gadd45a has been shown as a poor prognostic factor in human
leukaemia (Perugini et al. 2013). In the next chapter I will continue investigating Gadd45a




The role of Gadd45a in GMP
derived MLL-ENL LSCs
5.1 Introduction
In the previous chapter, I highlighted Growth arrest and DNA damage-inducible protein alpha
Gadd45a as a β-catenin target unique to MLL-ENL pre-LSCs of GMP origin. As β-catenin has
been shown to be required for leukaemia development from MLL-ENL transformed cells of GMP
origin (Siriboonpiputtana et al. 2017), GMP specific β-catenin targets should provide us with
greater information of the mechanism by which β-catenin is required in vivo.
The primary function of Gadd45a is a growth arrest mediator, working in collaboration
with p53, therefore it makes sense that Gadd45a alone would act as a tumour suppressor.
Intriguingly, Gadd45a is also involved in the re-activation of genes silenced by DNA methylation
through (Barreto et al. 2007). Particularly in the context of cancer Gadd45a is also important for
maintaining cell-cell adhesion (Ji et al. 2007). In fact, silencing of Gadd45a in human leukaemia
via DNA methylation has been demonstrated as a factor for poor prognosis (Perugini et al. 2013).
Suppression Gadd45a was demonstrated to cause a block in myeloid differentiation (Perugini
et al. 2009). Gadd45a has also been shown to directly interact with β-catenin in leukaemia,
reducing its activity by translocation of β-catenin to the mitochondria (Voli et al. 2015; Lynch
et al. 2016). Gadd45a loss can protect MLL-fusion transformed Pre-LSCs from mitochondrial
reactive oxygen species (ROS) and cell death (Lynch et al. 2016).
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However, based on our RNA-Seq data, I hypothesise that the transcription of Gadd45a
may in fact be controlled by β-catenin itself in a feedback loop. I set out to test the importance
of Gadd45a in GMP derived MLL-ENL leukaemia experimentally using a two pronged approach:
Overexpression of Gadd45a in GMP derived LSCs to see if I can eliminate leukaemia and
phenocopy β-catenin KO in GMPME. In addition I used shRNA to knockdown Gadd45a in GMP
derived cells with a β-catenin KO background to see if I could rescue the leukaemic phenotype.
Finally, I tested the effect of Gadd45a overexpression on LSK derived cells to determine if



















Figure 5.1: Schematic illustrating the experimental set up for this chapter.
5.2 Methods
To reduce the time span of transplant experiments I used pre-existing origin specific MLL-ENL
transformed LSCs (previously transplanted into mice). As explained in section 1.6, Figure 1.5,
Pre-LSCs require further genetic or epigenetic events to occur in vivo to produce leukaemia in
vivo. However, it was shown in (Siriboonpiputtana et al. 2017) that β-catenin is still required in
GMP derived MLL-ENL transformed LSCs, therefore the readout of in vivo experiments should
theoretically be equivalent to Pre-LSCs. To confirm the expression of Gadd45a, I calculated
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RT-qPCR using the delta CT method. Where available, log2 fold changes are used to allow
display of standard error in a meaningful way. P.values for RT-qPCR are calculated with a
two-tailed t-test on delta CT values. Detailed methods for cloning are provided in section 2.6 &
2.7. Retroviral/ lentiviral transduction is explained in subsection 2.1.4.
Prior to transplanting cells, I performed in vitro assays to characterize the effect of
Gadd45a perturbation. Firstly, I used a colourimetric assay to measure the metabolic activity
of the cells (MTT assay) as described in subsection 2.7.1. Then, to measure the proliferation
capacity I performed a colony formation assay; I seeded 5000 cells into methylcellulose medium
which is a thick medium allowing each isolated cell to form distinct colonies. Counting the
number of colonies allows us to measure the proliferative capacity of the cells. If there were any
differences found using these assays, I then moved on to check the cell morphology by Cytospin
followed by Wright-Giemsa staining as described in subsection 2.7.2. Additionally, I used Annexin
FACS analysis as described in subsection 2.7.3 to measure the number of apoptotic cells.
To investigate the effects of Gadd45a overexpression or knockdown in leukaemia
development, cells were transplanted into SJL or Black 6 recipient mice as described in
subsection 2.1.5. Mice were sacrificed when they began showing signs of leukaemia or 6 months
after transplant. Following necropsy, I recorded the appearance, size and weight of the spleen
and liver. I took samples of peripheral blood to perform bloodcounts and smears. To confirm
leukaemia, I took white cells from the blood, bone marrow, spleen and liver and performed
immunophenotyping as described in subsection 2.1.5 and analysed the resulting FACS data
using FlowJo software, using the R package CytoML to pull the sample information from the
XML files. Note that in the Gadd45a overexpression experiment, CD45.1 positive cells were
transplanted into Black 6 mice (Figure 5.3D). In contrast, CD45.2 positive cells were
transplanted into SJL mice for the Gadd45a knockdown experiment (Figure 5.6B).
5.3 Results
5.3.1 Gadd45a overexpression shows little phenotypic effect in vitro
After transduction with Gadd45a expressing retrovirus and antibiotic selection, I tested the
expression of Gadd45a with RT-qPCR, achieving overexpression between 10 and 50 fold
(Figure 5.2A). To assess the phenotypic effect of Gadd45a in vitro I performed MTT and colony
114
forming assays. The MTT showed a mild,but insignificant decrease in proliferation after
transduction with pMSCV-Gadd45a (Figure 5.2B, p=0.322). No significant change in colony






















































































Figure 5.2: In vitro Overexpression of Gadd45a A) RT-qPCR showing overexpression
of Gadd45a. B) MTT assay for pMSCV empty vector or pMSCV-Gadd45a transduced cells.
Relative absorbance is calculated by deducting the absorbance of fresh media from the absorbance
of the cells. C) Colony forming assay of pMSCV empty vector or pMSCV-Gadd45a transduced
cells after antibiotic selection. P.values are as indicated and were calculated with a two-tailed
t-test.
5.3.2 Gadd45a overexpression in GMPME eliminates leukaemia in vivo
MLL-ENL transformed cells of GMP origin with confirmed Gadd45a overexpression, alongside
negative control GMPME cells transduced with empty pMSCV vector were transplanted into mice.
5 mice were transplanted each for empty pMSCV vector controls and Gadd45a overexpression.
This experiment was independently repeated once resulting in a combined total of 10 mice per
condition (Figure 5.3).
A leukaemic phenotype was confirmed by splenomegaly (Figure 5.3B & C) engraftment
in the bone marrow and infiltration into the spleen and liver (Figure 5.3D & E). A skew towards
the myeloid lineage was seen in immunophenotyping (Figure 5.3D & E). Mice that lived beyond 6
months were sacrificed and the absence of engrafted donor cells was confirmed by FACS analysis.
Remarkably, whilst showing little effect in vitro (Figure 5.2), Gadd45a overexpression in GMPME






































































































































































































































































































































































Figure 5.3: Gadd45a overexpression eliminates GMP derived MLL-ENL leukaemia
A) Survival curves for transplant of both GMPME with Gadd45a overexpression (purple) or empty
pMSCV vector (red). Censored values are indicated by a vertical line. B) Photograph of spleens
at necropsy. C) Spleen and liver weights for each group at necropsy. P.values for decrease in
spleen and liver weight when Gadd45a is overexpressed are 1.1375E-06 and 3.218E-05 respectively.
D) Immunophenotyping of leukaemia cells from a representative individual transplanted with
GMPME cells transduced with pMSCV empty vector. E) Dotplot showing a summary of FACS
analysis across samples. The y axis indicates the percentage of the parent gate. Gates are as
shown in D.
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5.3.3 Gadd45a knock-down causes an increase in proliferation and
self-renewal
To knockdown Gadd45a expression, I cloned 3 different shRNA sequences into the pLKO lentiviral
backbone. Following lentiviral production and transduction of the shRNA, I tested knock-down
efficiency by RT-qPCR (Figure 5.4A). I found that one shRNA (shGadd45a 3) had markedly more
effective knockdown and was therefore selected for subsequent experiments. Interestingly, when
Gadd45a expression was reduced there was a noticeable and significant increase in proliferation
with or without deletion of β-catenin shown by colony forming assay (Figure 5.4C), this increase
in proliferation was also seen by the MTT assay, but it was statistically insignificant (Figure 5.4B).
I conclude that Gadd45a knock down causes a modest increase in cell proliferation regardless of





































































































Figure 5.4: In vitro knockdown of Gadd45a A) Log fold change of Gadd45a measured by
RT-qPCR following shRNA transduction. P. values are 0.761, 0.045, 0.001 for shRNA-1, shRNA-
2 and shRNA-3 respectively. B) MTT assay in the context of β-catenin deletion. The absorbance
between shScr and shGadd45a treated floxed cells was insignificant (p=0.294). The absorbance
between shScr treated floxed and deleted cells was significant (p=0.026). The absorbance
difference between shScr and shGadd45a treated deleted cells was insignificant (p=0.078). C)
Colony forming assay in the context of β-catenin deletion. shGadd45a expression showed a
significant increase in colony numbers in both floxed (p=0.020) and deleted cells (p=0.013).
β-catenin deletion conferred a significant decrease in colony numbers (p=0.007)
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5.3.4 β-catenin deletion results in apoptosis and differentiation in vitro
As we observed an in vitro phenotype in response to β-catenin deletion (Figure 5.4), which was
not described in Siriboonpiputtana et al. (2017), I went on to examine this effect further. To
investigate this, I monitored transformed β-catenin conditional cells by MTT every 24 hours for
72 hours following addition of 20 nM 4-OHT. The metabolic activity of LSKME is reduced after
24 hours but recovers after 48h (Figure 5.5B, top). This suggests that LSKME suffers toxicity in
response to 4-OHT or β-catenin knock-out, but later recovers without β-catenin present. GMPME
on the other hand continues to decline after 72 hours of 4-OHT treatment (Figure 5.5B, bottom).
Annexin FACS analysis (Figure 5.5C) also shows a greater number of dead or apoptotic cells after
72 hours with a greater effect seen in GMPMEs (bottom) than in LSKMEs (top). In Figure 5.5A
left it can be observed that the normal phenotype of LSKME and GMPME shows mostly large
round mono-nuclei cells also known as blasts. However, after addition of 4-OHT dead cells and
cells with lobed nuclei indicating differentiation are observed more frequently (Figure 5.5A, right).
I conclude that GMPME cell lines used in this study are sensitive to β-catenin deletion in vitro,
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LSK-ME ETOH LSK-ME 4-OHT
GMP-ME 4-OHTGMP-ME ETOH
LSK-ME ETOH LSK-ME 4-OHT
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PI                                                   PI
Figure 5.5: Effect of β-catenin KO with 20 nM 4-OHT. A) Cytospin with Wright-
Giemsa staining in response to 20 nM 4-OHT. Microscope images are labelled with their sample
and treatment. B) MTT assay at time points after 4-OHT treatment. Statistical significance
is not shown as only technical replicates were used for this assay. C) Annexin FACS analysis
to measure apoptosis. The x axis shows PI staining for dead cells. The y axis shows Annexin
staining for apoptotic cells.
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5.3.5 β-catenin deletion resistance emerges in GMPME in vivo
To investigate whether Gadd45a knockdown could rescue leukaemia in GMPME β-catenin knock-
out, I transplanted GMPMEs following confirmation of Gadd45a knockdown and β-catenin
knock-out. 5 mice were transplanted for both β-catenin KO with scrambled shRNA and β-
catenin KO with shRNA targeted to Gadd45a. For positive β-catenin floxed controls, 3 mice
were transplanted. This study was independently repeated once resulting in a total of 10 mice for
each β-catenin KO condition and 6 mice for β-catenin floxed cells. In these transplant studies the
β-catenin conditional cell lines displayed incomplete penetrance with only 40-60% of each group
coming down with leukaemia (Figure 5.6A). Surprisingly, β-catenin KO cells expressing only
the negative scrambled shRNA control was the deadliest of all groups (Figure 5.6A). However,
although there was greater incidence of leukaemia there was a reduction in c-kit cells (Figure 5.6B)
suggesting that there is some effect on the phenotype of the resulting disease.
As LSCs are assumed to acquire addition mutations (see section 1.6, Figure 1.5) in vivo,
it may be speculated that some LSCs become resistant to β-catenin deletion through accumulation
of oncogenic mutations. However, additional experiments also showed that GMPME Pre-LSCs
can develop in vivo resistance to β-catenin KO (Figure 5.7A). In all cases of β-catenin knock-outs
producing leukaemia, I confirmed that the leukaemias were not caused by β-catenin cells which
escaped deletion by performing genotyping PCR for β-catenin on DNA extracted from the
tissues of these mice (Figure 5.7C). As I was unable to replicate in vivo β-catenin dependency
of GMPME, the effect of Gadd45a knockdown on β-catenin dependent MLL-ENL transformed
cells remains inconclusive. Following these data, I wanted to test whether the effect of Gadd45a
overexpression was specific to GMPME. In order to do this I repeated the overexpression of

































































































































































Figure 5.6: β-catenin KO cells showed no significant difference in two transplant
experiments. A) Survival curves for groups in shRNA study indicated by the key (right).
Censored values are indicated by a vertical line. 10 mice were transplanted for each group across
2 independent experiments. B) Representative FACS analysis showing myeloid leukaemia arising
from β-catenin deleted GMPME cells. C) Percentage of FACS populations in bone marrow of
leukaemic mice for each experimental group.
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0 75 150 225 300
LSK fl/fl 60 n=3
LSK fl/fl 69 n=3
LSK -/- 60 n=4
LSK -/- 69 n=4
GMP fl/fl 60 n=3
GMP fl/fl 69 n=3
GMP -/- 60 n=5




















































































































































































Figure 5.7: Survival curve for transplant of cells used for sequencing in this study
A) Survival curve for pre-LSCs used in this study. Groups which are not visible all survived past
300 days. B) Representative example FACS analysis showing engraftment of β-catenin deleted
Pre-LSCs cells. C) PCR to confirm KO is still complete following transplant.
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5.3.6 Gadd45a overexpression in LSKME eliminates leukaemia in vivo
Interestingly, Gadd45a overexpression was found to eliminate leukaemia in LSK derived cells
(Figure 5.8D). As previously described, GMP derived leukaemia was shown to have a greater
latency than LSK (Figure 5.3A & 5.8D). Interestingly, compared with LSKME, increased
variability in GMPME is also seen in FACS analysis (Figure 5.3E and Figure 5.8F) with
surprisingly less infiltration into organs and peripheral blood and a reduction in gr1 and ckit
positive cells in all tissues (Figure 5.3E and Figure 5.8F). It was also apparent that consistently
higher overexpression was achieved in LSKME than in GMPME (Figure 5.2A and Figure 5.8A). I


































































































































































































Figure 5.8: Gadd45a overexpression eliminates LSK derived MLL-ENL leukaemia
A) RT-qPCR showing overexpression of Gadd45a. B) MTT assay for pMSCV empty vector
or pMSCV-Gadd45a transduced cells. C) Colony forming assay of pMSCV empty vector or
pMSCV-Gadd45a transduced cells after antibiotic selection. D) Survival curves for transplant of
both LSKME with Gadd45a overexpression (green) or empty pMSCV vector (blue). Censored
values are indicated by a vertical line. E) Spleen and liver weights for each group at time of
sacrifice. Spleen weight was significantly greater in control experiments (p= 7.012E-08). Liver
weight was not significantly different (p=0.237). F) Immunophenotyping of leukaemia cells from




The aim of this chapter was to investigate whether Gadd45a is a key mediator of GMP-origin
MLL-ENL leukaemia development. Gadd45a overexpression did not show a significant phenotype
in vitro (Figure 5.2B & C). It is interesting to note that from 3 independent experiments, Gadd45a
overexpression was markedly higher in LSKME than GMPME (Figure 5.2A and Figure 5.8A).
In these experiments the same conditions for infection and the same batch of virus was used.
Therefore, one could speculate that GMPME is more susceptible to high expression of Gadd45a
and these cells are lost before the end of antibiotic selection. Another explanation could be that
GMPME derived cells are in general more resistant to retroviral integration.
Whilst no significant phenotype is detectable in vitro (Figure 5.2B & C, Figure 5.8B &
C), Gadd45a eliminated leukaemia in vivo (Figure 5.3A & 5.8D). Although both LSK and GMP
derived leukaemia was eliminated by Gadd45a overexpression, there are significant differences in
disease latency (Figure 5.3A compared to 5.8D) and organ infiltration (Figure 5.3E compared
to 5.8F) which has been demonstrated before (Krivtsov et al. 2013). Organ size was markedly
increased in GMPME compared with LSKME (Figure 5.3C compared to 5.8E), however the values
are not normalized by animal weight so this may be due to ageing. More work is required
to underpin the molecular mechanism for disease elimination via Gadd45a overexpression in
vivo and its drug resistance properties and to link β-catenin depletion to its transcription.
Moreover, it would be interesting to see if the effects of Gadd45a overexpression is specific to
MLL-ENL leukaemia or if other fusions or mutations would also be affected. Notably, retroviral
overexpression was not comparable to physiological changes in expression (Figure 5.2A & 5.8A
compared to Figure 4.3). One could argue that we may see a difference in cell-of-origin effect
if we were to overexpress Gadd45a at more physiological levels. Further experiments could be
improved by titrating the virus in combination with using a vector with a weaker promoter
to obtain a similar level of overexpression to that seen following β-catenin deletion. However,
the fact that Gadd45a overexpression eliminates leukaemia in LSKME does not discredit the
hypothesis that Gadd45a may confer β-catenin dependency specificity in GMPME.
As there was a significant reduction in viability after β-catenin knock-out (Figure 5.4B,
C & 5.5), I decided to transduce cells with Gadd45a shRNA prior to β-catenin knock-out.
The effect of β-catenin deletion was also markedly worse in GMPME than LSKME (Figure 5.5).
However, it is possible that this ordering may be critical to the phenotype produced by Gadd45a
knock down in vitro. Moreover, this result was unexpected as previously, no significant differences
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in cell cycle or proliferation were reported following β-catenin KO (Siriboonpiputtana et al. 2017).
Interestingly, knocking down Gadd45a mildly increases proliferation of GMPME cells, and some
of this advantage was retained after β-catenin KO (Figure 5.4C) suggesting downregulation of
Gadd45a unlocks greater proliferative capacity, consistent with its roles in leukaemia (Perugini
et al. 2013).
Despite the exaggerated phenotype observed in response to β-catenin deletion in vitro
(Figure 5.5), β-catenin KO GMPME LSCs and Pre-LSCs unexpectedly and repeatedly gave
rise to leukaemia in vivo (Figure 5.6 & 5.7). This suggests that while originally sensitive to
β-catenin deletion, mutations or epigenetic states may be acquired in vitro which allow GMPMEs
to overcome their β-catenin requirement in vivo. It could be argued that development of
tolerance to β-catenin KO may have been encouraged via leakiness of Cre-recombinase, which is
demonstrated in Figure 3.1A and Figure 5.7C. As discussed in section 4.4, this could be due
to transcriptomic acclimatisation. Because of the inconsistencies in β-catenin requirement for
leukaemia development from GMPME with Siriboonpiputtana et al. (2017), as can be seen in
Figure 5.6 & 5.7, I was unable to test if Gadd45a knockdown could rescue the β-catenin deletion
phenotype in GMPME.
To determine if the phenotypic differences seen between leukaemias with distinct
cell-of-origin could be due to selective mutations, Siriboonpiputtana et al. (2017) investigated
genic and intergenic Single Nucleotide Polymorphisms (SNPs). This analysis showed that the
number of SNPs between cell lines of different cellular origins wasn’t significantly different to
the number of SNPs found between cell lines derived from different FACS experiments and
MLL-ENL transductions. However, this analysis was limited in that we did not have the original
genome sequence of the cells-of-origin preceding transformation. Additionally, the functional
consequences of individual SNPs were not explored. Genomic DNA used for SNP analysis in the
Siriboonpiputtana et al. (2017) study was taken from the batch of cells that I had previously
cultured for RNA-Seq.
Cultured cell lines are the lifeblood of cancer research leading to many cornerstone
discoveries. However, whilst original studies had shown that cell lines were relatively stable in
vitro, recent research reveals that cancer cell lines and even short-term cultured primary tumour
cells are highly genetically and transcriptomically unstable (Ben-David et al. 2017; Ben-David
et al. 2018; Fong et al. 2015). Meta-analysis comparing cancer cell lines with that of primary
patient samples found that there was often more differential expression between cell lines than
cancer type. This suggests that over time, culturing conditions can lead transcriptional programs
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away from those of their primary origin (Gillet et al. 2011). Recently, sophisticated bar-coding
studies of single clones demonstrated how positive selection leads to cell line evolution fine-tuned
to culture conditions (Ben-David et al. 2018). Indeed, the rapid adaptive nature of leukaemia
cells was recently exploited to create an in vitro model of drug resistance through exposure to
stress (Fong et al. 2015). These studies highlight the need for greater genomic characterization
of cell lines and give some insight behind the growing irreproducibility crisis in cancer research.
In cancer, genetic or transcriptional dependency doesn’t have a binary definition, rather
dependency may be scored by effect (Tsherniak et al. 2017). Whilst β-catenin has recurrently
been shown to be critical for MLL-fusion transformation, the degree of dependency shows
variation (Siriboonpiputtana et al. 2017; Gandillet et al. 2011; Griffiths et al. 2010; Siapati et al.
2011; Wang et al. 2010a; Yeung et al. 2010; Ng et al. 2014). With the exception of our paper
(Siriboonpiputtana et al. 2017), β-catenin dependency in these studies can be interpreted as
a significant reduction of Leukaemia Initiating Cells (LICs) rather than complete leukaemia
abolishment. Nevertheless, even if there is a 1000-fold reduction in LIC it is still possible
that leukaemia will still arise with greater latency. For example, Ng et al. (2014) showed that
leukaemia would arise from MLL-AF9 transformed LSK β-catenin deleted cells with a similar
latency to β-catenin intact cells if over 1×104 cells were transplanted. It is noteworthy that in this
case, β-catenin deletion was induced in vivo whereas in my experiments and (Siriboonpiputtana
et al. 2017) deletion was induced in vitro. However, unexpectedly in both of my experiments,
β-catenin deleted GMPMEs were the first group to show signs of leukaemia (Figure 5.6A and
5.7A). Additionally, the failure of floxed cell lines to induce leukaemia seen in Figure 5.7A
highlights possible technical issues with this particular experiment. Genomic deletion of retro-
virally introduced transgenes has been frequently observed (Migliaccio et al. 2000), it is therefore
possible that failure to induce leukaemia could be due to decreases in MLL-ENL expression over
time.
Furthermore, analysis including both samples from (Siriboonpiputtana et al. 2017) and
RNA-Seq produced independently for this study showed that the effect of β-catenin deletion
is largely equivalent in LSKME and GMPME (see subsection 3.3.7 & 3.3.8, Figure 3.7 & 3.8).
Therefore, we may expect that the transcriptomic and epigenomic effects of at least β-catenin
KO should remain equivalent regardless of the conflicting dependency observed. Considering








Abnormal DNA methylation and chromatin modification are crucial features of CSCs, in addition
to mutational and transcriptional profiling, increasingly, we are exploring the epigenomes of cancer
cells in our search for therapeutic strategies targeting CSCs (Mohammad et al. 2019). Chromatin
precipitation coupled with next generation sequencing (ChIP-Seq) allows us to sequence DNA
which is bound by specific proteins. β-catenin has been shown to associate with epigenetic factors
such as histone modifying enzymes (see section 1.7 and Figure 1.6). To elucidate mechanisms of
transcriptional control mediated by β-catenin and explore cell-of-origin differences, I performed
ChIP-Seq and analyses for key histone modifications. Histone modifications were explicitly
chosen for their known effects on transcription: H3K4 tri-methylation for active promoters,
H3K4 mono-methylation H3K27 acetylation for enhancers and H3K27 tri-methylation for silent
promoters. Specifically, H3K4me3 is crucial for the initiation of transcription whilst H3K27me3
inhibits transcription elongation.
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Before the biological questions of this chapter can be addressed it is paramount that we
assess the ChIP-Seq quality in terms of read quality, mappability, duplication and enrichment
over noise. Following confirmation of successful ChIP-Seq, to ensure antibody specificity, I should
observe histone modification patterns congruent with the literature. In a similar vein, I seek
the expected correlations between histone modification and RNA-Seq data. Furthermore, I will
investigate if based on these histone modification data, I can predict cis-regulatory elements with
known characteristics. Once I have characterised these data, I will quantify changes in histone
modification at cis-regulatory elements dependent on cell-of-origin and β-catenin status. I will
determine whether there are common biological themes of deregulated promoters and enhancers;
pathways of coordinated regulation or motifs which may shed light on the transcription factors
involved. Finally, I will attempt to correlate any of these changes with direct β-catenin binding.
6.2 Methods
6.2.1 ChIP-Seq Generation
With the aim to maintain compatibility with RNA-Seq, I performed ChIP on cell pellets which
had been fixed and frozen at -80°C on the same day that cells were collected for RNA extraction.
A large number of aliquots were fixed as occasionally multiple attempts were required to achieve
comparable sonication profiles within the same experiment. Consistent sonication was found
to be the most crucial step of the assay to control non-specific DNA pull-down. As thoroughly
described in section 2.8, I performed ChIP for: H3K4me3, H3K4me1, H3K27ac and H3K27me3.
Before library preparation and sequencing, I first tested for enrichment using positive
and negative control regions by ChIP-qPCR. Percentage input, the proportion of total input DNA
pulled down by the ChIP assay, was calculated using the ΔCT method. ChIP-qPCR reactions
were set up in triplicate to adjust for technical variance. Following ChIP-qPCR validation, I
sequenced samples at low coverage (4-5 million reads) to determine enrichment at the genomic
level; with the exception of H3K4me3 which was sequenced in a single run. Following satisfactory
results, I re-sequenced libraries with the aim to obtain approximately 20 million reads per sample.
For each histone modification ChIP, sequencing libraries from all samples were multiplexed
together in the same lane to avoid introducing technical batch effects. Details of all sequencing
runs are shown in Table 6.1.
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Table 6.1: ChIP-Seq samples generated for this study
Cell-of-Origin Factor β-catenin Rep Run ID(s) Date(s)
LSK input fl/fl 69 241 Jan-16
LSK input -/- 69 242 Jan-16
GMP input fl/fl 69 243 Jan-16
GMP input -/- 69 244 Jan-16
LSK H3K4me3 fl/fl 60 229 Jan-16
LSK H3K4me3 -/- 60 230 Jan-16
LSK H3K4me3 fl/fl 69 233 Jan-16
LSK H3K4me3 -/- 69 234 Jan-16
GMP H3K4me3 fl/fl 60 231 Jan-16
GMP H3K4me3 -/- 60 232 Jan-16
GMP H3K4me3 fl/fl 69 235 Jan-16
GMP H3K4me3 -/- 69 236 Jan-16
LSK H3K4me1 fl/fl 60 239, 279, 452 Jan16,Apr16,May16
LSK H3K4me1 -/- 60 277, 450 Apr16,May16
LSK H3K4me1 fl/fl 69 273, 446 Apr16,May16
LSK H3K4me1 -/- 69 274, 447 Apr16,May16
GMP H3K4me1 fl/fl 60 240, 280, 453 Jan16,Apr16,May16
GMP H3K4me1 -/- 60 278, 451 Apr16,May16
GMP H3K4me1 fl/fl 69 275, 448 Apr16,May16
GMP H3K4me1 -/- 69 276, 449 Apr16,May16
LSK H3K27me3 fl/fl 60 723, 770, 790 Apr17,May17
LSK H3K27me3 -/- 60 724, 771, 791 Apr17,May17
LSK H3K27me3 fl/fl 69 727, 774, 794 Apr17,May17
LSK H3K27me3 -/- 69 728, 775, 795 Apr17,May17
GMP H3K27me3 fl/fl 60 725, 772, 792 Apr17,May17
GMP H3K27me3 -/- 60 726, 773, 793 Apr17,May17
GMP H3K27me3 fl/fl 69 729, 776, 796 Apr17,May17
GMP H3K27me3 -/- 69 730, 777, 797 Apr17,May17
LSK H3K27ac fl/fl 60 731, 778, 798 Apr17,May17
LSK H3K27ac -/- 60 732, 779, 799 Apr17,May17
LSK H3K27ac fl/fl 69 735, 782, 802 Apr17,May17
LSK H3K27ac -/- 69 736, 783, 803 Apr17,May17
GMP H3K27ac fl/fl 60 733, 780, 800 Apr17 May17
GMP H3K27ac -/- 60 734, 781, 801 Apr17,May17
GMP H3K27ac fl/fl 69 737, 784, 804 Apr17,May17
GMP H3K27ac -/- 69 738, 785, 805 Apr17,May17
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6.2.2 Correlating ChIP-Seq with RNA-Seq
Initial processing steps of ChIP-Seq analysis are detailed in section 2.9. ChIP heatmaps were
generated using the R package EnrichedHeatmap v1.16.0 (Gu et al. 2018). To simplify these
data for visualisation, replicates for each condition were merged into an average value. To
quantify the relationship connecting gene expression and individual histone modifications, I used
countOverlaps from the GenomicRanges v1.38.0 package (Lawrence et al. 2013) to count the
number of reads falling at the promoter or gene body. To ensure the RNA-Seq and ChIP-Seq
were annotated consistently, coordinates for genomic features were created using the same
annotation file used for RNA-Seq processing. To ensure that there was a single ChIP-Seq value
for each histone mark for each gene, in this analysis I defined promoters as 1 kb upstream and 2
kb downstream of the most upstream TSS of each gene. Using base R functions, I calculated
the Spearman’s correlation between normalised gene expression and ChIP-Seq tags per million
mapped reads at the promoter or gene body. To perform PCA and calculate the global Pearson’s
correlation between ChIP-Seq samples I used csaw v1.20.0 (Lun and Smyth 2016) to count reads
falling into 10 kb non-overlapping bins across the entire genome. Counts were normalised using
trimmed mean of M-values (TMM) normalisation.
6.2.3 Regulatory state segmentation
ChromHMM (Ernst and Kellis 2017) uses a multivariate Hidden Markov Models (HMM) to
learn and characterise patterns in genomic data. Markov models are suited to this task, as the
regulation of transcription is fundamentally a stochastic process. The first step in the process
required that aligned reads are converted to binarised data (0 or 1) depending on the presence
or absence of ChIP-Seq tags above a threshold within bins of pre-determined length. I trained
ChromHMM v1.20 (Ernst and Kellis 2017) to find 4-16 chromatin states based on the four
histone modifications in 200 bp bins; after training ChromHMM to discover up to 16 states, I
decided that 6 states were sufficient to segment the genome into non-redundant functional units.
To compare chromatin states between conditions, I split the segments back into 200
bp non-overlapping bins. Slight shifts of the boundaries of regulatory elements which could
simply due to fractionation differences may be falsely detected as chromatin state transitions.
Attempting to eliminate these false positives, I merged transitions where there was a break of
under 400 bp. Chromatin states are predicted with ChromHMM for each sample individually.
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To look at transitions between chromatin states depending on experimental conditions I
took only chromatin states which were consistent between replicates. I then compared consistent
states across replicates for each 200 bp bin and represented transitions as chord diagrams using
the circlize v0.4.9 package (Gu et al. 2014). I plotted heatmaps for ChromHMM states using
EnrichedHeatmap v1.16.0 (Gu et al. 2018).
6.2.4 Gene-centric quantitative differential ChIP-Seq analysis
The most widespread pipelines for ChIP-Seq analysis depend on characterizing enriched regions,
or “peaks”, to call high confidence DNA-protein binding events. Following peak calling, we may
qualitatively or quantitatively compare peak regions between conditions. In comparison to
transcription factor ChIP-Seq, histone modification data rarely show discrete patterns especially
when observing heterogeneous cell populations. Histone modification differences between
experimental conditions are more likely to show continuous changes in signal and differing
spatial deposition patterns. Using peaks to identify quantitative differences between conditions
in predominantly continuous data reduces the resolution for differential signal detection (Lun
and Smyth 2016).
Considering this, I chose to use analysis workflows provided in the csaw v1.20.0 package
(Lun and Smyth 2016), which can be used to quantify reads in sliding windows and calculate
significantly differentially bound regions using edgeR v3.28.0 (Robinson et al. 2010). After
calculating window-based statistics, windows can be grouped based on areas of interest, such
as genes or promoters. This allows us to keep the resolution of observed differences, while
maintaining error control. Firstly, I counted reads into windows between 150 bp and 2 kb.
Next, I counted 10 kb bins across the genome to determine global background. I filtered for
windows with a read count at least 2 log fold above the global background signal. To account for
systematic differences in enrichment between samples I applied trimmed mean of M-values (TMM)
normalisation for enriched regions. Differential expression analysis for ChIP-Seq between LSKME
and GMPME or “celltype” was performed using a design model to account for experimental
replicate: ~experiment+celltype. Differential expression analysis for ChIP-Seq between β-catenin
floxed and β-catenin deleted or “genotype” was performed for LSKME and GMPME separately
using a design model to account for experimental replicate: ~experiment+genotype.
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To group windows of different sizes, I used the consolidateWindows function from
csaw. Windows were aggregated over five different region categories: 1. “Genes” Gene-bodies
minus the promoter region. 2. “Naïve” regions created by merging nearby windows of high
enrichment. 3. “peaks” MACS2 peaks. 4. “Promoter by gene” regions 2 kb upstream and 1 kb
downstream of the first annotated TSS. 5. “Promoter by transcript” regions 2 kb upstream and
1 kb downstream of every annotated TSS. To identify common themes amongst differentially
bound regions I subjected the genes associated with significantly differentially modified regions
to pathway analysis with clusterProfiler v3.14.3 (Yu et al. 2012). Ensembl gene identifiers were
converted to Entrez gene IDs with Ensembl biomaRt v2.42.0 (Durinck et al. 2009). To create
genomic coverage tracks for visualisation, I used deepTools bamCoverage v2.5.4 (Ramírez et al.
2014; Ramírez et al. 2016), the signal was normalised using a scale factor. The scale factor
was calculated by first multiplying the total number of reads by the TMM normalisation factor
calculated with csaw, 1×106 was then divided by this number. Coverage tracks were plotted
using functions from rtracklayer v1.46.0 (Lawrence et al. 2009) and Gviz v1.30.0 (Hahne and
Ivanek 2016).
6.2.5 Enhancer Analysis
Putative enhancers were crudely defined as H3K4me1 peaks present in both replicates for each
condition. To filter out promoters, peaks overlapping 2 kb upstream and 1 kb downstream of
TSSs were removed. Putative enhancer regions were then filtered for those co-localised with
H3K27ac peaks to identify active enhancers. For identifying quantitative histone modification
differences at putative enhancers, I used DiffBind v2.14.0 (Stark and Brown 2011), which uses
total count numbers for specified regions, such as peaks or promoter regions. To look for de novo
enhancers I also compared peak locations using DiffBind.
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6.2.6 Motif Enrichment
Histone ChIP binding sites as opposed to transcription factor ChIP, are not usually appropriate
for de novo motif discovery as it is unlikely that a single motif is present in most or all of the
sequences. Therefore, I used the R package PWMEnrich v4.18.0 (Stojnic and Diez 2018) to
discover the locations of known motifs within differentially bound regions. PWMEnrich scans
input sequences and calculates their enrichment over expected occurrence using a precomputed
background within mouse promoters.
6.2.7 Comparisons with published β-catenin ChIP-Seq
To elucidate whether the changes in ChIP-Seq signal could be directly linked to β-catenin
occupancy I collected all available β-catenin ChIP-Seq data I could identify from public databases
(GEO, ENA, SRA and DRA), these are listed in Table 6.2. I processed the ChIP-Seq data as
previously described in section 2.8 and calculated quality control metrics. Peak locations from
β-catenin ChIP-Seq experiments in mice with sufficient quality were compared with promoters
exhibiting differential histone modification levels following knock-out. The significance of
overlaps between differentially modified regions and β-catenin ChIP-Seq peaks was calculated
using permutation tests with functions from regioneR v1.18.0 (Gel et al. 2016).
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Table 6.2: Available published β-catenin ChIP-Seq data




































GSE84456* H102; SantaCruz mouse Colon crypt NA
(Schuijers
et al. 2015)













































GSE117944 71–2700;ThermoFisher human K562 Wnt3a
(Shooshtarizadeh
et al. 2019)
* Raw data not available.
6.2.8 β-catenin ChIP in constitutively active β-catenin cell lines
Attempts to achieve β-catenin ChIP enrichment were unsuccessful using the β-catenin floxed
MLL-ENL transformed cell lines in this study. To overcome this and get insight into β-catenin
binding in MLL-ENL transformed cells, I utilised a β-catenin activation model. I crossed mice
harbouring an allele of Ctnnb1 with LoxP sites flanking exon 3, with transgenic mice expressing
Cre-ER and produced MLL-ENL transformed cells from their bone marrow using the RTTA
method described in section 2.1. As explained in subsection 2.1.1, deletion of exon 3 of Ctnnb1
results in expression of a constitutively active form of β-catenin.
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Exon 3 of Ctnnb1 was excised by treating cell lines with 20 nM 4-OHT. To detect
presence of the truncated β-catenin protein I used western blot and immunofluorescence as
described in section 2.4 & 2.10 respectively. Using anti-β-catenin antibodies from BD Biosciences
(#610154) and Cell Signalling Technology® (#8480) and anti-TCF4/TCF7L2 antibody from
Cell Signalling Technology® (#2569), I performed ChIP as described in section 2.8 followed by
ChIP-qPCR. β-catenin binding sites were obtained from literature involving β-catenin ChIP and
are shown in Table 6.3. The expression of a well known β-catenin transcriptional target, Cyclin
D1 (Cnnd1 ) (Nusse 2019) was quantified by RT-qPCR in ETOH treated control cells and those
expressing constitutively active β-catenin.
Table 6.3: β-catenin ChIP-qPCR primers
Primer Orientation Sequence (5’ to 3’)
Myc TSS Forward GTCACCTTTACCCCGACTCA
Myc TSS Reverse TCCAGGCACATCTCAGTTTG
Myc Enhancer Forward TCTTTGATGGGCTCAATGGT
Myc Enhancer Reverse TTCCCTTCACCTGATGAACC
Ccnd1 TSS Forward CCGGCTTTGATCTCTGCTTA
Ccnd1 TSS Reverse CGCGGAGTCTGTAGCTCTCT
Axin2 TSS Forward GAGCGCCTCTGTGATTGG
Axin2 TSS Reverse GCGAACGGCTGCTTATTTT
6.3 Results
6.3.1 Successfully enriched ChIP was obtained
Before analysis of histone modifications can proceed, quality assessment of these data should
be performed to ensure that meaningful results may be extracted. Quality control steps are
carried out both before and after sequencing. Prior to sequencing, I performed ChIP-qPCR for
positive and negative control regions. Homeobox genes: Myeloid Ecotropic Viral Integration Site
1 (Meis1 ) and Homeobox A9 (Hoxa9 ), are targets of MLL fusions and therefore were used as
positive controls of active promoters and enhancers.
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Consistently, the active chromatin marks H3K4me3 and H3K27ac were found to be
enriched at these promoters (Figure 6.1). H3K4me1 was shown to have enrichment for both the
Meis1 promoter and a known Meis1 enhancer element. Cyclin Dependent Kinase Inhibitor 2A,
Cdkn2a, also known as p16, was used as a positive control for repressed promoters and showed
significant enrichment for the repressive histone mark H3K27me3. Notably, H3K27me3 was
found at Meis1, however, following additional of ChIP-qPCR for Hoxa9 promoter regions which
showed little enrichment, it was determined that pull-down at the Meis1 promoter was likely to
be real signal rather than non-specific pull-down. Primers designed on a gene desert region were




























































































































































































































































































Figure 6.1: ChIP-qPCR for positive and negative control regions. Four bar charts
showing the percentage of input chromatin pulled down by immunoprecipitation from each ChIP
experiment which were sent for sequencing. The key at the top indicates the quantified target
region.
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6.3.2 Successfully enriched ChIP-Seq data were obtained
After receiving and processing ChIP-Seq reads through initial mapping and peak calling stages, I
assessed the quality of ChIP-Seq data using ChIPQC v1.22.0 (Carroll et al. 2014), these quality
metrics are listed in Table 6.4. Firstly, I found that through multiplexing error some samples
received fewer reads than others, namely H3K4me1 for fl/fl replicate “60” LSKME and GMPME.
However, the duplication rates for these samples were low and therefore following filtering, the
number of usable reads was acceptable. The duplication rate varies from as low as 6% to as high
as 43%, however this range is still acceptable within ENCODE standards (ENCODE Project
Consortium 2019).
The percentage of reads in peaks (RiP%) is also sufficiently high to indicate successful
enrichment in all samples. The SSD score is the standard deviation of read pileup along the
genome. In a successfully enriched ChIP-Seq library, a small proportion of the genome should
account for most the of signal pileup giving a high SSD score. It can be seen in Table 6.4 that all
ChIP samples have a greater SSD than input DNA and more punctuate marks (H3K27ac and
H3K4me3) have a greater SSD than broader marks (H3K27me3 and H3K4me1). Once quality
of enrichment and reads was confirmed, I then compared the global patterns of these histone
modifications with their published characteristics to verify antibody specificity.
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Table 6.4: Quality control results for ChIP-Seq generated for this study
Origin Factor βc Rep Read Pairs Dup% Frag Len Rel CC SSD RiP%
LSK input fl/fl 69 18449538 11.1 247 2.2 0.9 NA
LSK input -/- 69 17013527 10.7 267 13 0.9 NA
GMP input fl/fl 69 19299982 12.1 247 1.8 0.9 NA
GMP input -/- 69 18371420 10.9 247 1.9 0.9 NA
LSK H3K4me3 fl/fl 60 16449673 10.4 249 1.6 4.3 45
LSK H3K4me3 -/- 60 16170088 11 247 1.7 4.6 50
LSK H3K4me3 fl/fl 69 19253018 7.6 247 1.6 7.5 68
LSK H3K4me3 -/- 69 16160071 10.4 250 1.6 5.8 60
GMP H3K4me3 fl/fl 60 16888912 7.6 248 1.6 6.9 66
GMP H3K4me3 -/- 60 14058856 8.8 247 1.7 5.8 62
GMP H3K4me3 fl/fl 69 15618923 10.9 250 1.6 7.5 73
GMP H3K4me3 -/- 69 16193481 9 247 1.6 6.2 60
LSK H3K4me1 fl/fl 60 8510117 8 250 1.5 1.4 38
LSK H3K4me1 -/- 60 40208082 30.4 249 3.5 2.7 57
LSK H3K4me1 fl/fl 69 38251913 24.8 249 2.3 2.9 61
LSK H3K4me1 -/- 69 34279331 25 247 2.7 2.7 61
GMP H3K4me1 fl/fl 60 9519836 5.7 247 1.7 1.4 39
GMP H3K4me1 -/- 60 27513021 40.5 247 4.4 2.4 50
GMP H3K4me1 fl/fl 69 25017964 26.1 248 4 2 42
GMP H3K4me1 -/- 69 33049539 37.4 247 6 2.2 41
LSK H3K27me3 fl/fl 60 24306814 43.8 247 5.9 2.4 24
LSK H3K27me3 -/- 60 29062920 38.2 247 7.2 2.2 27
LSK H3K27me3 fl/fl 69 30501030 16.9 247 2.8 1.7 17
LSK H3K27me3 -/- 69 31246898 43.8 249 2.2 2 18
GMP H3K27me3 fl/fl 60 35660713 13.1 248 6.7 1.3 11
GMP H3K27me3 -/- 60 28725499 40.1 247 5.1 2.2 22
GMP H3K27me3 fl/fl 69 27135151 16 247 6.2 1.7 18
GMP H3K27me3 -/- 69 24394960 17.4 247 6.6 1.6 14
LSK H3K27ac fl/fl 60 29834972 7.6 247 1.8 4.4 22
LSK H3K27ac -/- 60 33963197 9.3 248 2 3.7 19
LSK H3K27ac fl/fl 69 29881504 11 249 1.8 5.1 24
LSK H3K27ac -/- 69 25277815 12.3 247 1.9 4.2 26
GMP H3K27ac fl/fl 60 37007168 8.3 247 1.8 6.2 27
GMP H3K27ac -/- 60 28407232 12.2 247 1.8 4.9 24
GMP H3K27ac fl/fl 69 25508436 14.4 249 1.9 6.4 27
GMP H3K27ac -/- 69 28712079 15.9 249 1.4 7.2 32
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6.3.3 Histone modification data demonstrates expected patterns at the
TSS
The histone modifications studied in this chapter have well established patterns or profiles
in relation to gene architecture and gene transcription (Heintzman et al. 2007; Barski et al.
2007; Zhou et al. 2011; ENCODE Project Consortium and others 2012). These patterns are
demonstrated in Figure 6.2; average signal across all samples for each histone modification
are plotted for 2 kb upstream of the TSS and 10 kb downstream. To allow assembly of
protein complexes which facilitate transcription, nucleosomes are displaced creating an accessible
nucleosome free region (NFR) at enhancers and promoters, flanked by their relevant histone
modifications. H3K4me3 is found at active promoters; just upstream of the TSS resides a NFR
causing a drop in H3K4me3 signal. Nucleosomes just downstream of the TSS are generally highly
localised which appears as high H3K4me3 signal in active promoters often spreading far into the
gene body of highly expressed genes. Notably, H3K4me3 is consistently found at many inactive
promoters (Guenther et al. 2007).
Although associated with positive regulation of transcription, H3K4me-di and mono
are progressively distanced from the TSS of active genes (Barski et al. 2007). The width of the
dip in H3K4me1 signal surrounding the TSS correlates with higher gene expression signifying
greater displacement with H3K4-tri methylation. H3K27ac is found at active enhancers and also
at active promoters showing a similar pattern to H3K4me3 but more punctuate in appearance.
H3K27me3 binding is low at active promoters and broad regions of modest enrichment are seen
at silenced promoters. In this section I have confirmed that the histone modification ChIP-Seq























































































































Figure 6.2: Heatmaps and average profiles for all histone marks from the TSS to
10 kb into the genebody Approximately 12,000 genes are displayed in this heatmap, genes
were selected with at least one RNA-Seq count per million reads in at least two samples. Each
horizontal line represents a single promoter, the intensity of colour indicates the read density at
that location. The location of the TSS is indicated by “start” on the scale at the bottom and
by a dotted vertical line. Genes/promoters are ordered by average RPKM gene expression. To
simplify each gene to one promoter, the most upstream TSS of each gene was chosen, despite
that this may not necessarily be the most active TSS. To show a generalised pattern, ChIP
signal is plotted as an average value for all samples in the study. Gene regions are split into
4 quartiles labelled Q1-4 based on their average RNA-Seq RPKM value with the most highly
expressed genes in Q4 and the lowest in Q1. Above each histone modification is a line graph
depicting the average signal profile of each quartile represented by a different colour line as
indicated by the key (top right).
6.3.4 Histone modification signal at gene loci correlates with corresponding
gene expression data
To further illustrate the relationship between histone marks and gene expression, I calculated the
Spearman’s correlation between all individual ChIP-Seq and RNA-Seq samples. RPKM values
were calculated for the average transcript length (the sum of exons) or the promoter and gene
body (including introns, exons and Untranslated Regions (UTRs)) for RNA-Seq and ChIP-Seq
respectively, the resulting correlation matrix is shown as a heatmap in Figure 6.3.
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Firstly, as expected, all histone modifications group separately by hierarchical clustering.
Clusters do not clearly resolve by cell-of-origin or genotype and have a short branch distance.
Both in the promoter (Figure 6.3A) and gene body (Figure 6.3B), active marks H3K4 tri-
methylation and H3K27 acetylation are positively correlated with transcription. On the other
hand H3K27 methylation is inversely correlated with transcription. H3K4 mono-methylation also
shows a mildly negative correlation with transcription. The only mark which shows statistically
weak correlations below the cut-off is H3K4me1 indicating a more complex relationship with
gene expression. The greatest correlation in the matrices presented in Figure 6.3 is the positive
relationship between H3K4me3 and H3K27ac. Out of all histone marks, H3K4me3 across the gene
body correlates most closely to transcription (Figure 6.3B), however if only the promoter region
is considered, H3K27ac has a mildly stronger correlation with transcription (Figure 6.3A). In this
section I confirmed that our ChIP-Seq for histone modifications show the expected directional







































































































Figure 6.3: Correlation between RNA-Seq and ChIP-Seq Spearman’s correlation
between log RPKM normalised gene expression and counts at the promoter (A) or gene body
(B). Each square represents the correlation between any two individual samples and its colour
indicates the correlation value. Samples are ordered by hierarchical clustering, indicated by the
dendrograms along the top and left sides. Note that the ordering is different in A and B. The
colour block annotation on the top of the heatmaps and the innermost left indicate the assay.
Three other factors, “celltype” (cell-of-origin), genotype and replicate are indicated by colour
bars on the left. All correlations depicted are statistically significant (P <0.05) with exception of
those marked with a cross, which are labelled with their actual P.value.
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6.3.5 Variation and Correlation between ChIP-Seq samples
As previously demonstrated in Figure 6.3, genomewide PCA also shows that ChIP-Seq samples
cluster by assay (Figure 6.4A). It is interesting to note that H3K27ac samples appear to cluster
most closely with H3K4me1 (Figure 6.4A) possibly due to their coexistence outside of promoter
regions. As highlighted in chapter 5, there are observable qualitative differences in phenotype
between replicate samples. We therefore may speculate that there are differences at the chromatin
level. We previously observed that there is greater transcriptomic variation amongst GMPME
replicates than LSKMEs (see subsection 3.3.1, Figure 3.2), this can also be seen in the PCA plot
for ChIP-Seq samples in Figure 6.4B. Samples show some separation between different cells-of-
origin, however within-group variation between replicates greater than treatment (Figure 6.4).










































































Figure 6.4: Relationships between ChIP-Seq samples A) Principal component analysis
PCA plots. A) All histone modification data coloured by modification. B) Separate PCA plots
for each modification, colour and shape define their sample identity.
To further visualize the relationships between different biological samples, I plotted
their genome wide correlations in Figure 6.5. All samples are highly similar, all correlations had
R2 values greater than 0.9 and P.values below 0.001. The correlation between ETOH treated
biological replicates is weaker than the correlation between ETOH and 4-OHT treated samples.
In the majority of cases, the correlation between ETOH treated biological replicates is equal
to or weaker than biological replicates with different cells-of-origin (LSKME versus GMPME).
The only exception is that the correlation between H3K27me3 signal LSKME and GMPME from
replicate “60” is slightly less correlated than LSKME biological replicates (Figure 6.5, bottom




























































































































































































































































































Figure 6.5: Global correlation between ChIP-Seq samples This figure shows the
correlation between all samples as scatter plots. Values were obtained by counting the number
of reads in 10 kb bins across the entire genome. Notable comparisons are highlighted with a
coloured border. As indicated by the key on in the top right: A black border signifies biological
replicates of ETOH controls. A red border highlights the plots comparing individual replicates
after β-catenin deletion. Green borders highlight the comparison between cell types. In the top
left corner of each plot is the Pearson’s correlation coefficient, the asterisks indicate significance
level. (***P.value <0.001)
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6.3.6 Histone modification data segment the genome into biologically
relevant chromatin states
To take advantage of all histone modification data in symphony, I employed ChromHMM to
segment the genome into different chromatin states. With just a 6-state model, we were able to
see separation of the genome into segments with predictable biological functions (Figure 6.6A).
Figure 6.6A shows the probability of a mark residing in each state. No histone modification
implies heterochromatin regions (Het). The presence of only H3K27me3 signifies polycomb
repression (ReprPC). The presence of only H3K4me1 identifies possible enhancers, additional
presence of H3K27ac transforms these enhancer regions from bivalent (EnhBiv) to active (EnhA).
Finally, H3K4me3 combined with H3K27ac or H3K27me3 defines active TSS (TssA) or bivalent
TSS (TssBiv) respectively. As expected, most of the genome is unmodified and therefore
heterochromatin (Figure 6.6B). Following heterochromatin, the most abundant chromatin states
are bivalent enhancers, which require only the presence of H3K4me1. These regions may be
sensitive to the binarisation threshold, therefore may contain noisy regions. Active enhancers
and polycomb repressed regions are about equally represented. Next comes active TSSs and
finally bivalent TSS is the rarest state.
The total estimated size of the mouse genome, omitting centromeres is 160 mega-bases
(Mb). Considering this, we can interpret 1.6Mb in the scale in Figure 6.6C-E as being 1/100 of the
genome. As would be expected only a small proportion of states in the genome change between
conditions. The vast majority of these changes in both cell-of-origin and β-catenin deletion are
between Heterochromatin (“Het”) and single modification states (“ReprPC” and “EnhBiv”). To
take a closer look at the more interpretable states (between active and inactive promoters and
enhancers) I removed these from the plot. Most promoters remain stable to change, however
more segments belonging to enhancers transition. To elucidate if there are qualitative differences
between biological replicates at the chromatin level, I plotted the chromatin states of detected
transitions at the TSS in a heatmap form (Figure 6.7). Although there are some transitions which
appear legitimate, I was unable to filter out noisy transitions using the methods I developed.
The results of these analyses were difficult to interpret and were concluded to be unsuitable
for the comparisons in this study. However, chromatin state segmentation further validates the












































































































































































































Figure 6.6: Global chromatin state assignment and transitions between
experimental conditions A) Emission parameters for assigned states. The intensity of
each cell indicates the probability of the presence of the indicated modification (bottom) in each
state (Left): heterochromatin or unmodified (Het), polycomb repressed (ReprPC), bivalent TSS
(TssBiv), bivalent enhancers (EnhBiv), active enhancers (EnhA) and active TSS (TssA). B) Pie
chart showing the proportion of assigned states across the genome. C-E) Chord diagrams showing
flow of transitioning states between experimental conditions. The connections of the segments
between the bottom and top of the semi-circular axis represent the transition from one state to
another. Scales are shown in mega-bases (mb) of DNA. C) Chromatin state transitions between
different cells-of-origin. Left: Simplified chord diagram including all transitional states, an arrow
is drawn to demonstrate the direction of transition. Right: Chord diagram with dominant
transitions removed (EnhBiv & ReprPC) to reveal remaining interactions in greater detail. D:E)
Chromatin transitions following Ctnnb1 KO in LSKME (D) and in GMPME (E). Layout for D:E










































Figure 6.7: Chromatin state changes between conditions at the TSS. Heatmaps
showing the states called by ChromHMM 2 kb upstream and 5 kb downstream of the TSS which
were detected to transition between LSKME and GMPME. The location of the TSS is indicated
by “start” on the scale at the bottom and by a dotted vertical line. The colour of each state
is as indicated in the key on the right. Regions are shown which transition between TssA to
TssBiv or ReprPC. The labels on the left indicate in which replicate the state change was found
and the direction of that change in relation to promoter activity (up or down).
6.3.7 Variation of histone modification observed at the HoxA locus
As described in subsection 1.2.1, the Homeobox A (HoxA) locus is a critical target in MLL-
fusion-transformed leukaemia (Zeisig et al. 2004; Ayton and Cleary 2003; Faber et al. 2009; Milne
et al. 2010). Activity at the HoxA locus may therefore confer the “level” of transformation by
MLL fusions. Interestingly, visualisation of normalized ChIP signal at the HoxA locus reveals
considerable differences in histone modification between cell-of-origin and replicate (Figure 6.8).
Whilst both LSKME replicates appear similar, GMPME from replicate “60” shows unique extension
of H3K27me3 into the HoxA locus and H3K4me1 reduction (Figure 6.8A). This sample also
shows reduction in H3K4me3 and H3K27ac at Hoxa9 and flanking regions resulting in lower
transcription of Hoxa9 (Figure 6.8C). These changes could imply a less extreme transformation of
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the cells or a more heterogeneous population. GMPME replicate “69” exhibits unique enrichment
for H3K4me3 and H3K27ac and a decrease in H3K27me3 resulting in expression of Homeobox
A11 (Hoxa11 ) (Figure 6.8B). Interestingly, both GMPs “60” and “69” show increased active
marks and transcript expression of Homeobox A2 Hoxa2 (Figure 6.8D). For simplicity, only
β-floxed samples are plotted, however the described patterns remain after knock-out.





























































































































Figure 6.8: Transcriptomic and epigenetic variation at the HoxA locus in MLL-ENL
transformed cells Normalised signal for all four histone marks and RNA-Seq. The assay
shown in each track is labelled on the left. The identity of the biological sample is labelled on
the right. Replicate dependent differences (A-C) and cell-of-origin dependent (D) differences
are highlighted and described in the main text. The scales on the right are in TMM normalised
CPM.
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To compare the observed differences at the HoxA locus with the modification of this
region in normal sorted populations I plotted the normalised coverage from publicly available
data in Figure 6.9, (Bernt et al. 2011; Lara-Astiaso et al. 2014). Interestingly, like GMPME
replicate “60”, there is greater H3K27me3 across the entire HoxA locus in GMP compared to
LSK (Figure 6.9A). Also similarly to GMPME replicate “60”, there is reduced H3K4me3 and
H3K27ac in GMP versus HSC (Figure 6.9C). Conversely, at the Hoxa11 locus there is higher
H3K27ac and H3K4me3 in HSC than in GMP (Figure 6.9B), which is the opposite trend to what
is seen in GMPME replicate “69” versus LSKME. I conclude that there is considerable variation
between replicates at the HoxA locus which may correspond to biologically important differences
in their normal cell-of-origin.
Hoxa1 Hoxa4 Hoxaas3 Hoxa9 Hoxa11 Hoxa13























































Figure 6.9: Transcriptomic and epigenetic variation at the HoxA locus in normal
cells Normalised signal taken from the Gene Expression Omnibus (GEO). Tracks are labelled
with their cell type and GEO accession. GSE29130 and GSE59636 were taken from Bernt et al.
(2011) and Lara-Astiaso et al. (2014), respectively. A-C are the same regions highlighted in
Figure 6.8.
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6.3.8 Gene-centric quantitative analysis of histone modification between
samples with different cells-of-origin
Statistically differentially epigenetically modified regions between LSKME and GMPME were
detected with csaw. Cell-of-origin dependent differences in histone modification and overlaps
with differentially expressed genes are summarised in Figure 6.10. The general trend in histone
mark changes for cell-of-origin reflect RNA-Seq; the majority of differentially modified genes
are upregulated in GMPME compared with LSKME. Activating marks, H3K4me3 and H3K27ac,
are mostly upregulated in GMPME compared with LSKME (Figure 6.10A). The repressive mark
H3K27me3 is mostly downregulated in GMPME compared with LSKME (Figure 6.10A).
Of all histone modifications probed, H3K4me3 shows the most cell-of-origin related
differences. 322 unique genes are differentially modified by H3K4me3 (Figure 6.10A), over 30%
of these genes were also found to be differentially expressed in RNA-Seq (Figure 6.10B). 79
unique genes are differentially modified by H3K27ac and over 50% of these are also differentially
expressed (Figure 6.10B). Just 27 regions are differentially modified by H3K27me3 however over
60% (17) of these are also differentially expressed (Figure 6.10B). Only 15 genes are differentially
modified by H3K4me1 and over 70% (11) of these are also differentially expressed (Figure 6.10B).
None of the regions differentially modified by H3K4me1 were identified at the promoter and
lie somewhere in the gene body (Figure 6.10A). Using the “Naïve” method to group adjacent
windows gave similar numbers or less than gene centric analysis for H3K4me3 and H3K27me3
(Figure 6.10A). On the other hand, there were many additional changes for H3K4me1 and
H3K27ac found lying outside gene bodies (Figure 6.10A). This implies there are significant
changes at other regulatory features such as enhancer regions.
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To visualise the relationship between differential H3K4me3, H3K27ac and gene
expression, I plotted the H3K4me3 and H3K27ac signal at the TSS of differentially modified
and/or differentially expressed genes (Figure 6.11). There are few genes differentially modified
by H3K27ac and differentially expressed. The H3K27ac differential regions undetected in
RNA-Seq appear inconsistent between replicates (Figure 6.11A). There are many genes with low
H3K27ac signal which do not exhibit changes but are differentially expressed (Figure 6.11A).
However, of these, the most extreme differences in H3K27ac appear to correlate with differential
expression. The H3K4me3, differential regions undetected in RNA-Seq appear inconsistent
between replicates (Figure 6.11B). Additionally for H3K4me3, like H3K27ac, the most extreme
changes reflect the expression of differentially expressed genes in RNA-Seq although it is less
clear (Figure 6.11B).
To visualise individual events of cell-of-origin differential ChIP-Seq, I plotted
normalised signal tracks for selected gene loci in Figure 6.12. Myb/SANT DNA Binding Domain
Containing 3 Msandt and Pre-B-Cell Leukaemia Homeobox 3 Pbx3 were found to have
decreased HK27me3, increased H3K27ac, H3K4me3 and gene expression in GMPME compared
to LSKME (Figure 6.12A). Zinc finger protein 951 Zfp951 was found to have decreased H3K27ac,
H3K4me3 and gene expression in GMPME compared to LSKME (Figure 6.12A). Acyl-CoA
Synthetase Short Chain Family Member 2 Acss2 was found to have increased H3K27ac,
H3K4me3 and gene expression in GMPME compared to LSKME (Figure 6.12A). Of note,
although there was no difference in gene expression, SMAD Family Member 4 (Smad4 ) and
Nuclear Receptor Subfamily 4 Group A Member 2 (Nr4a2 ) exhibited significant decreases in
H3K27me3 in GMPME compared with LSKME (Figure 6.12B). Complementary to the variation
shown at the HoxA locus in subsection 6.3.7, Figure 6.8, notable replicate specific differences in
histone modification are shown in Figure 6.12C. Hoxa11 and Frizzled Class Receptor 1 Fzd1
exhibit increased H3K27ac, H3K4me3 and gene expression in GMPME replicate “69”. CD48
molecule (CD48, also known as Signalling Lymphocytic Activation Molecule 2) exhibits
increased H3K27ac, H3K4me3 and gene expression in GMPME replicate “60”.
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Direction Up Down Mixed
A
 B
Figure 6.10: Summary of significantly differentially modified regions between
LSKME and GMPME The colour of the vertical bars represents the proportion of regions
showing up-regulation (red), down-regulation (blue) and mixed regulation (yellow). This is
indicated by the colour key at the top, right. A) The number of significantly differentially
modified regions for each histone modification detected by csaw with an FDR cut-off of 0.05. The
histone modification for each bar chart is labelled on the left. The x-axis describes which region
category was examined for each bar. Genes: whole gene bodies. Peaks: peaks detected with
MACS2. Naïve: regions created by simply merging adjacent windows with significant ChIP-Seq
enrichment. Promoter by gene: the most upstream promoter region for a given gene. Promoter
by transcript: promoters at all annotated TSSs. B) The overlaps between histone mark changes
and RNA-Seq. This diagram is equivalent to a 5 set Venn diagram. The horizontal histogram
shows the total number of significantly different genes for each sequencing assay. The vertical
histogram shows the number of significantly different genes in each intersect. The assay(s)
belonging to the members of each set are defined in the matrix below. The shaded dots indicate


































































































































































GMP-LSK LSK GMP GMP-LSK LSK GMP
Figure 6.11: H3K27ac, H3K4me3 and gene expression at differentially modified
and/or expressed genes between LSKME and GMPME A) Differential H3K27ac
compared with RNA-Seq. B) Differential H3K4me3 compared with RNA-Seq. Heatmaps
are plotted 2 kb upstream and 10 kb downstream of the TSS. The location of the TSS is
indicated by “start” on the scale at the bottom and by a dotted vertical line. The biological
replicate (“60” or “69”) is indicated by labels at the top. Heatmaps labelled “GMP-LSK” show
the difference in ChIP signal between GMP and LSK derived cell lines. Heatmaps labelled “LSK”
or “GMP" show the normalised signal for the indicated modification for the LSKME and GMPME
sample respectively. The penultimate heatmap shows normalised gene expression. The final
heatmap shows the location of CpG islands in yellow. The heatmaps are clustered into 3 groups:
1. “Both”: genes which are significantly different in ChIP-Seq and RNA-Seq. 2. “H3k27ac” or
“H3K4me3”: significant in ChIP-Seq only. 3.“RNA-Seq”: significant in RNA-Seq only. Within





























































































































































































































































































































































Figure 6.12: Signal tracks of loci exhibiting cell-of-origin dependent changes in
histone modification The blocks underneath the tracks signify statistically significant changes
in modification or CpG islands, as indicated by the key (top right). The colours in the key
also correspond to the assay shown in each signal track. Gene models are also shown beneath
the tracks. Each plot has a key indicating the distance shown. Sample identity is indicated on
the left. The signal scale is TMM normalised CPM. A) Consistently differentially expressed
genes which also show changes in histone modification. B) Changes in H3K27me3 which do not
correlate with gene expression. C) Cell line specific changes in histone modification and gene
expression.
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6.3.9 Pathway analysis of differentially modified genes between different
cells-of-origin
To investigate if there were coordinated changes in histone marks at promoter regions I
performed pathway analysis for their associated genes (Figure 6.13). H3K27me3 differences were
enriched in developmental terms, including Smad4 and Nr4a2 (Figure 6.13A). H3K4me3 and
H3K27ac mirrored some of the pathways which were found in differential expression analyses
(see subsection 3.3.4, Figure 3.4) such as “Transcriptional Missregulation in Cancer” and
“Cellular Senescence” (Figure 6.13B & C). As there were so few genes differentially marked by
H3K4me1, there were no enriched GO terms or KEGG pathways for H3K4me1.
A                                                B
C
Figure 6.13: GO and KEGG analysis for genes with differentially bound promoters
between LSKME and GMPME A) Enriched biological process GO terms for promoters
differentially bound by H3K27me3. B) Enriched KEGG pathways for promoters differentially
bound by H3K27ac. C) Enriched KEGG pathways for promoters differentially bound by
H3K4me3. The x axes show the ratio between the number of genes in the pathway and number
of differentially marked genes in the enriched term. The size and colour of the dots indicate the
number of differential genes (Count) and FDR respectively.
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6.3.10 Cell-of-Origin associated Enhancer analysis
As highlighted previously in Figure 6.8, there were more epigenetic differences outside of the
promoter region between cells of different origin. Therefore, it would be informative to investigate
these regions and attempt to uncover their potential biological functions giving rise to the
phenotypic differences seen between LSKME and GMPME. Enhancers were crudely defined as
H3K4me1 peak regions outside of the promoter region which were defined as 1 kb upstream
2 kb downstream of TSSs. Putative enhancers which appeared in more than one sample were
catalogued. To detect changes in enhancer activity between LSKME and GMPME differential
expression of H3K27ac at enhancers was calculated with DiffBind. De novo enhancers were
determined by comparing overlaps of active enhancers exhibiting H3K27ac enrichment between
conditions. Enriched motifs found in de novo active enhancers or enhancers with differential
activity between different cells-of-origin are shown in Figure 6.14.
Enhancers unique to LSKME: n=342
Increased enhancer activity in GMPME: n=58
Target PWM Motif ID P−value In top
motifs
Cebpg M0313_1.02 2.69e−06 22 %
Cebpd M0274_1.02 1.32e−05 21 %
Cebpb M0314_1.02 1.14e−07 19 %
RUNX1 RUNX1 0.000155 19 %
Cebpa M0304_1.02 5.57e−07 17 %
Ets1 Ets1 7.02e−05 17 %
Sox17 Sox17 0.00686 17 %
Cebpb M0315_1.02 3.88e−07 16 %
Target PWM Motif ID P−value In top
motifs
Mafk M0290_1.02 0.00268 42 %
Cebpg M0313_1.02 3.46e−05 42 %
Tef M0293_1.02 0.000907 33 %
Cebpb M0314_1.02 0.000662 33 %
Mycn M1927_1.02 0.0219 33 %
Arid5a M0108_1.02 0.0108 25 %
Setbp1 M0130_1.02 0.00248 25 %
Cebpd M0274_1.02 0.000211 25 %
Target PWM Motif ID P−value In top
motifsTarget PWM Motif ID P−value
In top
motifs
Sox2 Sox2 0.033 23 %
Sox6 Sox6 0.0124 21 %
Sox30 SCI09/Sox30 0.00599 17 %
Bhlha15 M0218_1.02 0.0462 15 %
Mafg M0308_1.02 2.46e−07 15 %
Atf4 M5988_1.02 0.00348 15 %
Dlx2 0.00426 15 %
Hoxb3 Cell08/Hoxb3_1720.2 0.0124 15 %
jolma2013 Dlx2
Increased enhancer activity in LSKME: n=12
























Figure 6.14: Motif analysis of enhancers exhibiting cell-of-origin specific activity
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6.3.11 β-catenin related changes in histone modifications
Statistically differentially epigenetically modified regions between β-catenin floxed β-catenin
deleted GMPME and LSKME were detected with csaw. β-catenin dependent differences in histone
modification and overlaps with differentially expressed genes are summarised in Figure 6.15.
Interestingly, no significant changes were found for H3K27me3 (Figure 6.15A). Very few significant
changes were detected for H3K4me1 (Figure 6.15A). In GMPME β-catenin KO, the only significant
change in H3K4me1 was a decrease found at the gene: Non Imprinted In Prader-Willi/Angelman
Syndrome 1 (Nipa1 ). Following β-catenin deletion in LSKME, decreases in H3k4me1 were found
at 6 genes: Nipa1, NLR Family pyrin domain-containing 3 (Nlrp3 ), Bactericidal/Permeability-
Increasing Fold-Containing Family C (Bpifc), Early Endosome Antigen 1 Eea1, Mitochondrial
Ribosomal Protein S26 (Mrps26 ) and Ctnnb1.
In line with RNA-Seq analyses, H3K4me3 is mostly upregulated in β-catenin deleted
samples compared with β-catenin floxed (Figure 6.15A). β-catenin deletion in LSKME resulted
in significant H3K4me3 changes associated with 100 genes, almost 50% were also differentially
expressed in RNA-Seq (Figure 6.15B). Furthermore, 147 genes were differentially marked by
H3K4me3 following β-catenin deletion in GMPME, however less than 30% of these were also
found in RNA-Seq (Figure 6.15B). In contrast with RNA-Seq analyses, H3K27ac is mostly
downregulated after β-catenin deletion (Figure 6.15A). In LSKME, 119 genes were differentially
modified by H3K27ac, only 15 of these were also differentially expressed (Figure 6.15B). Similarly
in GMPME, 100 genes were differentially modified by H3K27ac and only 9 of these were also
differentially expressed (Figure 6.15B). Using the “Naïve” method to group adjacent windows gave
similar numbers or less than gene centric analysis for H3K4me3 and H3K27Ac (Figure 6.15A).
This suggests that there is little detectable differential modification outside of genic regions.
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Direction Up Down Mixed
LSK ME GMP ME
A
B
Figure 6.15: Summary of significantly differentially modified regions following β-
catenin knock-out A) Significantly differentially bound regions detected with csaw with a
FDR cut-off of 0.05. B) The overlaps between significant histone mark changes and RNA-Seq.
Left: LSKME, Right: GMPME. The axes and layout of these plots are as described in the legend
of Figure 6.10.
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To visualise the relationship between differential H3K4me3, H3K27ac and gene
expression, I plotted the H3K4me3 and H3K27ac signal at the TSS of differentially modified
and/or differentially expressed genes in LSKME (Figure 6.16A) and GMPME (Figure 6.16B).
When ordered by differential H3K27ac, most significantly differentially expressed genes detected
in RNA-Seq after β-catenin KO in both LSKME and GMPME visually segregate into
upregulated and downregulated genes (Figure 6.16A & B, top). However, genes which exhibit
significant differential H3K27ac but were not detected as differentially expressed in RNA-Seq
are largely incongruent with transcription (Figure 6.16A & B, top). Amongst these there are a
collection of histone protein genes. (Figure 6.16A & B, top). On the other hand, changes in
H3K4me3 are mostly congruent with gene expression whether or not they are differentially
expressed (Figure 6.16A & B, bottom), this is particularly clear in GMPME (Figure 6.16B,
bottom). Interestingly, there appeared to be an enrichment for CpG islands in the promoters of
genes which were differentially modified (especially for H3K27ac) and a depletion of CpG in
promoters which were differentially expressed but not differentially modified (Figure 6.16).
As Gadd45a was found to be uniquely differentially expressed in GMPME upon β-
catenin deletion, it would be interesting if we could observe congruent changes in epigenetic
modification. Despite changes in gene expression, no statistically significant differences in histone
modifications were detected within 10mb of the Gadd45a locus. Normalised signal tracks of all
histone marks around the Gadd45a locus are visualised in Figure 6.17. To visualise individual
events of β-catenin conditional differential ChIP-Seq, I plotted normalised signal tracks for
selected gene loci in Figure 6.18. Tgm2 and Thrombospondin 1 (Thbs1 ) exhibited decreases
in H3K27ac, H3K4me3 and transcript expression (Figure 6.18A). Cyclin Dependent Kinase
Inhibitor 1A Cdkn1a was detected as differentially expressed in LSKME KO but not in GMPME
KO. At Cdkn1a, significant differences in H3K27ac and H3K4me3 were detected in LSKME KO
but only differential H3K4me3 was detected in GMPME KO (Figure 6.18A, right). H3K27ac
and RNA-Seq were plotted at clusters of histone genes (Figure 6.18B). As previously seen in
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Figure 6.16: H3K4me3 and H3K27ac signal and gene expression at differentially
modified or expressed genes following β-catenin knock-out A) β-catenin related changes
in LSKME. B) β-catenin related changes in GMPME. The layout of these plots is the same as
outlined in the legend of Figure 6.11. Within each cluster, rows are ordered by difference in
histone modification between β-catenin floxed and deleted. Notable genes are labelled on the


































































































































Figure 6.17: Histone modification and RNA-Seq tracks at the Gadd45a locus The
biological condition for each track is labelled along the left side. The scale of the tracks is the
TMM normalised CPM. The assay for each track is indicated by its colour and is decoded by
the key (top right). The distance key (top left) specifies the length of 400 bp. Below the signal
tracks, the location of a CpG island is indicated by a yellow bar. At the bottom, the position





































































































































































































































































































































































































Figure 6.18: ChIP signal at selected significantly differentially modified regions
following β-catenin knock-out The scale of the tracks is the TMM normalised CPM.
Below signal tracks, blocks indicate the location of CpG islands and windows with significantly
differential signal as decoded by the key (top). The colour key also indicates the assay of the
signal tracks. At the bottom of each plot are the gene models at the given loci. Each plot has a
key indicating the region size at the top. A) H3K27ac, H3K4me3 and RNA-Seq signal at Tgm2,
Thbs1 and Cdkn1a. B) H3K27ac and RNA-Seq signal across clusters of histone genes.
162
6.3.12 β-catenin related changes in histone modifications: pathways
To elucidate whether β-catenin conditional changes in histone modification are coordinated
into pathways, I performed GO and KEGG pathway analysis for their associated genes. Genes
with increased H3K4me3 in both LSKME and GMPME β-catenin KO are enriched in GO terms
involving the inflammatory response (Figure 6.19A & C). Enriched KEGG pathways include
infectious diseases, the p53 signalling pathway and the Toll-like receptor signalling pathway
(Figure 6.19B & D). These terms are in line with what was seen in RNA-Seq (Figure 3.8 & 4.2).
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Figure 6.19: Gene ontology and pathways associated with increases in H3K4me3
following β-catenin deletion A & C) Enriched gene ontology terms for increases in H3K4me3
at the promoter in GMPME and LSKME respectively. B & D) Enriched KEGG pathways for
increases in H3K4me3 at the promoter in GMPME and LSKME respectively. The y axes are
labelled by the enriched GO term or KEGG pathway. The x axes show the ratio between the
number of genes in the pathway and number of differentially marked genes in the enriched
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Figure 6.20: Gene ontology and pathways associated with decreases in H3K27ac
following β-catenin deletion Comparison of enrichment of gene ontology terms (A), KEGG
pathway (B) and Reactome pathways (D) in LSK and GMP following β-catenin deletion. C)
A Euler diagram to show the overlaps between differentially acetylated promoter in LSK and
GMP with a curated list of histone genes.
Intriguingly, the vast majority of genes with de-acetylation at the promoter are histone
proteins Figure 6.20C. Peculiarly, almost all genes in the enriched Reactome pathways
Figure 6.20D including “Formation of the β-catenin: TCF transactivation complex”, are the
same group of histone genes. Histone genes are expressed in G1-Phase of the cell cycle and are
critical in progressing to S phase, a reduction of these genes is consistent with cell cycle arrest.
GMPME has even more histone genes significantly de-acetylated than LSKME and this is
reflected in additional GO-terms related to nucleosomes, these histone genes are also responsible
for the KEGG pathway: Transcriptional missregulation in cancer. Specifically, non-histone
genes which were uniquely deacetylated in GMPME play roles in: the cytoskeleton (Ankyrin 3:
Ank3, Microtubule-associated proteins 1A/1B light chain 3B: Map1lc3b) RNA binding (Phax)
ring/zinc finger (RING finger protein 10: Rnf10, Zinc finger with KRAB and SCAN domains 17:
Zkscan17 ), small nuclear RNAs (U3B small nuclear RNA complex: Rnu3b, U3B small nuclear
RNA 3: Rnu3b3 ) and metabolism (Alpha-Tocopherol Transfer Protein: Ttpa, Aldehyde
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Dehydrogenase 7 Family Member A1: Aldh7a1, Metabolism Of Cobalamin Associated C:
Mmachc). In LSKME uniquely downregulated genes are mostly involved in the endoplasmic
reticulum and cell cycle. Common de-acetylated genes which were not histone proteins included
genes involved in formation of the cytoskeleton (FYVE, RhoGEF And PH Domain Containing 4:
Fgd4, Myosin Light Chain 10: Myl10 ) protein processing (Hypoxia up-regulated protein 1:
Hyou1, Methyltransferase-like protein 1: Mettl1, Stromal Cell-Derived Factor 2-Like 1: Sdf2l1 )
ion transport (Retinoic Acid Induced 1: Rai1,Nipa1 ) and innate immune response (NOD-, LRR-
and Nlrp3 ). As shown in RNA-Seq and H3K4me3 ChIP-Seq, Transglutaminase 2 (Tgm2 ) and
Thrombospondin 1 (Thsb1 ) were also significantly deacetylated, these genes have been found to
have oestrogen responsive elements at their promoters and therefore could respond directly to
4-OHT treatment.
As there were few promoters with greater H2K27ac after KO (9 in LSKME, 21 in
GMPME, see Figure 6.15), these genes did not return any enriched terms by hypergeometric
analysis. Although there is no overlap between H3K27ac upregulated genes in LSKME and
GMPME, KO shows similar biological themes in both LSKME and GMPME. In GMPME,
upregulated targets included genes which are pro-apoptotic (BCL2 Binding Component 3: Bbc3,
Thioredoxin Interacting Protein: Txnip), protein processing (Exostosin Glycosyltransferase 1:
Ext1, Glioma Pathogenesis-Related Protein 1: Glipr1, Sterol Carrier Protein 2: Scp2 ), zinc
finger-domain containing (Zinc Finger And BTB Domain Containing 2: Zbtb2, Zinc finger
protein 958: Zfp958, Forkhead box protein P1: Foxp1 ) immune response (Interleukin 1 family,
member 6 Il1f6, Tumor necrosis factor alpha-induced protein 2: Tnfaip2, Interferon-induced
transmembrane protein 10: Ifitm10, Interleukin-1 receptor-associated kinase 3: Irak3, Vacuole
membrane protein 1: Vmp1, Phospholipase D Family Member 4: Pld4 ) and cell-cell interaction
(Podocan Like 1: Podnl1, Signal Regulatory Protein Alpha: Sirpa, Netrin G2: Ntng2, Sialic
Acid-Binding Ig-Like Lectin 3: CD33 ). In LSKME we also see pro-apoptotic/p53 regulated
genes (Pleckstrin Homology Like Domain Family A Member 3: Phlda3, Cyclin Dependent
Kinase Inhibitor 1A: Cdkn1a), protein processing (Integrator complex subunit 12: Ints12 ),
zinc-finger (Zinc Finger Protein 106: Zfp106 ), cytoskeleton (Myosin-6: Myo6, Annexin
A1:Anxa1, Tubulin Gamma Complex Associated Protein 3: Tubgcp3 ), immune response
(T-Lymphocyte Activation Antigen: Cd86, Anxa1 ) and cell-cell interaction (Carbohydrate
Sulfotransferase 11: Chst11 ). In summary, genes with increased acetylation in both LSKME and
GMPME tell a similar tale to up-regulated H3K4me3 and RNA-Seq: β-catenin deletion in vitro
with 4-OHT treatment causes apoptosis, immune response and alterations to cell adhesion.
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6.3.13 β-catenin related changes in histone modifications motifs
To see if there are enriched motifs for known interactors of β-catenin, I performed gene-based
motif analysis using the web-based tool, opossum (Kwon et al. 2012). There were no enriched
motifs found at gene differentially modified by H3K4me3. Interestingly, for de-acetylated regions I
found that the E2F1 motif was highly enriched (Table 6.5). Transcription factor E2F1 expression
has been shown to be a direct target of the Wnt/β-catenin pathway (Zhou et al. 2008). HDAC1 is
recruited to E2F1 target genes and reduces their transcriptional activity through de-acetylation
of histones. E2F1 has been shown to cooperate with deacetylases and regulate the expression of
chromatin components (Gokhman et al. 2013). This is a possible mechanism for how β-catenin
deletion is implicated in cell cycle arrest through loss of E2F1 expression. However, for critical
genes such as histone proteins there is transcription factor redundancy, Sox10 and Smad4 are
also highly enriched at these genes (Table 6.5). Smad4 is particularly interesting as it was found
that Smad4 is uniquely polycomb repressed in LSKME, (Figure 6.12). Smad4 competes with
β-catenin for binding and represses β-catenin target genes (Salazar et al. 2013).
Table 6.5: Enriched motifs found within promoter regions of differentially H3K27ac
marked genes
GMPME Name P-value Adjusted p-value
E2F1 (mouse) 1.96E-06 0.0004988
E2F4 (human) 0.00002822 0.003584
SOX10 (mouse) 0.00006366 0.00539
SMAD4 (mouse) 0.0007246 0.04601
LSKME Name P-value Adjusted p-value
SOX10 (mouse) 8.04E-15 1.95E-12
E2F1 (mouse) 4.13E-11 5.02E-09
E2F4 (human) 0.0004416 0.02146
CPEB1 (mouse) 0.0004114 0.02146
NFYB (mouse) 0.0004114 0.02146
NFYA (mouse) 0.001091 0.04417
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6.3.14 Comparison to publicly available β-catenin ChIP-Seq
In our cell lines, β-catenin ChIP-Seq was not successful. As explained in section 1.7, β-catenin
does not bind directly to DNA and cooperates with transcription factors to activate gene
expression. Although cross-linking theoretically would anchor all proteins directly or indirectly
bound to DNA, there is a greater chance that the epitopes will be unavailable to antibodies
decreasing the likelihood of immunoprecipitation. Most of the successful high-quality ChIP-Seq
data for β-catenin is shown in cell lines with a β-catenin activating mutation, APC loss or
drug/ Wnt stimulation to elevate β-catenin’s transcriptional activity (Table 6.2 & 6.6). Landt
et al. (2012) recommends a FRiP score at least 1% where there are 1000s to 10,000s of binding
sites, on the other hand, Carroll et al. (2014) suggests at least 5%. Indeed, the most relevant
β-catenin ChIP-Seq data in mouse was reported by Fong et al. (2015). However it was found
that this dataset was very poor quality and could not be compared with our dataset (Table 6.6).
Nevertheless, we compared the putative binding sites from these analyses with significantly
differentially modified regions found in this study following β-catenin deletion. We did not find
any overlaps which were statistically significant compared to randomly generated regions.
6.3.15 β-catenin exon three cell lines could be used for further work
As it was discovered that the majority of successful β-catenin ChIP-Seq assays required some
form of β-catenin activation (Table 6.2 & 6.6), I sought a method to activate β-catenin in
MLL-ENL transformed cells. I produced cell lines using an available mouse model which carries a
conditionally active β-catenin allele, the Ctnnb1 Mmt/flox GOF allele, as described in section 2.1,
Figure 2.1B. I crossed these mice with mice expressing Cre-ER to allow conditional activation of
Ctnnb1. From these mice I sorted bone marrow into LSK and GMP populations and performed
retroviral transduction and transformation with MLL-ENL as described in section 2.1.
Expression of the constitutively active form of β-catenin following 4-OHT treatment
and excision of exon 3 of Ctnnb1 was confirmed by western blot (Figure 6.21A). The band at 97
kDa indicates the expression of the full length β-catenin protein, whereas the 66 kDa band shows
expression of β-catenin with exon 3 removed (Figure 6.21A). It is notable that there is a weak band
at 66 kDa inETOH controls, indicating leaky Cre-recombinase (Figure 6.21A). In line with this,
mice harbouring the Ctnnb1 Mmt/flox GOF allele and Cre-ER frequently exhibited developmental
deformities indicating spontaneous recombination (data not shown). To observe β-catenin in
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the nucleus I employed immune fluorescence staining (Figure 6.21B). The permeabilisation
technique used only allows visible foci in the nucleus of cells as it destroys cell membrane proteins.
Very little β-catenin can be seen in β-catenin floxed or deleted cells (Figure 6.21B). However,
β-catenin is visible in the nucleus of β-catenin GOF cells (Figure 6.21B). Using the Cell Signalling
Technology #8480 β-catenin antibody, ChIP enrichment for the promoters of Axin2, Cnnd1, Myc
and the Myc enhancer was significantly greater than the negative control region (Figure 6.21C).
Interestingly in β-catenin GOF cells, we also see significantly increased expression of the known
β-catenin target, Cnnd1 (Figure 6.21D).
Table 6.6: Published β-catenin ChIP QC GEO: project data were derived from.
Condition/Tissue/Factor: Metadata associated to sample. Reads: Number of reads in sample.
Dup%: Percentage of reads marked as duplicates. FragLen: Estimated fragment length by
cross-coverage method. FragLenCC: Cross-Coverage score at the fragment length. RelCC:
Cross-coverage score at the fragment length over Cross-coverage at the read length. SSD: SSD
score. RIP%: Percentage of reads within peaks. Wnt ‘act’ refers to Wnt stimulation, Wnt ‘null’
refers to a lack of Wnt stimulation. ‘Res’ refers to BET inhibitor resistance, ‘Sen’ refers to BET
inhibitor sensitivity and DKK refers to treatment with the Wnt antagonist DKK1. ‘GSKi’ refers
to GSK inhibitor
GEO Condition Tissue Reads Peaks Dup% RelCC SSD RiP%
GSE39837 GSKi Nephronprogenitors 27634935 5203 40% 4.1 0.83 0.95
GSE39837 GSKi Nephronprogenitors 28988702 7420 49% 4.6 0.97 0.84
GSE35213 Wnt3a Hepatocytes 10101444 228 23% 2.2 0.66 0.12
GSE63682 Sen ckit+MLL-AF9 17883129 108 74% 0.55 1.3 0.021
GSE63682 Res ckit+MLL-AF9 17941355 9 16% 5.6 0.78 0.0039
GSE63682 Res DKK ckit+MLL-AF9 15020797 172 85% 0.31 2 0.083
GSE43565 No GSKi ESCs 20970288 472 45.6% 2.49 1.57 0.0618
GSE43565 GSKi ESCs 24924737 11647 36 % 2.33 1.62 6.17
GSE43565 GSKi ESCs 29223738 10736 36 % 2.33 1.01 3.61
GSE84456* - Colon crypt - 2915 - - - -
* Raw data not available.
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Ctnnb1 Mmt/flox (GOF mutant)











































































Figure 6.21: Validation of conditionally activated β-catenin MLL-ENL transformed
cell lines A) Western blot for β-catenin in LSKME and GMPME Ctnnb1 Mmt/flox (GOF)
heterozygous cells with the addition of ethanol ETOH or 4-OHT. Bands at 97kDa are full length
β-catenin. Bands at 66kDa represent β-catenin with exon 3 excised. B) Immunofluorescence
images for β-catenin (green) and DAPI (blue) in β-catenin activated (Ctnnb1 Mmt/flox with exon
3 excised), β-catenin floxed and β-catenin deleted MLL-ENL transformed cells. C) ChIP-qPCR
at known β-catenin binding sites. Chromatin was precipitated using three antibodies, BD
Biosciences Bcat, CST Bcat and CST TCF4. D) RT-qPCR for cyclin D1. Log fold changes are
shown between ethanol controls and 4-OHT treated Ctnnb1 Mmt/flox LSKMEs and GMPMEs. (
*P < 0.05, **P < 0.01,***P < 0.001, two tailed t-test)
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6.4 Discussion
The aim of this chapter was to uncover epigenetic changes following β-catenin KO and elucidate
potential cell-of-origin “epigenetic memory”. Firstly it was neccessary to determine the quality
of ChIP-Seq enrichment. We obtained good quality ChIP-Seq data (Table 6.4) which was shown
to follow expected patterns of spatial deposition around the transcription start sites of genes
(Figure 6.2) and correlates with gene expression (Figure 6.2 & Figure 6.3. The only highlighted
issues in quality were the unexpectedly high duplication rate of libraries of broad modifications
Table 6.4. Of all the marks H3K4me1 appeared to be the least optimal (Table 6.4). Despite
some noticable variation in enrichment between histone marks and samples, all samples were
acceptable by ENCODE standards (ENCODE Project Consortium 2019).
Further confirmation of the expected arrangement and relationships between different
histone marks was realised by unsupervised pattern discovery with ChromHMM (Figure 6.6A). A
six state model allowed us to cluster the genome into the main known functional transcriptionally
regulatory elements; promoters and enhancers in activated, silenced, poised or bivalent form
(Figure 6.6). A limitation of this method is that it uses binarised data and Boolean logic, presence
or absence of signal is determined by a thershold cut-off. Therefore, if segmentation is used to
compare between experimental condtions we will not detect quantitative differences in histone
modification. The calling of regulatory states is also highly sensitive to the chosen threshold.
This was demonstrated by frequent detection of switches between heterochromatin and states
requiring only one mark (Figure 6.6 C-E). Most detectable chromatin state transitions between
experimental condtions could be attributed to boundary shifts which can be seen in Figure 6.7.
To overcome the limitations of binarisation others have developed programs such as
“Segway”(Chan et al. 2018) which uses continuous signal values and Dynamic Bayesian networks
to segment the genome. However, although some methods predicting chromatin state changes
between experimental conditions have been developed, interpretation requires a lot of additional
ad hoc analyses (Sohn et al. 2015; Yen and Kellis 2015; Zeng et al. 2013). I was unable to
differentiate between true state switches and boundary shifts with simple filtering methods. It
was therefore assertained that this method was not suitable for this study and that large switches
in chromatin state were not observed.
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The HoxA locus is crucial to MLL-ENL leukaemic transformation (Zeisig et al. 2004),
in normal cells, the HoxA locus confers stemness (Lawrence et al. 2005) of HSCs. Interestingly,
we found that GMPME replicate “60” has similar differences with LSKME at the HoxA locus
(Figure 6.8) as seen between normal GMP and HSC/LSK (Figure 6.9). On the other hand,
replicate GMPME “69” shows patterns of histone modification which more closely resemble
normal HSC than GMP (Figure 6.8 & 6.9). Based on modification at the HoxA locus, it be could
argued that GMPME “60” is GMP-like and GMPME “69” is LSK-like. However, this assumption
is not supported by our in vivo data. In the previous chapter, subsection 5.3.5, Figure 5.7, it
appears that GMPME “60” does not require β-catenin in vivo and therefore based on the findings
of Siriboonpiputtana et al. (2017), is acting like LSK derived cell lines.
There are two main approaches for analysing multiple ChIP-Seq samples across
conditions of interest. Firstly, you may establish binding sites for your protein of interest by
comparing the signal between biological replicates. When it is established that biological
replicates are sufficiently similar, they may be merged to increase the sensitivity of binding site
discovery. Following this you may qualitatively compare presence or absence of binding across
the conditions of interest. The qualitative approach relies on sufficient sequencing depth to
ensure true binding sites are captured. This method is not suited to the analysis of histone
marks as they are often ubiquitously detectable, for example, H3K4me3 is found at most
inactive promoters (Guenther et al. 2007). Therefore, a quantitative method is more appropriate
to study the dynamics of histone modifications across conditions. Like differential expression in
RNA-Seq, quantitative ChIP-Seq analysis relies on adequate biological replication for sufficient
statistical power and accurate variance estimation.
Using quantitative analysis methods, in line with RNA-Seq data, activating marks
were generally upregulated in GMPME whilst the suppressive mark, H3K27me3 was upregulated
in LSKME. Between LSKME and GMPME, H3K4me3 exhibited the most significant changes
(Figure 6.10A). However, many of these differences were not concordant with changes in gene
expression (Figure 6.10B & 6.11B). Nevertheless, a number of common pathways were observed
(Figure 6.13). There was a small number of genes which were significantly differentially marked
by H3K27me3 between LSKME and GMPME (Figure 6.10). Quantitative analysis revealed many
significant differences in H3K4me1 and H3K27ac outside of genic regions (Figure 6.10A).
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To predict transcription factors which may influence cell-of-origin dependent gene
expression, motif analysis was performed on cell-of-origin specific activated enhancers
(Figure 6.14). Enhancers which were more active in GMPME were uniquely enriched for SOX
family genes. Enhancers which were more active in LSKME were uniquely enriched for
oncogenes including MYB, ERG and MYCN. Interestingly, TCF12, a downstream β-catenin
target was also enriched in uniquely active LSKME enhancers. These results are in line with
LSKME utilising additional self renewal pathways to GMPME (Siriboonpiputtana et al. 2017)
and producing a more aggressive leukaemia (Krivtsov et al. 2013).
Quantitative analysis of histone modification changes following β-catenin revealed
changes in H3K4me3 which were highly congruent with transcriptional changes (Figure 6.17 &
Figure 6.18) and identified similar pathways to RNA-Seq analysis (Figure 6.19). On the other
hand, many changes in H3K27ac were detected which did not correlate with gene expression
(Figure 6.17 & 6.18). Interestingly, most of the genes found to be differentially marked by
H3K27ac were histone genes (Figure 6.20. From this set of genes, the E2F motif was found
to be highly enriched (Table 6.5). Given its roles in cancer and known interactions with
Wnt/β-catenin signalling (Zhou et al. 2008; Kent and Leone 2019), it would be interesting
to speculate that following β-catenin deletion, E2F transcription factor activity may decrease,
leading to recruitment of deacytylases and reduction of cell cycle progression through repression
of transcription for chromatin components and other genes (Gokhman et al. 2013).
For normalisation I used the TMM on enriched regions over background to adjust
for efficiency bias. However, it is possible that efficiency bias is trended with high-abundance
binding sites, in this case, a single linear scaling factor in will not correct for this. In order to
effectively control for trended biases, a non-linear method such as quantile normalisation or
cyclic loess would need to be applied (Lun and Smyth 2016). It could be that histone genes, as
they are particularly highly expressed are affected by trended biases leading to false detection of
differential binding. Therefore, further validation may be required to confirm the specificity of
differential H3K27ac binding.
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The technology of ChIP-Seq has moved swiftly in the last 5 years and increasingly
it is becoming popular to perform ChIP-Seq and RNA-Seq with small populations of cells or
single cells to consider the dynamics of the whole cell population (Shema et al. 2019). The
current procedure used in this study requires a large bulk of cells as we are limited by the
antibody efficiency and require at least 1 ng of ChIP DNA to produce a ChIP-Seq library with
sufficient complexity. Because we require several million cells, we are likely to come across some
heterogeneity which may reduce our ability to detect effects of treatment. Many are moving to
ATAC-Seq (Assay for Transposase-Accessible Chromatin using sequencing) as a way to interogate
gene expression control with good predictive capabilities and higher signal-to-noise ratio. It is
also easier to perform on smaller cell numbers than ChIP-Seq (Jiang and Mortazavi 2018).
The only way to determine direct regulation of gene expression via β-catenin genome
wide is with β-catenin ChIP-Seq. In this study, I was unable to produce β-catenin in LSKME
or GMPME floxed Ctnnb1 LOF cells. I was also unable to correlate any changes in histone
modification with binding sites found in publicly available data (subsection 6.3.14). However, I was
able to obtain enriched ChIP in LSKME and GMPME Ctnnb1 activated GOF cells (Figure 6.21).
This implies that with β-catenin activation, β-catenin ChIP-Seq may be possible in MLL-ENL
Pre-LSCs. However, in the absence of β-catenin ChIP-Seq, ATAC-Seq may also be used to find
potential β-catenin binding sites. High depth ATAC-Seq has been used to find protected sites
within nucleosome free regions in order to detect transcription factor binding sites. However,
this method, known as “footprinting” is still in its infancy and requires very high sequencing
depth to give statistical assurance (Jiang and Mortazavi 2018).
In this study, we do not find widespread epigenetic deregulation following β-catenin
depletion. If the transcriptional regulatory role of β-catenin plays a major part in the maintenance
of leukaemia we will may not see it in vitro under normal tissue culture conditions. Generally,




Particularly aggressive subtypes of acute leukaemia harbouring MLL gene translocations have
been described as “prototypical epigenetically driven cancer” (Neff and Armstrong 2013). It
has been widely shown that β-catenin is critically involved in the initiation, progression and
drug resistance of MLL fusion leukaemia (Gandillet et al. 2011; Griffiths et al. 2010; Siapati
et al. 2011; Wang et al. 2010a; Yeung et al. 2010). We hypothesised that β-catenin, which
interacts with many epigenetic modulators plays a key role in the epigenetic transformation of
MLL-fusion associated leukaemia. Whilst others have investigated the functional role of β-catenin
in leukaemia, to our knowledge, the potential involvement of β-catenin in fatefully shaping the
epigenome of leukaemia cells had not been explored.
Despite the importance of β-catenin demonstrated in models of leukaemia, treatment
of human leukaemia with inhibitors of β-catenin shows variable results (Gandillet et al. 2011). β-
catenin dependency varies by disease, driver mutations and as suggested by our group, specifically
in the case of MLL-ENL, cell-of-origin (Siriboonpiputtana et al. 2017). We used existing β-catenin
conditional MLL-ENL transformed Pre-LSC cell lines which previously demonstrated β-catenin
dependence in vivo. These cell lines were of particular interest as their in vivo dependency was
specific to their cell-of-origin: whilst stem cell derived LSK Pre-LSCs were independent, GMP
derived Pre-LSCs were dependent. In this thesis we aimed to characterise the transcriptional,
epigenetic, and functional targets of β-catenin in MLL-ENL transformed Pre-LSCs applying a
β-catenin conditional loss of function (LOF) model.
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Firstly, to examine downstream transcriptional targets of β-catenin we performed
RNA-Seq analyses in floxed and deleted Pre-LSCs. β-catenin loss was shown to have modest
effects on transcription and did not reveal any patterns of expression in line with published
results. When compared with pre-existing RNA-Seq from the same cell lines (Siriboonpiputtana
et al. 2017), similar pathways were perturbed however the effect was more subtle in this repeat
experiment. This was likely in-part due to accumulation of irreversible β-catenin deletions in
untreated cells by leaky-Cre activation and potentially in vitro cell line evolution. Additionally,
much of the previously described cell-of origin “transcriptional memory” was no longer detectable.
Nevertheless, pathway analysis identified activation of innate immune pathways as the primary
transcriptional readout of β-catenin deletion, with similar effects in both LSKME and GMPME.
It was initially thought that the absence of known β-catenin targets in our knock-out
transcriptional signature signified unique roles of β-catenin in AML. Interestingly, comparing
transcriptomic data of studies utilising the same β-catenin deletion model revealed that the effects
of β-catenin are highly context dependent, even in MLL fusion-associated leukaemia. Another
explanation for the lack of classical β-catenin targets seen in β-catenin knockout studies as
compared with β-catenin activation studies is transcriptional compensatory mechanisms activated
by the expression of faulty β-catenin mRNA (Ma et al. 2019). Although suppression of the innate
immune system is an intriguing role for β-catenin in AML, similar non-specific signatures had
been found in studies using the same Cre-ER system for different knockouts which may reflect
the cytotoxic effects of Cre activation. Therefore, we must interpret these results with caution
and further validating work with appropriate Cre-negative controls needs to be done to confirm
that this response is specific. To support that suppression of the immune response is a potential
reason for β-catenin requirement in GMPME, one suggestion could be to use anti-inflammatory
cytokines to attempt to rescue the phenotype. Similarly to how caffeine treatment was used to
inhibit the DNA damage response caused by MLL-ENL expression in a knock-in mouse model
(Takacova et al. 2012).
With these RNA-Seq data we then sought to examine potentially functionally important
β-catenin targets through expression perturbation. Because β-catenin was required in GMPME
specifically, it was expected that downstream β-catenin targets specific to GMPME would have
greater therapeutic potential. Gadd45a was found to be a unique β-catenin target in GMPME
and was validated by qPCR. However it was found that Gadd45a overexpression indiscriminately
eliminates leukaemia arising from GMPME and LSKME in vivo. Gadd45a is already known to
be a tumour suppressor, therefore it is not too surprising that extreme overexpression would
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impair leukaemia. We may be able to observe a cell-of-origin dependent response to Gadd45a
by reducing its overexpression to more physiological levels by using a retroviral vector with a
weaker promoter and titrating the virus. To illuminate the function of our β-catenin targets it
was originally planned to probe our entire β-catenin knockout signature with an in vivo shRNA
screen. As shown in chapter 5, we were unable to replicate the cell-of-origin specific dependency
of β-catenin in vivo or even significantly delay leukaemia development. Additionally, for in vivo
experiments in this study, there were issues with inconsistent engraftment. It was revealed
that β-catenin dependency may be lost with prolonged culture, possibly due to transcriptional
adaptation. This phenomenon greatly limited our ability to address our biological questions.
Finally, to investigate potential epigenetic modifications mediated by β-catenin we
produced ChIP-Seq for histone modifications. In line with RNA-Seq analyses, ChIP-Seq revealed
subtle epigenetic responses to β-catenin loss. Whilst only modest statistically significant changes
were detected, H3K4me3 and H3K27ac were the most dynamic and generally mirrored RNA-Seq
regardless of FDR cut-offs. The innate immune response signatures revealed in RNA-Seq were
further confirmed via epigenetic analyses. Intriguingly, H3K27ac appeared to be perturbed at
replication dependent histone clusters which were enriched for E2F motifs. It is interesting to
speculate that this could reveal a mechanism by which β-catenin modulates cell cycle progression
(Gokhman et al. 2013). However, these changes did not correlate with gene expression, therefore
it is difficult to interpret their biological readout. The only way to detect β-catenin direct
targets with confidence is via ChIP-Seq. In this study I was unable to produce ChIP-Seq for
β-catenin, I speculate that this is largely due to the low presence of nuclear β-catenin which may
be exacerbated by leaky Cre reducing the amount of available β-catenin. We were also unable to
correlate differential ChIP-Seq regions with binding sites from β-catenin ChIP in other tissues.
In this study, ChIP-Seq did not shed light on how β-catenin modulates the expression of its
targets in MLL-fusion associated leukaemia. Similar results were likely to have been obtained
with ATAC-Seq which would be more time and cost affective.
In summary, major transcriptomic or epigenetic changes in MLL pre-LSCs following
β-catenin loss were not detectable using our methods. Inconsistent behaviour of the cell lines in
relation to β-catenin dependency casts considerable doubt over the biological relevance of our
transcriptomic signatures. Genomic sequencing technologies such as ChIP-Seq and RNA-Seq are
extremely sensitive which makes them ideal for uncovering systemic patterns explaining underlying
molecular mechanisms for the observable biology. However, the sensitivity of genomewide studies
means that all variation from unwanted sources will be captured. To avoid losing biologically
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interesting signal to confounding effects, we need to reduce variation as much as possible whilst
maximising the biological signal being investigated without becoming too artificial.
7.1 Suggestions for Future Work
To address the original biological question to elucidate the transcriptional and epigenetic changes
mediated by β-catenin we could use either a β-catenin LOF model or a GOF model. As mutations
in the β-catenin pathway such as Axin2 or APC are rare in leukaemia, a LOF was deemed
to be more physiologically relevant for this study. However the effect of deletion by 4-OHT
administration was greatly reduced by decreasing level of β-catenin due to leaky Cre-recombinase
activity and may also be affected by NITC. Moreover, insufficient molecular groundwork was
done to determine that β-catenin was activated highly enough in these Pre-LSCs to influence
transcription before it was deleted. It is important to note that Pre-LSC were previously reported
not to show a phenotype related to β-catenin deletion in vitro (Siriboonpiputtana 2014).
It is known that although MLL fusions alone can somewhat activate β-catenin in a
subpopulation of cells, the activation of β-catenin is much higher in fully fledged LSCs (Yeung
et al. 2010). To counteract these problems, one proposal could be to repeat molecular analyses
using LSCs rather than Pre-LSCs and to use a self-excising Cre (Silver and Livingston 2001) to
delete β-catenin. However, the mechanisms for β-catenin activation in MLL-fusion transformed
LSCs are not clearly defined, these could be is genetic, epigenetic or due to external signalling
from the bone marrow niche. LSCs will develop different mutations and undergo clonal expansion
in the mouse adding to unwanted variation to the study. To avoid obfuscating effects, it may be
better to explore β-catenin perturbation methods to create a cleaner model which mimics how
β-catenin is activated in clinically relevant leukaemia.
Most studies with good quality β-catenin ChIP-Seq data and most RNA-Seq datasets
studying β-catenin transcriptional control use some form of β-catenin stimulation, either through
chemical inhibitors of the β-catenin destruction complex, Wnt ligand or by genetic mutations
known to disrupt the destruction complex. To this end I created MLL-ENL transformed cell
lines expressing constitutively active β-catenin and was able to obtain β-catenin ChIP. It could
be argued however that this is not physiologically relevant as β-catenin mutations are generally
not seen in leukaemia. As mentioned in section 1.5, FLT3-ITD mutations have been shown to
increase β-catenin protein by direct phosphorylation, Indeed MLL-ENL and FLT3-ITD models
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have been created with retroviral transformation (Barabé et al. 2007; Kajiguchi et al. 2007).
Alternatively, activation of β-catenin could be achieved by use of controllable external factors
such as a combination of Rspo3 and Wnt3a as suggested by Yi et al. (2013) which was found to
activate β-catenin in MLL-AF9 LSCs.
One of the other limitations in this study was heterogeneity in the cell lines used. Firstly,
it could be seen that cell lines became more variable over culture time and therefore culture time
should be strictly minimised for in vitro molecular and in vivo studies. It is known that the cell
lines were derived from multiple mice whose bone marrow was pooled (Siriboonpiputtana 2014).
Pooling individuals will increase the heterogeneity in each cell line and could contribute to the
variance seen in this study. It is possible to get enough material from a single mouse to produce
retrovirally transformed cell lines from LSKs or GMPs and where possible, litter mates should
be used as replicates. Furthermore avoiding retroviral transformation by use of MLL-ENL mouse
models could greatly improve the detection of β-catenin’s molecular signature. However, these
models would not produce a GMPs derived transplantable leukaemia.
The greatest improvement for this study would be to increase the number of biological
replicates for RNA-Seq and ChIP-Seq. It is not uncommon to find inconsistencies between
RNA-Seq studies with few biological replicates (Baccarella et al. 2018; Peixoto et al. 2015;
Conesa et al. 2016; Liu et al. 2014; Schurch et al. 2016). The number of replicates required
depends on the variance of the biological system; the greater the variance the more replicates
are needed to maintain error control. It has been recommended that at least six biological
replicates are used for RNA-Seq for reproducible results (Schurch et al. 2016). In this study,
we obtained approximately 10-20 million mapped reads for RNA-Seq. However, by perturbing
read depth and replicates in analysis Baccarella et al. (2018) found that differential expression
analysis performance was not negatively affected above 2 million reads. On the other hand,
they determined that a loss of performance was shown when less than seven biological replicates
were used for each condition (Baccarella et al. 2018). Considering this, I would recommend that
future studies require at least 6 replicates. Similarly, differential ChIP-Seq analyses using count
data will benefit from greater replication over sequencing depth.
The multidisciplinary perspective of this thesis provides unique insight into the
interpretation of multi-omics data. Taken together, this study contributes to the scientific
community by highlighting key limitations in of the use of genomics to explain the molecular
mechanisms of transcription factor activity in the context of leukaemia. The need for strict
experimental design control, replicates and use of appropriate models is discussed.
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